The Regulation of Net Hepatic Glucose Uptake in vivo by DiCostanzo, Catherine Anne
THE REGULATION OF NET HEPATIC GLUCOSE UPTAKE IN VIVO 
 
By 
 
Catherine Anne DiCostanzo 
 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
in 
 
Molecular Physiology and Biophysics 
December, 2005 
Nashville, Tennessee 
 
Approved: 
David Wasserman 
Stephen Davis 
Naji Abumrad 
Masakazu Shiota 
 
   
 
 
 
 
 
 
To my parents, Richard and Diane 
 
 
 
 
 
 
 
 
 
 
 
  
 
ii 
 ACKNOWLEDGMENTS 
 
 I would first, and foremost like to thank my mentor, Alan Cherrington. 
When I entered the lab in March of 2001, neither he nor I knew of all that would 
occur over the next five years. Alan has stood by me through both my saddest and 
proudest moments and without his support, my time here at Vanderbilt would not 
have been the same. He has been a wonderful mentor but a better friend and my 
debt of gratitude will never be able to be paid in full.  
 A very special thank you to Patsy Raymer. Not only does she take care of 
Alan, but more importantly she takes care of everyone in the lab, myself included. 
I will never be able to repay her for countless phone calls when all I needed to 
know was that someone cared where I was or her always-open office where I 
could confide in her my deepest problems. She has truly been a second mother to 
me. 
 I would also like to thank the members of my dissertation committee, 
David Wasserman, Stephen Davis,  Masakazu Shiota, Naji Abumrad, and Debbie 
Clegg. In spite of our infrequent meetings, their overall suggestions and guidance 
throughout my graduate career were extremely valuable. I would like to extend a 
special thanks to Debbie Clegg who, despite being in Ohio, was always there to 
give me direction in both my research interests as well as my side interests, 
including running. 
 I would like to thank the people from whom I received help in my research 
over the last five years. First, the Cherrington lab has become my family, even 
iii 
 though at times it has proven to be dysfunctional. Without the technical expertise 
of Doss Neal, Ben Farmer, and Tiffany Rodewald my numerous experiments 
would have never been so successful. Margaret Lautz, Melanie Scott, Jon 
Hastings, and Marta Smith have all been true supporters during my time here. 
Past and present graduate students have included Jamie Grubert, Stephanie 
Gustavson, Kathryn Stettler, and Noelia Rivera, and they have all contributed to 
my experimental work. My appreciation also goes to Dale Edgerton, our current 
research instructor, who has always made me think outside the box in both lab 
and life. Excellent assistance was provided by the individuals from the Animal 
Resources Core with special thanks to Phil Williams, Brooks Lacy, and Amy 
Nunnally. In addition, numerous individuals from the Hormone Core Laboratory 
were instrumental in my graduate career including Eric Allen, Angelina Penaloza, 
E. Patrick Donahue, and Wanda Snead.  
 There are several individuals whom I have met in the Cherrington lab that 
have played particularly important roles in my time here at Vanderbilt. First, I 
would like to thank Dominique Dardevet who was the greatest lab partner that I 
could have ever asked for. His ability to make me smile, laugh, and think all at the 
same time was priceless. Merci, Dominique, pour le tout. 
 Secondly, I would like to thank Genie Moore. Genie guided me through 
my very first studies and without all of her help, I would not be as knowledgeable 
as I am today. I would like to thank her for always having that open chair in her 
office where I could ask her any question ranging from science, to family, to life 
 iv
 in general. She has been a very special friend to me and she deserves more credit 
than she receives. 
 Most importantly, I would like to thank Carrie Everett. Who would have 
guessed that two girls who barely knew each other would join the same lab and 
become life long best friends? There is no one who understands all that I have 
been through in completing this dissertation more than Carrie. She has always 
been my greatest support and without her shoulder to cry on or her side to laugh 
by, I would not be who I am today. In the past five years, both Carrie and I have 
lived through life’s greatest personal tragedies and triumphs and I feel privileged 
to have shared so much of my life with her and I am honored that she has shared 
so much of hers with me. 
 Lastly, I would like to thank my parents. My mother Diane has shown me 
what it means to persevere through some of my life’s most difficult challenges. 
She has also shown me what it means to be a great mother and without her love 
and support, I could not accomplish all that I have.  
 My father and I had ample opportunities to talk about everything that life 
has to offer before he passed away in September of 2002. He taught me more in 
the last year of his life than I may ever learn in the rest of mine. He also made me 
promise that I would complete this Ph.D. no matter what happened. I am thankful 
he never got to see the times get tougher. But I have kept my promise and all of 
this is for him. I love you and miss you, dad. 
 
 
 v
 TABLE OF CONTENTS 
              Page 
DEDICATION........................................................................................................ ii 
 
ACKNOWLEDGEMENTS................................................................................... iii 
 
LIST OF TABLES................................................................................................. ix 
 
LIST OF FIGURES .................................................................................................x 
 
Chapter 
 
I.   INTRODUCTION .......................................................................................1 
 
        Basic Glucose Metabolism .........................................................................3 
 Hepatic Glucose Production ........................................................................7 
         Effect of Insulin on Hepatic Glucose Production ............................7 
             Specific Aim I- Insulin and Net Hepatic 
                                Glucose Production..........................................17 
  Glucagon Regulation of Hepatic Glucose Production ...................17 
 Hepatic Glucose Uptake ............................................................................18 
  Effect of Hyperglycemia on Hepatic Glucose Uptake...................19 
  Effect of Insulin on Hepatic Glucose Uptake ................................19 
  The “Portal Glucose Signal” Story ................................................21 
  The Relationship between the Portal Glucose Signal,  
               Hepatic Glucose Load and Insulin....................................23 
  Nonhepatic Effects of the Portal Glucose Signal...........................25 
  The Portal Glucose Signal in Humans ...........................................26 
  The Effect of Other Nutrients on the Portal Glucose Signal .........30 
  Mechanism of Portal Signaling......................................................30 
               Specific Aim II- Sympathetic Nerves and  
                          Net Hepatic Glucose Uptake .................................38 
               Specific Aim III- Parasympathetic Nerves and  
                          Net Hepatic Glucose Uptake .................................41 
  The Mechanism of Action of the Portal Glucose Signal ...............42 
  Other Mediators of Net Hepatic Glucose Uptake ..........................43 
               Serotonin ...........................................................................43 
               Nitric Oxide ......................................................................44 
                           Specific Aim IV- Nitric Oxide and Net  
                                        Hepatic Glucose Uptake ..........................48 
 
 II.   MATERIALS AND METHODS...................................................49 
 
 Animals and Surgical Care Procedures......................................................49 
vi 
   Animal Care ...................................................................................49 
  Surgical Procedures .......................................................................49 
 Collection and Processing of Samples.......................................................55 
  Blood Samples ...............................................................................55 
  Tissue Samples...............................................................................57 
 Sample Analysis.........................................................................................57 
  Plasma Glucose..............................................................................57 
  Plasma Non-esterified Fatty Acid (NEFA)....................................58 
  Whole Blood Metabolites: Lactate and Glycerol...........................59 
  Hormones.......................................................................................61 
               Insulin ...............................................................................62 
               Glucagon...........................................................................63 
               Cortisol..............................................................................64 
               Catecholamines .................................................................65 
  Blood flow .....................................................................................67 
  Glucose Mixing in the Portal Vein ................................................72 
 Calculations................................................................................................72 
  Net Hepatic Substrate Balance.......................................................72 
  Nonhepatic Glucose Uptake and Clearance...................................76 
  Sinusoidal Hormone Concentrations .............................................78 
  Statistical Analysis.........................................................................78 
 
III. SPECIFIC AIM I: SIMULATED FIRST-PHASE INSULIN RELEASE  
 USING HUMULIN OR HIM2 IS ASSOCIATED WITH PROLONGED  
 IMPROVEMENT IN POST PRANDIAL GLYCEMIA...........................79 
 
 Aim ............................................................................................................79 
 Experimental Design..................................................................................79 
 Statistical Analysis.....................................................................................81 
 Results........................................................................................................81  
 Discussion..................................................................................................84 
 Tables and Figures .....................................................................................90 
 
IV. SPECIFIC AIM II: THE ROLE OF THE HEPATIC  
 SYMPATHETIC NERVES IN THE REGULATION OF NET  
 HEPATIC GLUCOSE UPTAKE AND THE MEDIATION OF THE  
 PORTAL GLUCOSE SIGNAL.................................................................97 
 
 Aim ............................................................................................................97 
 Experimental Design..................................................................................97 
 Statistical Analysis.....................................................................................99 
 Results........................................................................................................99 
 Discussion................................................................................................102 
 Tables and Figures ...................................................................................110 
 
 vii
 V. SPECIFIC AIM III: THE EFFECT OF SIMULATING THE PORTAL 
GLUCOSE SIGNAL BY VAGAL COOLING ON CANINE NET 
HEPATIC GLUCOSE METABOLISM IN THE PRESENCE OF 
PERIPHERAL HYPERGLYCEMIA .....................................................117 
 
 Aim ..........................................................................................................117 
 Experimental Design................................................................................117 
 Statistical Analysis...................................................................................118 
            Results......................................................................................................118 
            Discussion................................................................................................121 
            Tables and Figures ...................................................................................127 
 
VI. SPECIFIC AIM IV: THE EFFECT OF AN INTRAPORTAL NITRIC 
OXIDE (NO) DONOR (SIN-1) ON CANINE NET HEPATIC  
            GLUCOSE METABOLISM IN THE PRESENCE THE PORTAL                   
            GLUCOSE SIGNAL ..............................................................................134 
  
            Aim ..........................................................................................................134 
            Experimental Design................................................................................134 
            Statistical Analysis...................................................................................136 
            Results......................................................................................................136 
            Discussion................................................................................................140 
            Tables and Figures ...................................................................................148 
 
VII.      SUMMARY AND CONCLUSIONS......................................................156 
REFERENCES ....................................................................................................162 
 viii
 LIST OF TABLES  
 
 
Table                          Page 
 
 
4.1 Hepatic norepinephrine content in each of the seven lobes of 42-h- 
 fasted dogs with innervated (CON) or denervated (DEN) livers 
 (n=10/group). ...........................................................................................104 
 
4.2 Total hepatic blood flow and hepatic glucose load during the  
 experimental periods in experiments on 42-h-fasted dogs with  
 innervated (CON) or denervated (DEN) livers........................................105 
 
4.3 Arterial blood lactate and glycerol and hepatic balance of lactate  
 and glycerol during the basal and experimental periods in  
            experiments on 42-h-fasted dogs with innervated (CON) or  
 denervated (DEN) livers ..........................................................................106 
 
4.4 Net hepatic glucose uptake, net hepatic glucose fractional  
 extraction, and nonhepatic glucose uptake during the experimental  
 periods on 42-h-fasted dogs with innervated (CON) or denervated  
 (DEN) livers.............................................................................................107 
 
5.1 Arterial, portal, and total hepatic blood flow in the basal and 
 experimental periods in both sham cooled (SHAM) and vagally 
 cooled (COOL) 42-h-fasted conscious dogs (n=6/group) .......................121 
 
5.2 Arterial plasma and hepatic sinusoidal insulin, glucagon, and 
 cortisol levels during the basal and experimental periods in both 
 sham cooled (SHAM) and vagally cooled (COOL) 42-h-fasted  
 conscious dogs .........................................................................................122 
 
5.3 Arterial blood lactate levels and net hepatic lactate balance during 
 the basal and experimental periods in both sham cooled (SHAM) 
 and vagally cooled (COOL) 42-h-fasted conscious dogs ........................123 
 
6.1 Heart rate and systolic and diastolic blood pressure in 42-h-fasted 
 conscious dogs during the basal and experimental periods in the 
 control and and SIN-1 groups (n=9/group)..............................................142 
 
6.2 Average hepatic arterial, portal, and total blood flow in 42-h-fasted 
 conscious dogs during the basal and experimental periods in the 
 control and and SIN-1 groups (n=9/group)..............................................143
ix 
 LIST OF FIGURES 
 
 
Figure              Page 
 
3.1 Arterial plasma insulin (top) and liver sinusoidal plasma insulin  
 (bottom) in 42-h-fasted conscious dogs maintained on a pancreatic 
 clamp. During the experimental period, insulin was kept basal (BI), 
 or Humulin spoke (HI), and HIM2 spikes (HIM2) were created on 
 the background of basal insulin (n=6/group). ............................................85 
 
3.2 Net gut glucose balance (top) and arterial plasma glucose levels 
 (bottom) in 42-h-fasted conscious dogs maintained on a pancreatic  
 clamp during the basal and experimental periods in the BI, HI, and   
 HIM2 groups)............................................................................................86 
 
3.3 Net hepatic glucose balance (top) and hepatic glucose load   
 (bottom) in 42-h fasted conscious dogs maintained on a pancreatic  
 clamp during the basal and experimental periods in the BI, HI, and   
 HIM2 groups).............................................................................................87 
 
3.4 Arterial blood glycerol levels (top) and net hepatic glycerol uptake  
 (bottom) in 42-h-fasted conscious dogs maintained on a pancreatic 
 clamp during the basal and experimental periods in the BI, HI, and            
 HIM2 groups..............................................................................................88 
 
3.5 Arterial plasma non-esterified fatty acid (NEFA) levels (top) and 
 net hepatic glycerol uptake (bottom) in 42-h-fasted conscious dogs 
 maintained on a pancreatic clamp during the basal and 
 experimental periods in the BI, HI, and HIM2 groups ..............................89 
 
3.6 Arterial blood lactate levels (top) and net hepatic lactate balance 
 (bottom) in 42-h-fasted conscious dogs maintained on a pancreatic 
 clamp during the basal and experimental periods in the BI, HI, and  
 HIM2 groups..............................................................................................90 
 
3.7 Nonhepatic glucose clearance in 42-h-fasted conscious dogs 
 maintained on a pancreatic clamp during the experimental period 
 in the BI, HI, and HIM2 groups.................................................................91 
 
4.1 Arterial and portal plasma glucose levels in control (CON) (a) and 
 hepatic denervated (DEN) (b) 42-h-fasted conscious dogs 
 maintained on a pancreatic clamp during the basal and 
 experimental periods (n=10/group) .........................................................108 
 
4.2 Arterial plasma insulin (a), arterial plasma glucagon (b), liver 
x 
  sinusoidal insulin (c), and liver sinusoidal glucagon (d) levels in 
 42-h-fasted conscious dogs maintained on a pancreatic clamp 
 during the basal and experimental periods in both the CON and 
 DEN groups .............................................................................................109 
 
4.3 Net hepatic glucose uptake (a) and non hepatic glucose uptake (b) 
 in 42-h-fasted conscious dogs maintained on a pancreatic clamp 
 during the peripheral and portal glucose infusion periods in both 
 the CON and DEN groups .......................................................................110 
 
5.1 Heart rate in both sham cooled (SHAM) and vagally cooled 
 (COOL) 42-h-fasted conscious dogs maintained on a pancreatic 
 clamp during the basal and experimental periods (n=6/group) ...............124 
 
5.2 Arterial (a) and portal (b) plasma glucose levels in sham cooled 
 (SHAM) and vagally cooled (COOL) 42-h-fasted conscious dogs 
 maintained on a pancreatic clamp during the basal and 
 experimental periods................................................................................125 
 
5.3 Hepatic glucose load (a), net hepatic glucose balance (b), and net 
 hepatic fractional extraction (c) in sham cooled (SHAM) and 
 vagally cooled (COOL) 42-h-fasted conscious dogs maintained on 
 a pancreatic clamp during the basal and experimental periods................126 
 
5.4 Nonhepatic glucose uptake (a) and nonhepatic glucose clearance in 
 sham cooled (SHAM) and vagally cooled (COOL) 42-h-fasted 
 conscious dogs maintained on a pancreatic clamp during the basal 
 and experimental periods .........................................................................127 
 
6.1 Hepatic sinusoidal plasma insulin (a) and glucagon (b) levels in 
 42-h-fasted conscious dogs maintained on a a pancreatic clamp 
 during the basal and experimental periods in both the control and 
 SIN-1 treated groups (n=9/group)............................................................144 
 
6.2 Arterial plasma glucose levels (a) and hepatic glucose load (b) in 
 control and SIN-1 treated 42-h-fasted conscious dogs maintained 
 on a pancreatic clamp during the basal and experimental periods...........145 
 
6.3 Net hepatic glucose balance (a) and net hepatic glucose fractional 
 extraction (b) in 42-h-fasted conscious dogs maintained on a 
 pancreatic clamp during the basal and experimental periods in both 
 the control and SIN-1 treated groups .......................................................146 
 
6.4 Nonhepatic glucose uptake (a) and nonhepatic glucose clearance 
 (b) in 42-h-fasted conscious dogs maintained on a pancreatic 
 clamp during the basal and experimental periods in both the 
 xi
  control and SIN-1 treated groups.............................................................147 
 
6.5 Arterial blood lactate (a) and net hepatic lactate balance (b) in 42 
 h-fasted conscious dogs maintained on a pancreatic clamp during 
 the basal and experimental periods in both the control and SIN-1 
 treated group ............................................................................................148 
 
6.6 Arterial plasma NEFA levels (a), arterial blood glycerol levels (b), 
 hepatic plasma NEFA balance (c), and hepatic blood glycerol 
 uptake (d) in 42-h-fasted conscious dogs maintained on a 
 pancreatic clamp during the basal and experimental periods in both 
 the control and SIN-1 treated group.........................................................149
 xii
 CHAPTER I 
 
INTRODUCTION 
 
 Glucose homeostasis reflects a delicate balance between glucose 
production and glucose uptake. This balance is best demonstrated during periods 
following food consumption and fasting when plasma glucose levels change only 
modestly. Glucose production and glucose uptake are tightly regulated by 
hormones and substrates and it has been shown that the liver plays a pivotal and 
unique role in glucose homeostasis. This is due to both its anatomical location (it 
receives a systemic and portal supply of absorbed nutrients) as well as its ability 
to both consume and produce glucose in a net sense (188).There have been 
numerous studies and much work done in the diabetes field examining hepatic 
glucose production but much less is known about hepatic glucose uptake. This is 
in part due to the inherent difficulty of measuring hepatic balance in the human 
(i.e, impossible to catheterize the hepatic portal vein). Thus, the following 
dissertation aims to further understand the post-prandial state by further clarifying 
the effect of insulin and the portal signal on net hepatic glucose uptake. 
 Following an overnight fast (in the post absorptive state), the liver is the 
major contributor of endogenous hepatic glucose production with the only other 
contributing organ being the kidney. The contribution of the kidneys to 
endogenous glucose production has been estimated to be 5-23% in the overnight 
fasted human (46, 83, 268), and 10%  (178) or less (121)in the overnight fasted 
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 dog leaving the remaining 90% to be produced by the liver. The liver is thus the 
principal organ which delivers glucose to both the non-insulin-sensitive (nervous, 
red blood cells, skin, smooth muscle) and the insulin sensitive (muscle and fat) 
tissues. Thus the factors which regulate hepatic glucose production are extremely 
important to glucoregulation. 
 Equally important are those mechanisms which regulate net hepatic 
glucose uptake in the post-prandial state. In the non-diabetic individual, the liver 
minimizes post-randial hyperglycemia by suppressing endogenous glucose 
production and by increasing glucose uptake(112). Following a modest sized oral 
glucose load, one third of the load is taken up by the muscle, one third is taken up 
by the liver, and the remaining third is taken up by non-insulin sensitive tissues 
such as the brain and red blood cells (215). However, if the glucose levels are 
elevated to an even greater extent by larger loads, the excess glucose will be taken 
up by the muscle and liver. In individuals with Type 2 diabetes, excessive post-
prandial hyperglycemia may be due to reduced splanchnic glucose uptake, 
excessive (inadequately suppressed) endogenous glucose production, and reduced 
peripheral uptake due to defective oxidation or storage of glucose (112). Thus the 
liver is a critical organ in the regulation of postprandial hyperglycemia.  
 In the following introduction, important regulators of both glucose 
production and glucose uptake will be discussed. A review of basic glucose 
metabolism will precede two major sections titled “Hepatic Glucose Production” 
and “Hepatic Glucose Uptake.” In the “Hepatic Glucose Production” section, the 
effect of insulin on hepatic glucose production will be reviewed in light of 
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 specific aim I, which will examine the ability of first phase insulin release to 
modify net hepatic glucose uptake in the post-prandial state. In addition, the effect 
of glucagon and catecholamines on hepatic glucose production will be briefly 
discussed within this section. In the “Hepatic Glucose Uptake” section, the three 
main factors which impact net hepatic glucose uptake (the insulin concentration at 
the liver, the glucose load to the liver, and the portal glucose signal) will be 
reviewed. The focus of this section will be on the portal glucose signal and the 
potential mechanisms of portal signaling. These include both the afferent and 
efferent parasympathetic and sympathetic nerves, and the roles of these nerves 
will be further clarified in specific aims II and III. Lastly, the role of other 
mediators, such as serotonin and nitric oxide, on net hepatic glucose uptake will 
be reviewed with the focus on nitric oxide since specific aim IV will further 
clarify the role of nitric oxide on hepatic glucose production.  
 
Basic Glucose Metabolism 
 Glucose possesses the ability to regulate its own plasma level by directly 
impacting both its own production and uptake by the liver (188). There has been 
both in-vitro and in-vivo work that has demonstrated a relationship between net 
hepatic glucose balance and the overall glucose concentration, independent of any 
changes in the plasma insulin concentration (68, 257). In the presence of basal 
insulin and glucagon concentrations, hyperglycemia alone can bring about a 
suppression of net hepatic glucose output. In the presence of modestly elevated 
hyperglycemia levels, minimal net hepatic glucose uptake (NHGU) can occur in 
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 the presence of basal insulin. It is only at very high (supraphysiological) plasma 
glucose levels that NHGU can occur at a substantial rate if insulin is not elevated. 
 Glucose itself can suppress gluconeogenesis under conditions such as 
prolonged fasting, which results in very low and/or completely depleted glycogen 
stores (188). When glycogen stores are adequate, glucose autoregulates itself by 
suppressing glycogenolysis and by stimulating intrahepatic glucose cycling 
(glucose Æ glucose-6-phosphate (G-6-P) Æ glucose) (222, 236, 260). 
 Therefore, the size of the G-6-P pool is an important factor in regulating 
basic glucose metabolism as G-6-P acts as an activator of glycogen synthase (42, 
93) and an inactivator of glycogen phosphorylase (8, 9).  Glucose must be able to 
enter the cell in order to be metabolized. GLUT-2 is a membrane bound glucose 
transporter found in the liver and pancreatic beta cells (22, 286). It is a low 
affinity transporter that is not easily saturated at even high plasma glucose levels. 
Thus when the plasma glucose level increases, there is a rise in cellular glucose 
due to an increase in glucose transport by GLUT 2; this allows the beta cells, as 
well as the hepatocytes, to act more like glucose sensors (174) and respond 
accordingly. For instance, as the plasma glucose level rises, the hepatocyte 
decreases its hepatic glucose production. Although glucose transport into the liver 
is a critical step in determining the G-6-P pool, it is not a rate limiting step. 
 There are several other important regulators that determine the size of the 
G-6-P pool. Glucokinase (GK), an enzyme that phosphorylates glucose when it 
enters the liver, and G-6-Pase, the opposing enzyme which catalyses the last rate-
determining step prior to the release of glucose by the liver are two other 
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 important regulators. If GK is suppressed or G-6-Pase is activated, there will be a 
decrease in G-6-P. In the basal state, GK is bound to the glucokinase regulatory 
protein (GKRP) in the hepatocyte nucleus. Hyperglycemia triggers the release of 
glucokinase from GKRP allowing it to translocate to the cytosol where it can then 
phosphorylate the entering glucose (253, 277). It has also been shown that 
fructose or sorbitol, which are precursors of fructose-1-phosphate (F-1-P), 
increase F-1-P content in isolated hepatocytes and stimulate the release of GK 
from GKRP(6). In our laboratory, Shiota et al. (254)showed that an intraportal 
infusion of even a small amount of fructose (no more than 5-10% of the mass of 
the glucose infused) in the presence of a hyperinsulinemic, hyperglycemic clamp 
enhanced NHGU and hepatic glycogen storage in conscious dogs.  
 Having entered the cell and been phosphorylated, the glucose can then be 
oxidized via the Embden-Myerhof glycolytic pathway. Glycolysis will convert 1 
mole of glucose into 2 moles of ATP, 2 moles of NADH, and 2 moles of 
pyruvate. This ATP can then be utilized for cellular energy while the NADH and 
pyruvate can act as substrates for other energy-producing reactions; for example, 
pyruvate can be converted to acetyl CoA and then enter the tricarboxylic acid 
cycle (TCA) where an additional 36 moles of ATP will be generated for every 
mole of glucose consumed.  
 Pyruvate, and other carbon-3 compounds such as lactate and alanine, can 
serve as substrates for de novo synthesis of glucose via the gluconeogenic 
pathway. Gluconeogenesis first involves the conversion of pyruvate to 
oxaloacetate and then to phosphoenolpyruvate (PEP). PEP is then converted by 
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 phosphoenolpyruvate carboxykinase (PEPCK) to fructose-1-6 bisphosphate. It is 
then that another key enzyme of gluconeogenesis, fructose-1,6-bisphosphatase, 
converts fructose-1-6 bisphosphate to fructose-6-phosphate which is in 
equilibrium with G-6-P. 6-phosphofructo-1-kinase (6PF-1-K) is allosterically 
activated by fructose-2,6-bisphosphate (F-2,6-P2) in the glycolytic pathway. F-
2,6-P2 stimulates glycolysis by having a positive effect on PFK-1, the enzyme that 
converts fructose F-6-P into F-1,6-P. It in turn, has a negative effect on F-1,6-Pase 
which converts F-1,6-P into F-6-P.  Increasing F-2,6-P2  will also suppress HGP 
by increasing hepatic glycolysis possibly through the stimulation of hepatic GK 
gene expression in an insulin dependent manner (287).The final reaction is the 
conversion of G-6-P to free glucose by glucose-6-phosphatase. The liver and 
kidney are the only two sites which are known to express G-6-Pase (235) but it 
has been suggested that the gut could also be gluconeogenic (184). 
 Glycogen synthesis and breakdown are both important regulators of net 
hepatic glucose balance. Glycogen phosphorylase catalyzes the first step in 
glycogen breakdown by cleaving a single glucose-1-phosphate. This glucose-1-
phosphate is in equilibrium with G-6-P, thus glycogen phosphorylase increases G-
6-P following cleavage of the glycogen molecule. This G-6-P can then be 
dephosphorylated by G-6-Pase and released as free glucose. Glucagon can 
stimulate glycogen breakdown by increasing intracellular levels of cAMP. These 
in turn can activate protein kinase A which can phosphorylate the phosphorylase 
kinase rendering it active. This, in turn, phosphorylates glycogen phosphorylase. 
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 Insulin, on the other hand, stimulates protein phosphatase 1 which 
dephosphorylates glycogen phosphorylase thus inhibiting glycogen breakdown.  
 It has also been suggested that G-6-P promotes the stimulation of 
glycogen synthesis by mechanisms other than inactivation of phosphorylase, such 
as activation and translocation of glycogen synthase (122). Insulin will also cause 
the translocation of glucokinase thus allowing for a consequent increase in G-6-P. 
This glucokinase translocation may cause both the inactivation of phosphorylase 
and the activation of synthase (122). It is the synergy between these two 
convergent pathways that may explain why insulin has a large effect on 
glycogenic flux, despite its only modest effects on individual enzyme activities 
(122).    
 
Hepatic Glucose Production
 
Effect of Insulin on Hepatic Glucose Production 
 Insulin sensitively controls hepatic glucose production. In very early 
studies, a pancreatic clamp was used and insulin was either left unchanged or 
increased fourfold by increasing the portal insulin infusion rate (144, 263). 
Glucagon was replaced at basal amounts in both protocols. In the dogs that 
received basal insulin, net hepatic glucose output (NHGO) fell only slightly by 
10% as a result of a slight decrease in glycogenolysis that was not counteracted by 
an increase in gluconeogenesis. In those dogs that received the intraportal fourfold 
insulin infusion, NHGO decreased rapidly from 2.7 mg/kg/min to 1.6 mg/kg/min 
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 and then declined more slowly. This fall was mainly due to a decrease in 
glycogenolysis. There was a slight decrease in gluconeogenesis compared to that 
seen in the control group but it was not significant. Thus, a fourfold increase in 
insulin has a marked inhibitory effect on hepatic glucose production. 
 Acute insulin deficiency has the opposite effect on glucose production (48, 
51, 114, 260). In two separate groups, a pancreatic clamp was used to assess the 
importance of basal insulin in restraining hepatic glucose production in the 
overnight fasted conscious dog (51). In the control group, insulin was replaced 
basally throughout the experiment. In the test group, a basal insulin infusion was 
also given intraportally but was terminated at the onset of the experimental 
period, creating complete insulin deficiency. In both groups, glucagon was 
infused at basal rates. In the insulin deficient group, NHGO rapidly increased 
from 2.5 mg/kg/min to 8.7 mg/kg/min causing a significant rise in plasma glucose 
levels from 99 mg/dl to 288 mg/dl. Due to this increase in plasma glucose in the 
test group, glucose was infused peripherally in the control group to match the 
hepatic glucose loads between the two groups. This increase in arterial plasma 
glucose in the presence of basal insulin in the control group caused a decrease in 
NHGO. Thus the effect of insulin deficiency was the difference between the net 
hepatic glucose balances in the two groups and proved to be both quick and 
sustained. This response was primarily the result of an increase in glycogenolysis 
since gluconeogenesis changed only slightly.  
 A dose response curve can be constructed to relate the hepatic sinusoidal 
level to net hepatic glucose output in the fasted conscious dog. The basal hepatic 
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 sinusoidal level (18 µU/ml) lies slightly below the half maximally effective 
insulin concentration; this indicates that even basal insulin levels produce greater 
than 50% inhibition of net hepatic glucose production. In addition, the slope of 
the curve is very steep, indicating that even very slight changes in plasma insulin 
levels will have significant effects on glucose production by the liver. This dose 
response curve also shows that a fourfold increase in insulin secretion will almost 
completely inhibit net hepatic glucose production. 
 The mechanism by which insulin inhibits hepatic glucose production has 
been a topic of much interest and investigation. It is well known that the hepatic 
portal insulin concentration is greater than that seen in the systemic circulation in 
part due to insulin’s release into the portal vein. It is also well known that the liver 
degrades ~50% of the insulin that reaches it. It was assumed for many years that 
insulin’s ability to inhibit net hepatic glucose production was the result of a direct 
interaction of the hormone with its receptor on the hepatocyte. In 1987, Prager et 
al. (227) suggested that peripheral insulin infusion could suppress hepatic glucose 
production without any change in the portal insulin concentration, thus 
implicating an indirect mechanism of inhibition. This concept has since been 
supported by many investigators (2, 25, 111, 167, 258, 259). Sindelar et al.(258) 
showed that a selective rise in arterial insulin of almost four fold (when portal 
insulin was kept at basal levels) eventually led to the inhibition of hepatic glucose 
production by 50%. This was the same extent of inhibition that a selective rise in 
portal insulin (when arterial plasma insulin levels were kept basal) caused, yet the 
rise in portal insulin caused a significantly more rapid decrease in HGP. Sindelar 
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 et al. (258) went on to show that the decrease in hepatic glucose production was 
30% due to a drift down in the baseline with the remaining 70% due to the 
selective increase in insulin concentration.  
  The indirect effect of the selective rise in arterial insulin on the liver 
appeared to alter the gluconeogenic rate and the fate of glucose within the 
hepatocyte rather than affecting the rate of glycogenolysis. The rise in the arterial 
insulin caused a reduction in the availability of gluconeogenic precursors to the 
liver and therefore, net hepatic gluconeogenic precursor uptake fell. Lactate 
production, on the other hand, increased in response to the selective rise in arterial 
insulin. The source of this lactate was G-6-P which underwent glycolysis within 
the liver rather than being exported as glucose. There was a slight decrease in the 
glycogenolytic rate due to a small increase in liver sinusoidal insulin which 
resulted from the increase in arterial plasma insulin concentration.  
 The increase in net hepatic lactate production correlated in time with a 
decline in plasma nonesterifed fatty acids (NEFA) and a fall in net hepatic NEFA 
uptake. Thus, the fall in lipolysis may have explained the increase in net hepatic 
lactate output. In order to test this hypothesis, Sindelar et al. (259) again brought 
about a selective rise in the arterial plasma insulin concentration. In one group, 
they prevented the fall in the plasma NEFA and glycerol concentrations by 
infusing a lipid emulsion and heparin, while in the other group, neither lipid 
emulsion nor heparin was infused. In the group that did not receive the NEFA 
infusion, the results were similar to those seen in the previous studies. In the 
group that did receive the lipid emulsion and heparin infusion to prevent the fall 
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 in the plasma NEFA during the selective increase in arterial plasma insulin, the 
inhibition of net hepatic glucose output was reduced. The decrease in lipolysis 
could account for 50% of the fall in net hepatic glucose output caused by the 
selective rise in arterial insulin. Net hepatic lactate output did not increase when 
the NEFA levels were clamped. Thus the fall in net hepatic NEFA uptake 
triggered the re-direction of G-6-P to lactate rather than glucose. Clearly, the 
ability of the increase in arterial insulin concentration to suppress HGP was in 
part indirectly mediated by suppression of lipolysis (259).  
 Other investigators have also focused on this indirect mechanism of 
inhibition. Bergman and colleagues proposed the single gateway hypothesis by 
which the insulin that survives first pass degradation by the liver enters the 
systemic circulation where lipolysis is suppressed in the adipocyte. Their 
hypothesis posits that this reduction in NEFA then explains the fall in hepatic 
glucose production (2, 23).   
 Insulin can also indirectly affect net hepatic glucose production by acting 
on the α cell to inhibit glucagon secretion. It appears that insulin has a dose 
dependent effect on the suppression of glucagon which begins with a rise in 
arterial plasma insulin as small as 10 µU/ml (198). This is rather significant since 
glucagon has such a potent effect on glucose production by the liver. It has been 
shown in both dogs and humans that the insulin-induced suppression of α-cell 
function can explain a portion of the effect of a rise in systemic insulin on glucose 
production (110, 166). 
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  Although these indirect mechanisms do affect net hepatic glucose 
production, our lab has demonstrated that insulin within the liver sinusoids also 
potently regulates hepatic glucose production via a direct action. First, the effect 
of a selective rise in the liver sinusoidal insulin level was examined. Studies were 
carried out in the overnight fasted conscious dog in which portal vein (and thus 
liver sinusoidal) insulin concentrations were increased in the absence of any 
change in the arterial plasma level (258). Following a 40 min control period 
during which the pancreatic clamp was employed, the peripheral insulin infusion 
was terminated and the portal insulin infusion rate was increased to four fold 
basal. This resulted in an increase in the portal vein insulin from 18 to 32 µU/ml 
without any change in the arterial insulin concentration. Euglycemia was 
maintained by peripheral glucose infusion and glucagon was kept basal, as 
mentioned previously. NHGO dropped ~40% by 30 minutes and eventually 
decreased by 70%. This demonstrated the liver’s ability to respond quickly and 
sensitively to a selective rise in the liver sinusoidal insulin concentration. In 
addition, since there was no decrease in hepatic gluconeogenesis and no increase 
in net hepatic lactate output, the change in glucose production reflected a decrease 
in glycogenolysis.  
 The effects of a selective deficiency in the liver sinusoidal insulin 
concentration were then examined to verify the importance of the direct action of 
insulin on the liver (260). Again, the pancreatic clamp in the overnight fasted 
conscious dog was used. After establishing the clamp, the portal insulin infusion 
was terminated and a peripheral insulin infusion was started at half the portal 
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 infusion rate. The portal insulin concentration decreased from 25 µU/ml to 5 
µU/ml but the arterial insulin concentration remained unchanged. This selective 
decrease in hepatic sinusoidal insulin (∆ 15 µU/ml) was associated with a rapid 
(15min) increase in NHGO from ~1.5 mg/kg/min to ~5.5 mg/kg/min. NHGO 
declined thereafter. Gluconeogenesis by the liver did not increase during 
sinusoidal insulin deficiency, and net hepatic lactate output did not decrease. The 
rise in NHGO caused by the decline in liver sinusoidal insulin was a reflection of 
an increase in glycogenolysis. Thus, insulin acutely inhibits liver glucose output 
by directly effecting glycogenolysis and indirectly effecting glycolysis and/or 
gluconeogenesis. Thus in the case of endogenous insulin secretion, the direct 
action of the hormone is responsible for 60-85% of the hormone’s inhibitory 
effect on the liver with the remaining percentage being due to insulin’s ability to 
influence the liver indirectly by acting on muscle, fat, and the alpha cell (50). 
 Insulin also has an indirect effect on the liver through its action on the 
brain. It has been shown that hypothalamic insulin signaling is required for the 
inhibition of glucose production (211) in the rat. It has been previously shown that 
prolonged or chronic impairment of CNS insulin signaling leads to hyperphagia, 
increased plasma insulin levels, and decreased insulin sensitivity (40, 210). In a 
recent paper by Obici et al. (211), the infusion of insulin into the third cerebral 
ventricle suppressed glucose production independent of circulating levels of 
insulin and other glucoregulatory hormones. They also demonstrated that central 
antagonism of insulin signaling impairs the ability of circulating insulin to inhibit 
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 glucose production. Thus they concluded that the hypothalamus may also be a site 
of action of insulin on glucose production.  
 The concept of insulin having both a direct and indirect effect on hepatic 
glucose flux is critical since the normal insulin concentration gradient between the 
hepatic portal and systemic circulation (with the hepatic portal circulation being 
higher) is reversed in diabetic patients who are treated with subcutaneously 
injected insulin, creating higher systemic (arterial) than portal vein insulin 
concentrations.  
 Subcutaneously administered insulin is initially absorbed into the 
peripheral circulation of individuals with diabetes, resulting in fat and muscle 
being exposed to higher insulin levels than the liver. This peripheral 
hyperinsulinemia predisposes the individual to hypoglycemia and is thought to be 
linked to weight gain and other metabolic abnormalities which in turn can lead to 
microvascular and macrovascular disease (148). It has been shown that agents 
capable of rapidly increasing the insulin concentration in response to a glucose 
challenge are good regulators of hepatic glucose metabolism and are more 
effective controllers of post-prandial glucose concentrations than peripherally 
delivered insulin (38).For example, studies with Lispro, an insulin analog that 
provides faster systemic absorption from subcutaneous depots due to its greater 
water solubility (219), have consistently demonstrated that a rapid onset of action 
can lead to improvement in post-prandial blood glucose control (124, 125, 132). 
One problem with such rapid-acting insulin analogs is that the duration of action 
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 may be too short to provide optimal post-prandial control, as indicated by rising 
glucose levels in the postabsorptive state (59, 76).   
 More recently, the pulmonary delivery of insulin (Exubera, Pfizer) has 
been studied as an alternative method of insulin administration. It has been shown 
that inhaled insulin also has a rapid onset of action similar to that seen with the 
rapid acting insulin analogs and is considerably faster than regular insulin (230). 
The metabolic activity of such inhaled insulins declines more slowly than that of 
Lispro (230) but faster than that of Humulin. The intermediate absorption pattern 
may result from the pulmonary absorption of insulin being dependent on the size 
and dissociation rate of the particles and their aggregates (142, 143).   
 If insulin could be given orally, a normal portal vein/arterial insulin 
distribution could be restored. With the right pharmacokinetics, an oral insulin 
would eliminate the disproportionately high peripheral insulin levels while still 
delivering adequate amounts of insulin to the liver, thereby potentially being 
useful as a therapeutic agent.  
 The release of insulin in response to a glucose challenge is biphasic in 
nature with an early phase and a late phase. The early phase consists of two parts: 
a cephalic phase and a first phase. The cephalic phase is rapid (within 2 minutes 
after a meal) yet very small, only increasing arterial plasma insulin levels by ~5 
µU/ml. The more pronounced first phase occurs 5-10 minutes postprandially and 
is dependent on the amount of glucose present (285). The liver responds quickly, 
such that the first phase insulin pulse inhibits glucose production and/or causes an 
increase in hepatic glucose uptake in the presence of an oral glucose load (52). 
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 The way in which the liver responds to the first phase insulin release during a 
glucose challenge has been shown to affect subsequent plasma glucose responses 
and thus is critical in maintaining normal glycemia (75, 108). The late (second) 
phase of insulin release has a lower absolute peak but also plays a significant role 
in glucoregulation over the 2-3 hours following a meal challenge.  
People with Type 2 diabetes typically demonstrate a diminished or brief first 
phase insulin release. They often have an enhanced second phase insulin release 
so as to compensate for this loss (75). Loss of first phase insulin release has many 
metabolic implications. It is clear that it causes a significant impairment in the 
suppression of hepatic glucose production post-prandially. In a study carried out 
by Luzi and De Fronzo (172) abolition of the first phase insulin secretion by 
somatostatin caused the liver to continually produce glucose despite the subjects 
being both hyperglycemic and hyperinsulinemic. When first phase insulin was 
replaced, there was a complete normalization of the suppression of hepatic 
glucose production. Bruce et al (38)corrected a deficiency in early prandial insulin 
secretion using three different approaches in individuals with type 2 diabetes. One 
group received insulin (1.8 U total) over the first thirty minutes to simulate “first 
phase” insulin release following a glucose challenge. A second group received the 
same amount of exogenous insulin beginning thirty minutes post glucose 
challenge and continuing for 30 minutes, simulating “second phase” insulin 
release. A third group received the same amount of insulin again over the entire 
duration of the study, simulating both a first phase and second phase release. 
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 Postprandial glucose tolerance significantly improved in all individuals, even 
those who received only first phase insulin.  
 Previous experiments in our laboratory have looked at first and second 
phase insulin secretion in countering the action of glucagon on glucose turnover  
(262). Theses studies revealed that simulated first phase insulin was more 
effective than second phase in countering the glucagon effect. 
 In this context, specific aim 1 had two main intentions. The first was to 
examine the ability of first phase insulin release to modify net hepatic glucose 
uptake under conditions mimicking oral glucose loading in an insulinopenic state. 
The second was to explore whether a pulse of an insulin analog (hexyl-insulin 
monoconjugate 2, HIM2, Nobex Corp.), created to facilitate the absorption of 
orally delivered insulin, also has the ability to modify postprandial hepatic 
glucose metabolism.  
 
Glucagon Regulation of Hepatic Glucose Production 
 Hepatic glucose production is also affected by the plasma glucagon 
concentration. An increase in glucagon has been shown to rapidly increase net 
hepatic glucose output by stimulating glycogen breakdown with the effect on  
gluconeogenesis being rather modest (49, 56, 81, 280). A dose-response 
relationship between the liver sinusoidal glucagon levels and NHGO in the dog 
has been determined (47) and demonstrates several key features of the response to 
glucagon. First, basal plasma glucagon is found on the steepest part of the curve, 
indicating that small changes in hepatic sinusoidal glucagon levels will have 
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 significant effects on NHGO. Secondly, the curve plateaus at a concentration 
eightfold basal, which will rarely be seen in physiologic conditions. Thirdly, the 
half-maximally effective liver sinusoidal glucagon level is 110 ng/L, which is 
about 2.5 fold greater than that seen after an overnight fast in the canine. Thus it is 
clear that glucagon is an important regulator of NHGO and that its interaction 
with insulin allows for precise control of hepatic glucose output. 
 
Hepatic Glucose Uptake 
 
 Glucose ingestion results in significant hyperglycemia, as well as marked 
hyperinsulinemia and modest hypoglucagonemia. In a study by Abumrad et al.(1), 
conscious dogs received intragastric (mimicking oral) glucose at 1.63 g/kg. The 
arterial blood glucose concentration almost doubled, the plasma insulin level 
increased approximately 5 fold, and the plasma glucagon level fell minimally. 
The liver switched from a state of net hepatic glucose production during the basal 
period (~2 mg/kg/min) to a state of net hepatic glucose uptake during the glucose 
infusion period (~5 mg/kg/min).  
 There are three main factors that have been shown to impact net hepatic 
glucose uptake in response to an oral glucose tolerance test: the insulin 
concentration at the liver, the glucose load to the liver, and the portal glucose 
signal. These three factors work in concert with one another to bring about the 
resulting net hepatic glucose uptake. 
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 Effect of Hyperglycemia on Hepatic Glucose Uptake 
 Hyperglycemia brought about by a peripheral vein glucose infusion, in the 
presence of fixed basal levels of insulin and glucagon, will cause very little or no 
net glucose uptake by the liver (213). Studies in humans have demonstrated that 
an increase in the plasma glucose level to 125 mg/dl with basal insulin levels 
causes a decrease in net splanchnic glucose output from ~2.5 to 0.6 mg/kg/min 
but glucose uptake will not occur (69, 70). Doubling the hepatic glucose level in 
the dog, in the presence of basal insulin and glucagon, has similar results to those 
seen in the human, with a reduction in net hepatic glucose output from 2.2 to 0.9 
mg/kg/min but no evidence of net hepatic glucose uptake (53, 54). Thus 
hyperglycemia is able to reduce hepatic glucose production but, in the absence of 
an increase in insulin or oral/portal glucose delivery, it is unable to switch the 
liver to an uptake mode. 
 
Effect of Insulin on Hepatic Glucose Uptake 
 While the pancreas releases insulin in a pulsatile manner, many studies 
assessing the liver’s response to insulin have used constant infusion rates which 
create square waves. Our lab recently undertook a study to look at whether the 
secretion pattern of insulin in the presence of hyperglycemia influenced net 
hepatic glucose uptake and whether it entrained NHGU (117). This study 
demonstrated that NHGU was not augmented further by pulsatile insulin delivery 
compared to that of square wave delivery and that there was no entrainment in 
hepatic glucose metabolism. The authors concluded that the loss of insulin 
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 pulsatility likely has very little or no impact on the ability of insulin to regulate 
liver glucose uptake. Thus the manner by which insulin is administered, whether 
it be in a pulsatile fashion or a square wave, should not be a major consideration 
in the design of metabolic studies.  
 Hyperinsulinemia, under euglycemic conditions, is not very effective in 
promoting glucose uptake into the liver. In humans, in the presence of basal 
glucose levels and insulin levels greater than 100 µU/ml (8-10 times basal), net 
splanchnic glucose uptake was only 0.7 mg/kg/min (69). In euglycemic dogs, 
NHGU was 0.6 mg/kg/min in the presence of physiologic hyperinsulinemia (120 
µU/ml) (53) and only pharmacological concentrations of insulin (2044 µU/ml) 
achieved rates of NHGU as high as 3.2 mg/kg/min (179). Thus insulin alone is 
able to cause the liver to take up some glucose yet it is only at high concentrations 
that NHGU occurs at a significant rate. 
 NHGU increases in the presence of the combination of hyperinsulinemia 
and hyperglycemia brought about by a peripheral vein glucose infusion. In 
humans, the combination of hyperglycemia (plasma levels of 175-225 mg/dl) and 
hyperinsulinemia (arterial levels of 40-55 µU/ml) resulted in rates of net 
splanchnic glucose uptake of 1.0 to 1.6 mg/kg/min (69-71, 239). In the dog, 
arterial plasma glucose levels of 160-290 mg/dl and insulin levels of 35-384 
µU/ml resulted in rates of NHGU between 1.0 and 2.9 mg/kg/min (4, 19, 53, 138, 
197, 199). Despite the increase in hepatic response to combined hyperglycemia 
and hyperinsulinemia, it is clear that these two variables cannot account for the 
peak rates of NHGU that are evident following glucose ingestion (up to 7.5 
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 mg/kg/min; (1, 19, 24, 71, 92, 138, 185). Thus, it appears that both humans and 
dogs require some signal, in addition to an increased plasma insulin level and 
glucose load to the liver, to ensure adequate hepatic glucose uptake after feeding. 
 
The “Portal Glucose Signal” Story 
 In agreement with the Abumrad et al.(1) study mentioned before, a human 
study by DeFronzo et al. (71) demonstrated the unique effects of oral glucose. In a 
control group, glucose was administered through an arm vein resulting in 
hyperglycemia and hyperinsulinemia. There was very little net splanchnic glucose 
uptake in response to this treatment (1.3 mg/kg/min). If glucose was then given 
orally and the intravenous glucose infusion rate was reduced in order to match the 
arterial plasma glucose levels seen during peripheral glucose infusion alone, 
splanchnic uptake increased almost 5 fold (5.9 mg/kg/min). The levels of insulin 
following the oral glucose ingestion were higher than those seen during the 
peripheral glucose administration and although the arterial plasma glucose levels 
were matched, there was an increase in glucose load to the liver in the group 
which received oral glucose. These increases in the arterial insulin concentration 
and the glucose load, however, were not large enough to account for the total 
increase in splanchnic uptake.  
 This discrepancy seen between NHGU during peripheral glucose delivery 
and portal glucose delivery was initially attributed to an incretin effect associated 
with the oral glucose delivery (69). Several laboratories have shown since, 
though, that intraportal administration of glucose can mimic the results seen with 
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 oral glucose delivery (24, 138). This enhancement of NHGU by portal glucose 
delivery versus peripheral glucose delivery has been attributed to a  “portal 
glucose signal” (3). 
 Adkins et al. sought to determine if portal glucose delivery, which would 
generate a negative A-P (arterial-portal) glucose gradient, in the presence of 
hyperinsulinemia, would alter net hepatic glucose uptake (4). A pancreatic clamp 
was used, with somatostatin infused, and glucagon was replaced at basal levels 
while the insulin infusion rate was adjusted until plasma glucose was stabilized at 
a euglycemic level. At the onset of the test period, the insulin infusion rate was 
quadrupled. In the first group, glucose was infused peripherally to double the 
arterial plasma glucose during the first test period. During the second test period, 
glucose was infused intraportally to match that which was seen with the 
peripheral glucose infusion. The order of the test periods was reversed in the 
second group. The rate at which glucose reached the liver in response to the 
peripheral and portal glucose infusions was not significantly different between the 
two groups. NHGU was 1.4±0.7 mg/kg/min in response to peripheral glucose 
infusion and hyperinsulinemia but 3.5±0.8 mg/kg/min in response to portal 
glucose infusion in the presence of hyperinsulinemia. A similar effect of portal 
glucose delivery was seen in another study by Adkins et al (3) in which insulin 
was kept basal. In the presence of basal insulin, peripherally induced 
hyperglycemia did not trigger NHGU. Intraportal glucose administration in the 
presence of basal insulin stimulated NHGU at a rate of 1.4±0.3 mg/kg/min, 
almost the same change that was seen with peripheral hyperglycemia and 
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 hyperinsulinemia. This suggests that the portal route of glucose delivery and 
hyperinsulinemia have an additive effect in enhancing NHGU.  
 
The Relationship between the Portal Glucose Signal, Hepatic Glucose Load, and 
Insulin 
 In 1991, Myers et al examined the relationship between the portal signal, 
the hepatic insulin level, and the hepatic glucose load more extensively (197, 
199). In the first study (199), a pancreatic clamp was used and the arterial insulin 
level was increased by intraportal insulin infusion at two-, four-, or eight-fold 
basal during three 90 minute periods in two separate groups. Glucagon was kept 
basal throughout in both groups. In the first group, glucose was infused through a 
peripheral vein and was adjusted to match the arterial blood glucose 
concentrations across the three periods of differing insulin concentrations. In the 
second group, glucose was infused intraportally (~4-5 mg/kg/min) throughout the 
study and a peripheral glucose infusion was used to match the hepatic glucose 
loads in the second group to those in the first group. In the first group, NHGU was 
0.6±0.3, 1.5±0.4 and 3.0±0.8 mg/kg/min, respectively, in the 3 insulin infusion 
periods. When a portion of the glucose was infused intraportally, NHGU was two 
to three fold greater than the respective peripheral glucose periods (2.0±0.5, 
3.7±0.7, and 5.5±0.9 mg/kg/min) than when it was not. Thus at an arterial insulin 
level which was fourfold basal in the presence of hyperglycemia, insulin could 
account for roughly 60% of the increase in net hepatic glucose uptake with the 
remaining 40% attributable to the portal glucose signal.   
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  Interestingly, in the complete absence of insulin, brought about either by 
pancreatectomy or by suppression of insulin secretion by somatostatin, the liver 
did not respond to portal glucose delivery, indicating that the augmented hepatic 
response to intraportal glucose delivery requires the permissive presence of 
insulin (216). 
 In a following study (197), glucagon was again kept basal while insulin 
was maintained at fourfold basal with the use of the pancreatic clamp. In the first 
group, a peripheral glucose infusion was used to increase the load of the glucose 
reaching the liver by ~65, 140, and 220% in three 90 minute periods. In the 
second group an intraportal glucose infusion was begun at the start of the first 
period (~10 mg/kg/min) and a peripheral glucose infusion was used to match the 
hepatic glucose load that was seen in the corresponding periods of group one. In 
the absence of the portal glucose signal, NHGU was 1.2±0.4, 2.8±0.8, and 
5.1±1.2 mg/kg/min in the three periods, respectively. In the second group, which 
received a portal glucose infusion, NHGU was 3.8±0.4, 4.8±0.6, and 9.6±1.4 
mg/kg/min during the same time periods. NHGU was positively correlated with 
the hepatic glucose load regardless of the route of administration. However, at any 
given hepatic glucose load, NHGU was higher in the presence of intraportal 
glucose delivery than when glucose was infused peripherally. 
 Pagliassotti et al. (217) then went on to examine the relationship between 
NHGU and the magnitude of the negative A-P glucose gradient in the presence of 
a four-fold increase in insulin , basal glucagon, and a doubling of the hepatic 
glucose load. The magnitude of the A-P gradient was maintained by keeping the 
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 total amount of glucose infused constant but by varying the amount delivered 
peripherally or intraportally. When the A-P gradient was close to 0, NHGU was 
only 1.6 mg/kg/min. When the A-P gradient was -70 mg/dl, NHGU increased to 
7.6 mg/kg/min. The relationship between net NHGU and the A-P gradient is not 
linear. NHGU does not linearly increase with an increase in the magnitude of the 
A-P gradient past and A-P gradient of -20 mg/dl. These data indicate that the liver 
not only responds to the presence of a negative A-P gradient but the magnitude of 
the response is proportional to the magnitude of the gradient itself. In addition, in 
order to further augment NHGU, insulin and glucose must also be increased. 
  
NonHepatic Effects of the Portal Glucose Signal 
 Portal glucose delivery has a profound effect on the liver, but the question 
of how the portal glucose signal would effect nonhepatic glucose uptake was 
unanswered. In a study by Galassetti et al. (103), insulin was elevated three-fold 
while glucagon was replaced in basal amounts during somatostatin infusion. 
Arterial plasma glucose was clamped using a peripheral glucose infusion in one 
group. In the second group, a small amount of glucose was infused intraportally 
and the peripheral glucose infusion was adjusted to maintain similar glycemic 
levels between the two groups. The portal signal decreased glucose uptake by 
nonhepatic tissues by 40%. Simultaneous measurement of net glucose balance 
across the hindlimb (which is primarily muscle) confirmed that muscle was the 
site of this inhibition. This study also indicated that the portal signal inhibited 
nonhepatic glucose uptake in an amount equivalent to the enhancement of NHGU. 
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 This implies that that the portal signal does not increase whole body glucose 
clearance, but rather directs glucose to the liver and away from the muscle. This 
may be a way to ensure a balanced distribution of glucose following oral glucose 
consumption.  
 
The Portal Glucose Signal in Humans  
 The question arises as to the role of the portal glucose signal in the human. 
Much less is known regarding this phenomenon due to the inability to catheterize 
the portal vein in the human. This technical limitation leads the investigators to 
measure splanchnic uptake or whole body glucose uptake rather than net hepatic 
glucose uptake. 
 In the study of De Fronzo et al. (71) mentioned previously, a hepatic vein 
catheterization technique was used to determine whether the route of glucose 
delivery affects splanchnic glucose balance. In this study, they reported that net 
splanchnic balance was increased in the presence of ingested glucose despite the 
fact that the plasma glucose was maintained at 225 mg/dl. As previously 
mentioned, there was an increase in insulin concentrations following glucose 
ingestion as well as an increase in hepatic glucose load relative to the intravenous 
group. As noted earlier, the increases in insulin concentration and hepatic glucose 
load were not large enough to account for the entire increase in net hepatic 
glucose uptake seen. 
 In another study by Radziuk et al. (228, 229) in which a dual-isotope 
technique was used, no differences in hepatic glycogen storage were found 
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 between intravenous and intraduodenal delivery of glucose. This study, however, 
was performed under non-steady state conditions and no attempt was made to 
control glycemic or insulinemic excursions.  
 To further clarify the role of the route of glucose delivery on splanchnic 
glucose uptake in the human, Fery et al. (94) explored the effects of intraduodenal 
and intravenous glucose infusions. Using tracer methods and indirect calorimetry, 
they observed that, at a constant infusion rate of 6 mg/kg/min intraduodenally or 
intravenously, the distribution of glucose between glycolysis, oxidation, and 
storage in the whole body was not affected by the route of administration. The 
conclusion was limited in that there were higher insulin levels and lower glucose 
levels during intraduodenal glucose infusion. It is also not surprising that whole 
body glucose metabolism was not affected since it has been previously 
demonstrated that the increase in net hepatic glucose uptake seen in the presence 
of portal glucose delivery is concomitant with a proportional decrease in 
nonhepatic glucose uptake thus having no effect on whole body glucose 
metabolism but rather a redistribution of glucose uptake (103). 
 Vella et al. (279)attempted to overcome the limitations of the Fery et al 
(94) study by using a hyperglycemic hyperinsulinemic clamp to examine the 
effects of the route of glucose administration. In these studies, the route of 
glucose administration did not appear to affect whole body glucose uptake or 
hepatic glycogen synthesis, as estimated by the hepatic UDP-glucose turnover. 
Splanchnic glucose extraction was slightly higher during intraduodenal glucose 
administration (16.4 vs 12.8%) than when compared to the saline. Intestinal 
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 glucose extraction in dogs and pigs ranges from 4-10% (1, 265). Therefore, 
hepatic glucose extraction in this experiment could have ranged from 12.4 vs 8.8 
to 6.4 vs 2.8% respectively, on the intraduodenal glucose and saline study days. 
Thus, the latter calculation would suggest as much as a two fold increase in 
hepatic glucose uptake during intraduodenal glucose administration. One 
limitation to these studies was that the tracer glucose was infused alone rather 
than with carrier glucose in the intravenous group due to the fear that a small 
amount of the carrier glucose could elicit an enteric signal. It is possible that the 
glucose tracer was metabolized in the gut in the absence of the carrier glucose, 
leading to an overestimation of splanchnic glucose extraction when saline was 
infused intraduodenally. In support of this, the ratio of splanchnic glucose 
extraction with intravenous infusion (intraduodenal saline) averaged 12.8%, 
which is significantly higher than the average of 4% previously reported by De 
Fronzo et al. (70). It is also possible that the infusion rate used in the study 
resulted in a portal signal in the human that was near a threshold value and 
therefore was not detected.  
 The most recent study comparing the effects of intraduodenal and 
intravenous glucose metabolism in the human was carried out by Fery et al. (95), 
again using a dual-isotope technique and indirect calorimetry. Unlike the initial 
studies done by Fery et al. (94), these studies were carried out in the presence of a 
hyperinsulinemic euglycemic clamp. Their data indicated that the sum of hepatic 
and peripheral glucose disposal is not significantly influenced by the route of 
glucose delivery.  One drawback to this study is the use of the euglycemic clamp. 
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 In order to mimic the postprandial situation, a hyperglycemic clamp would have 
been preferable but in order to control the insulin concentrations, somatostatin 
would have had to have been used and the authors feared that that it would inhibit 
splanchnic blood flow (281) and possibly delay intestinal glucose absorption 
(151). Another drawback is that the measurement of net first-pass splanchnic 
uptake is not necessarily representative of hepatic uptake. It underestimates true 
hepatic uptake since the enteral glucose initially taken up by the liver can be 
recycled after passage through G-6-P and/or glycogen. On the other hand, 
however, splanchnic uptake overestimates hepatic uptake by an amount 
equivalent to the extrahepatic splanchnic uptake, although this parameter has not 
been quantified in humans for technical reasons. In addition, the authors 
calculated first pass splanchnic uptake by subtracting the appearance of 
exogenous glucose from the total glucose infusion rate. This rendered a value of 
0.38 mg/kg/min in the peripheral glucose group and only 0.30 mg/kg/min in the 
group that received intraduodenal glucose. Since the first pass splanchnic uptake 
is larger in the absence than in the presence of the intraduodenal infusion, the 
accuracy of the calculation for uptake may be questioned. Based on the large 
background value, it is difficult to draw any conclusion from the intraduodenal 
data 
 Thus the portal glucose signal probably exists in humans but its magnitude 
is still in question. Since the portal signal has been demonstrated so clearly in rats 
and dogs, it is possible that the drawbacks and limitations in the human studies 
obscure the ability to detect such a signal. 
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The Effect of Other Nutrients on the Portal Glucose Signal 
 It is interesting to note that the concomitant intake of other nutrients 
modulates NHGU during portal glucose delivery. When gluconeogenic amino 
acids were infused simultaneously with portal glucose (190), a 50% reduction in 
NHGU in conscious dogs occurred, compared with portal glucose delivery alone. 
When these amino acids were infused peripherally rather than intraportally in the 
presence of portal glucose delivery, there was no effect on NHGU suggesting that 
there may exist competitive neural signaling or actual substrate competition when 
both glucose and amino acids are infused intraportally together. Peripheral 
infusion of a lipid emulsion in the presence of portal glucose delivery in 
euinsulinemic, hyperglycemic dogs also reduced NHGU by 50% (242). This 
effect was most likely the result of a small stimulation of hepatic glucose release 
and a small reduction in hepatic glucose uptake. In non-diabetic humans, when a 
lipid infusion was administered during oral glucose ingestion (in the presence and 
absence of a pancreatic clamp), net splanchnic glucose uptake was not reduced 
but splanchnic glucose output was stimulated and peripheral glucose uptake was 
reduced (233). 
 
Mechanism of Portal Signaling 
 It is clear that the route of glucose delivery, therefore, is an important 
regulator of net hepatic glucose uptake. It had been previously shown by Niijima 
and his coworkers (204) that there are glucose sensitive cells in the hepatic portal 
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 vein. Thus, they (204) hypothesized that portal glucose delivery might generate a 
unique signal important in regulating net hepatic glucose uptake. The questions 
then arise as to how the portal glucose signal is sensed and how this signal exerts 
its effects.  
 It is known that the portal glucose level can be sensed by glucose-sensitive 
cells in the portal vein that signal the brain by use of vagal afferent fibers (204). A 
likely site for sensing of the arterial glucose level is within the hypothalamus 
(175). Numerous neurophysiological studies have shown the existence of neural 
pathways that link the brain and the liver (97, 226) and that an intact nerve supply 
to the liver appears to be important for the normal response to intraduodenal or 
intraportal glucose delivery (5, 218). These observations suggest that the brain 
may play an important role in the generation of the portal signal.  
 Hsieh et al (133) examined whether the comparison of the brain arterial 
glucose level with the portal glucose level initiated the stimulatory effect of portal 
glucose delivery on NHGU. A pancreatic clamp was used and insulin was 
increased 4 fold while glucagon was replaced intraportally at basal levels. 
Glucose was infused intraportally at ~4 mg/kg/min in both groups and a 
peripheral glucose infusion was begun so that the glucose load to the liver could 
be quickly doubled. In one group, glucose was infused into four head arteries to 
eliminate the glucose gradient between the arterial blood in the head and the 
portal vein. The peripheral glucose infusion was adjusted to fix the glucose load 
to the liver at twofold basal. In the second group, saline was infused into the head 
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 instead of glucose and, again, the peripheral glucose infusion was adjusted to 
maintain a similar hepatic glucose load seen in the previous period.  
 The arterial-portal glucose gradients and the hepatic glucose loads were 
similar between the two groups. NHGU was ~4.3±0.7 and 4.5±0.8 mg/kg/min in 
the glucose and saline groups, respectively. Thus they concluded that the head 
arterial glucose level was not the reference standard used for comparison with the 
portal glucose level in the generation of the portal glucose signal.  
 Gardemann et al (106) and Stumpel and Jungermann (267) demonstrated 
that a negative glucose gradient between the hepatic artery and the portal vein 
could create a metabolic signal locally within the liver. Horikawa et al (131) 
reported that both portal vein and hepatic arterial glucose infusion stimulated 
NHGU in conscious dogs and that glucose sensors within the liver, rather than the 
portal vein, were involved in the augmentation of NHGU. Thus, attention turned 
towards the possibility of a reference site within the liver. 
 Hseih et al. (135) designed a study to clarify the role of the hepatic arterial 
glucose level in the generation of the portal glucose signal. Fourfold insulin and 
basal glucagon were replaced intraportally with the onset of a somatostatin 
infusion. In test period one, glucose was infused via a peripheral vein to double 
the hepatic glucose load in all groups. In test period two, saline was infused 
intraportally in the control group while two other groups received glucose 
intraportally at 4 mg/kg/min. In one of the portal glucose infusion groups, saline 
was simultaneously infused in the hepatic artery while the other portal glucose 
infusion group received a glucose infusion into the hepatic artery to eliminate the 
 32
 negative A-P glucose gradient. The effects of the portal signal on net hepatic 
glucose uptake were markedly reduced by the elimination of the hepatic A-P 
glucose gradient in the portal glucose infusion group that also received the 
glucose infusion into the hepatic artery. The authors then went on to suggest that 
the portal signal may be sensed within the liver and that the transduction of its 
effect may be mediated by the autonomic nervous system outside the liver. 
 Since the studies performed by Hsieh et al (133, 135) supported the 
hepatic artery as the primary reference site for the portal signal, a follow up study 
was then carried out by Moore et al. (187) in which the hepatic artery was ligated. 
They hypothesized that ligation of the hepatic artery would result in an 
enhancement of NHGU during peripheral glucose delivery since the hepatic 
arterial glucose concentration would always be perceived as less than that in the 
portal vein. They also hypothesized that NHGU would not be enhanced by portal 
glucose delivery, in comparison with peripheral glucose delivery, after hepatic 
artery ligation since the maximal effects of the negative A-P gradient would be 
present at all times. The results demonstrated that NHGU in response to glucose 
delivered via a peripheral vein was identical in the dogs with the hepatic artery 
ligation and in dogs with intact arteries. More importantly, they demonstrated that 
portal delivery of glucose in dogs that had undergone the ligation still resulted in a 
significant increase in NHGU as well as a tendency for a suppression of 
nonhepatic glucose uptake. These data suggested that the portal signal could 
exhibit its effect on both the liver and nonhepatic tissues in dogs with hepatic 
artery ligation. Therefore, it appears that there may be one or more reference sites 
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 for comparison of portal vein glucose concentrations, in addition to the hepatic 
artery. Thus the system appears to exhibit redundancy. 
 Although extensive research has been carried out relating to hepatic 
afferents and efferents in the euglycemic and hypoglycemic states (45, 127, 140, 
141, 157, 176, 221) less is known about the hyperglycemic state and it remains 
unclear how the portal signal may be mediated by these nerves. Total hepatic 
denervation eliminates the ability of the liver to discriminate between portal and 
peripheral glucose delivery (5), reinforcing the notion that the response to the 
portal glucose signal is neurally mediated (204, 237). In dogs with denervated 
livers, rates of NHGU with peripheral hyperglycemia are in between the 
minimum rate of NHGU seen with peripheral glucose infusion and the maximum 
rate of NHGU seen with portal glucose infusion, in dogs with intact liver 
innervation. In the presence of total hepatic denervation, portal glucose delivery 
has no effect on NHGU suggesting the loss of a neural signaling pathway with 
total denervation. 
 These data are compatible with the idea that, in the basal state, the net 
effect of hepatic innervation is to inhibit NHGU. During intraportal glucose 
infusion, modification of neural input to the liver allows the full stimulation of 
NHGU. In the presence of hepatic denervation both the inhibition by the intact 
nerves (sympathetic input) and the stimulation by the intact nerves 
(parasympathetic input) are lost and the NHGU rests somewhere in between the 
two extremes.  
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   It has also been shown that the portal glucose signal rapidly activates 
NHGU, independently of a rise in insulin. The speed of the response is consistent 
with neural mediation of the portal signal (214). Pagliassotti et al. (214) examined 
the time course of effects of the portal glucose signal on the liver. In this protocol, 
glucagon and insulin were kept at basal values using the pancreatic clamp in both 
the control and the experimental groups. In both groups, there was an initial 
hyperglycemic period to set NHGU to near zero followed by a period in which 
various signals occurred. This allowed the authors to look at the time course of 
induction of NHGU. In the control group, the pre-existing conditions were 
continued. In the first experimental group, glucose was infused intraportally while 
the peripheral glucose infusion was adjusted to match the glucose loads to the 
liver seen in the control group. In the absence of the portal signal, the liver took 
up a small amount of glucose (0.4 mg/kg/min). In the experimental group, when 
the portal signal was generated under the same experimental conditions, NHGU 
rapidly increased (within 15 minutes) to almost 3 mg/kg/min. In the second 
experimental group, the insulin level was increased four fold in the absence of a 
portal signal. The ability of fourfold basal insulin to increase NHGU to 3 
mg/kg/min took almost 5 times the amount of time (90 minutes) seen with the 
portal glucose signal (214). In the third experimental group, in which insulin was 
increased fourfold in the presence of a portal glucose signal, NHGU reached a 
maximum of ~4.3 mg/kg/min after 60 minutes. Thus the portal signal activates the 
liver much more quickly than would otherwise be the case. It has also been shown 
that the effect of the portal signal on liver and muscle can also be turned off very 
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 rapidly with the cessation of portal glucose infusion, indicating that uncoupling is 
very efficient (134, 136).  
 Since it has been suggested that the portal signal may be neurally 
mediated, the parasympathetic and sympathetic nerves that innervate the liver are 
of interest. Glucose-sensitive neurons in the portal vein (204) have a discharge 
rate that is inversely correlated with portal vein glucose concentration. The 
change in afferent firing is accompanied by an increase in efferent firing in the 
pancreatic branch of the vagus nerve and decreases in the efferent firing of the 
hepatic branch of the splanchnic nerve and the adrenal nerve (200). 
In the 1960’s, Shimazu et al (251, 252) showed that the autonomic nerves from 
the hypothalamus control glycogen metabolism. Fluro gold and transsynaptic 
tracer pseudorabies virus (PRV) techniques have confirmed the presence of both 
parasympathetic and sympathetic nerve terminals within the liver, as well as 
direct connections between hypothalamic centers and the liver (41, 77, 154). 
These autonomic nerves innervate the liver along three routes: the portal vein, the 
hepatic artery, and the bile ducts. Efferent innervation by both parasympathetic 
and sympathetic nerve fibers has been shown to be responsible for hepatic 
hemodynamics, bile flow regulation, and control of carbohydrate and lipid 
metabolism (275). 
 Sympathetic nerve fibers reach the liver through the celiac ganglia, celiac 
plexus, and the splanchnic nerves (134, 136, 247-249). The sympathetic fibers 
form an anterior plexus around the hepatic artery. Alexander showed that the 
hepatic artery receives only sympathetic fibers (12). The sympathetic efferents 
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 penetrate into the acinus, where they end with varicosities in the space of Disse 
close to the hepatocytes (232) and the hepatic stellate cells (31).  Stimulation of 
the sympathetic efferents results in an increase in glucose output by the liver 
through rapid activation of glycogen phosphorylase (247-249, 275) as well as an 
increase in PEPCK activity, thus stimulating glycogenolysis and gluconeogenesis 
(209).  
 Norepinephrine (NE), the major sympathetic neurotransmitter, affects 
glucose metabolism at the hepatocytes via α1- adrenergic receptors (16, 104, 271).  
Epinephrine exerts most of its glucoregulatory effects in both dogs and humans 
(28, 55, 74, 234) via the β2-adrenergic receptor (55) which is the predominate 
adrenergic receptor subtype found in the canine liver (164, 180). In vitro (61, 
128), norepinephrine has a very low affinity for this β2-adrenergic receptor  (7% 
that of epinephrine) Likewise, in vitro data has shown the NE has a high affinity 
for α1- adrenergic receptors  and it is this α-adrenergic receptor subtype that is 
found in the canine liver (61, 128, 164).  
 The liver and the gut extract a large percentage of infused norepinephrine 
(approximately 86-93% and 45-55%, respectively) (57).  High levels of plasma 
catecholamines increase NE spillover from both the liver and the gut, suggesting 
that the percentage of NE released from the presynaptic neurons that can possibly 
escape the synaptic cleft is increased in the presence of high circulating 
catecholamine levels.  
 Besides NE, sympathetic nerves can release other neuropeptides such as 
NPY and galanin. These have both been implicated in the regulation of hepatic 
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 glucose metabolism (196, 270). Intraportally delivered galanin, in contrast to 
NPY, potentiates the NE-mediated glucose output from hepatocytes without 
having the effect on hepatic blood flow that is seen when NE is infused into the 
hepatic artery of the anesthetized dog (195). Peripherally infused galanin does not 
potentiate glucose output, while NPY inhibits the NE-elicited hepatic glucose 
output (171). 
 Specific aim II in this thesis addresses the importance of the sympathetic 
nerves and their possible role in mediating the effects of the portal glucose 
delivery. The hypothesis is that the sympathetic nervous system exerts a 
restraining effect on hepatic glucose uptake that can be reversed by the entry of 
glucose into the portal vein. Since stimulation of the sympathetic nerves is able to 
increase glucose output, they may act as inhibitors to glucose uptake. Thus by 
eliminating the sympathetic nerves using selective hepatic sympathectomy (more 
information on this procedure can be found in chapter II, as well as in the 
experimental design and discussion of chapter IV), we expected an increase in 
NHGU in response to peripheral glucose infusion and a reduction in the 
augmentation of net hepatic glucose uptake in response to the portal glucose 
signal. 
 The parasympathetic fibers, on the other hand, form a posterior plexus 
around the portal vein. The postganglionic parasympathetic nerves are derived 
from ganglia located at the hepatic hilus and within the portal spaces (100). These 
parasympathetic fibers are separate from any aminergic nerves found in the area 
(14, 62, 181, 231, 261, 269). Stimulation of the parasympathetic efferents results 
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 in an increase in glycogen synthesis due to an activation of glycogen synthase and 
a decrease or complete inactivation of PEPCK activity (247-250). Therefore 
signals from the hypothalamus down regulate gluconeogenesis in the liver. There 
are only two reports that actually document intrahepatic parasympathetic ganglia. 
Retrograde tracing experiments and Fluro gold staining experiments, which will 
discriminate the autonomic ganglia and neurons, do not show any existence of 
intrahepatic ganglia (225). Therefore, significant direct vagal cholinergic 
innervation of the liver is doubtful. Rather, it is more likely that the vagal nerves 
indirectly control functions of the liver by affecting celiac ganglia or microganglia 
near the celiac artery (26, 27). Vagal preganglionic terminals have been found in 
the celiac ganglia as well as microganglia near the celiac artery (276).   
 Afferent signals also emanate from the liver. Afferent fibers constitute 
90% of the fibers in the hepatic vagus nerve (267). They have been shown to 
convey information regarding plasma glucose (241) and other nutrients, as well as 
to be responsible for osmoregulation, ionoreception, and baroreception (276). It is 
likely that net glucose uptake by the liver is the result of an equilibrium between 
inhibitory sympathetic input and stimulatory parasympathetic input. These 
contrasting inputs appear to be simultaneously present in the post-absorptive state. 
The stimulation of NHGU should therefore result in a reduction in sympathetic 
tone and an increase in parasympathetic tone, or both. 
 Several studies have examined the role of the parasympathetic nerves in 
bringing about the effect of the portal glucose signal. Stumpel and Jungermann 
(267) showed in the perfused rat liver that the effect of the portal signal could be 
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 abolished by the addition of atropine but mimicked by an infusion of 
acetylcholine into the portal vein, leading to the conclusion that the effect was 
mediated by the parasympathetic nerves. Shiota et al. showed that an adrenergic 
blockade (portal vein phentolamine and propanolol infusion) and coincident 
cholinergic stimulation (portal vein acetylcholine infusion), brought about in the 
presence of hyperinsulinemic, hyperglycemic conditions, increased NHGU by 1.8 
mg/kg/min when compared to controls (255). These results were inconclusive, 
however, because portal vein administration of acetylcholine caused an increase 
in hepatic artery blood flow, leading to a rise in the glucose and insulin loads to 
the liver. Thus the increase in NHGU may have been in part load dependent. The 
possibility also exists that the mediator which increased the hepatic blood flow 
may have also increased NHGU directly. Since increased hepatic artery flow does 
not occur in response to portal glucose delivery, this raises a question as to the 
relevance of the above finding.  
 Recently, Cardin et al (44) showed that in the presence of 
hyperinsulinemia and hyperglycemia brought about by portal glucose infusion, 
vagal blockade (using cooling coils), which interrupts parasympathetic firing 
(101), had no effect on NHGU. This result can be interpreted in several different 
ways. First, since glucose was given intraportally, afferent vagal firing may have 
been maximally decreased before the vagal cooling took place. This would imply 
that the vagal efferents are not involved in the response to the portal glucose 
signal because efferent vagal firing would also have been eliminated and if 
present, may have caused a decrease in NHGU. It is also possible that the vagus 
 40
 nerve does not play any role in the mediation of the portal glucose signal and thus 
vagal cooling would have no effect on NHGU.  Thus specific aim III was 
undertaken to further examine the role of the vagus nerves in the absence of the 
portal signal. Assuming that the vagus nerve does play a role in mediating the 
portal glucose signal, we hypothesized that in the absence of the portal glucose 
signal, decreasing vagal firing using the vagal cooling technique, would increase 
net hepatic glucose uptake in a similar manner to that seen with portal glucose 
delivery. 
 Although very little is known in respect to the mechanism by which the 
portal glucose signal affects glucose uptake by nonhepatic tissues, two major 
hypotheses have been proposed (183, 272, 289, 290). The first hypothesis 
involves the mediation by a neural reflex while the second hypothesis involves the 
release of a hepatic humoral factor. Minokoshi et al. (183) and Takahashi et al. 
(272) have shown that stimulation of the ventromedial hypothalamus alters 
skeletal and cardiac muscle glucose uptake. If the afferent fibers that reach the 
brain are stimulated and therefore there is a change in their firing rates, the 
efferent nerves, those which emanate away from the brain, will respond 
accordingly. The sympathetic fibers that are present in the ventromedial 
hypothalamus may represent one of the efferent pathways stemming from the 
brain after apparent afferent stimulation. 
  The humoral factor hypothesis is supported by the finding that, in the cat, 
surgical liver denervation decreases insulin sensitivity in the skeletal muscle (289, 
290) suggesting that there may exist a factor that is released from the liver that 
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 directly affects insulin sensitivity at the muscle. It has also been shown that 
muscle insulin sensitivity can be restored by intraportal (but not peripheral) 
infusion of acetylcholine, suggesting that hepatic sympathetic stimulation may 
also have a distant effect on skeletal muscle, presumably via a humoral factor 
released by the liver. This hypothesized humoral factor that may mediate these 
effects will be discussed more thoroughly later in this introduction. 
 
The Mechanism of Action of the Portal Glucose Signal 
 The portal glucose signal causes a rapid and large increase in net hepatic 
glucose uptake and, subsequently, enhances the intrahepatic level of glucose-6-
phosphate in the hepatocyte (47). This increase in glucose-6-phosphate may be 
due to an enhancement of glucokinase translocation in the liver by the portal 
glucose signal (47). In the unstimulated state, glucokinase is sequestered in the 
hepatocyte nucleus where it is bound to its regulatory protein (GKRP) (7, 278). 
Treatment with fructose leads to a rise in intracellular fructose-1-phosphate which 
in turn causes the dissociation of GK from GKRP. This dissociation then allows 
GK to exit the nucleus and enter the cytosol where it can catalyze the 
phosphorylation of glucose, thus promoting glucose entry into the hepatocyte. 
This in turn would cause a rise in G-6-P levels that could then activate glycogen 
synthase; these changes would then result in an increase in glucose uptake and 
glycogen storage, two characteristics of the portal glucose signal. 
 Pagliasssotti et al. (214) has also shown that both insulin and the portal 
signal have the ability to increase glycogen deposition by increasing glycogen 
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 synthase activity. Initially, when glucose uptake is increased in the presence of the 
portal signal and hyperinsulinemia, there is a spike in lactate due to the increase in 
G-6-P (possibly brought about by the activation of GK by the portal signal) and 
increased flux down the glycolytic pathway. This increase in lactate wanes with 
time as the G-6-P pool increases due to the continuous increase in glucose uptake. 
Once this G-6-P pool is large enough and the portal glucose signal and insulin 
have activated glycogen synthase, an increase in glycogen deposition can occur. It 
has been suggested that ~75% of the glucose that enters the portal vein is directed 
into glycogen in the presence of the portal glucose signal while the remainder 
appears to leave the liver as lactate (214). 
 
Other Mediators of Net Hepatic Glucose Uptake 
 Other mechanisms for regulating NHGU also exist. The effect of the 
portal signal may have a centrally neurally mediated component but it may also 
be composed of an intrahepatic reflex which could involve other 
neurotransmitters such as serotonin or nitric oxide.  
Serotonin 
 Peptidergic innervation of the liver includes both aminergic and 
cholinergic neurons which contain such neuropeptides as NPY, substance P, 
vasoactive intestinal peptide, glucagon-like peptide, somatostatin, and serotonin 
(10, 84, 266). These nerves are typically found associated with the branches of the 
portal vein, hepatic artery, bile duct in the connective tissue of portal tracts (177). 
Serotonin is localized in the enterochromaffin cells of the gastrointestinal mucosa 
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 and within neurons in the enteric nervous system (212). It can be released into the 
blood or into the lumen of the gut and thus eventually reach the hepatic portal 
vein. The 5-HT2B receptor for serotonin is known to be expressed in the liver and 
kidney in humans (36), implying that serotonin may have a direct effect on 
hepatocytes. It has also been shown that an intraportal injection of 5-HT resulted 
in a decrease in the afferent firing of the hepatic branch of the vagus nerve and a 
stimulation of the efferent firing in the pancreatic branch of the vagus (207), 
similar to the effect of intraportal glucose injection (201), suggesting that 5-HT 
may elicit a neural signal that could enhance NHGU.  
 The effect of serotonin (5-HT) on NHGU has been previously examined in 
our laboratory. Intraportal infusion of 5-HT enhanced NHGU and blunted 
nonhepatic glucose uptake under hyperglycemic, hyperinsulinemic conditions 
(191) but also caused an increase in circulating levels of catecholamines and 
cortisol, evidence of  gastrointestinal distress. To more clearly demonstrate that 
the enhancement of NHGU was serotonin dependent, a selective serotonin re-
uptake inhibitor (fluvoxamine) was administered intraportally (192). Similar 
studies were also carried out by infusing 5-hydroxytryptophan (5-HTP), a 
serotonin precursor, into the portal vein (192). Both 5-HTP and fluvoxamine 
enhanced NHGU without elevating circulating serotonin or catecholamine levels. 
Nitric Oxide 
 Nitric oxide, an important biological mediator, is synthesized during the 
catabolism of the amino acid L-arginine to L-citrulline by nitric oxide synthase 
(NOS). Three isoforms of NOS have been elucidated. Endothelial NOS (eNOS) 
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 and neuronal NOS (nNOS) are both constitutive isoforms that are dependent on 
Ca2+/calmodulin binding and activation. Inducible NOS (iNOS), which is not 
dependent on Ca2+/calmodulin binding and activation, appears ubiquitously in the 
body in response to immunologic or inflammatory stimuli. 
 NO influences numerous physiological processes in multiple organs and 
tissues. NO effects energy substrate balance (including fatty acids and glucose) in 
adipocytes, skeletal muscle, heart and the whole body (102). Since NO can 
modulate peripheral glucose metabolism as well as lipolysis, it is not surprising 
that NO alterations may play an important role in the evolution of insulin 
resistance and type 2 diabetes (186). Although high circulating levels of NO have 
been found in individuals with type 2 diabetes in comparison to those seen in 
healthy volunteers (18, 186), it appears that individuals with type 2 diabetes may 
be less sensitive to nitric oxide than healthy volunteers. It has also been postulated 
that eNOS gene polymorphisms may be susceptibility factors for 
hyperinsulinemia, insulin resistance and type 2 diabetes (186). It is of interest that 
dietary administration of L-arginine, the substrate required for NO production, 
reduced body weight, increased lipolysis, and increased oxidation of glucose in 
abdominal and epididymal adipose tissue in Zucker diabetic fatty rats (102). It 
also improved peripheral insulin sensitivity in patients with Type 2 diabetes (223). 
Intrahepatic nerves containing the neuroeffector nitric oxide (NO) have been 
identified in a variety of mammalian species (87-89, 220). Hepatocytes can be 
exposed to NO derived from neighboring Kupffer cells, endothelial and Ito cells 
as well as autogenously-derived NO (274). The anterior hepatic plexus is 
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 comprised of several capsaicin-sensitive sensory fibers (86) including nitrergic 
neurons (246). 
  NO clearly plays a role in the regulation of glucose uptake at the muscle. 
Both nNOS and eNOS are expressed in skeletal muscle, and NO is released from 
the muscle at rest and release is increased with the onset of exercise (149). NO 
potentiates insulin-stimulated muscle blood flow therefore increasing the glucose 
availability to the muscle and indirectly allowing for greater muscle glucose 
uptake (63). In vitro studies have suggested that NO may stimulate muscle 
glucose transport directly by increasing cell surface GLUT4 protein levels (90). 
More recently, Higaki et al. (129), showed that NO can increase muscle glucose 
uptake through a mechanism which is clearly distinct from both the insulin and 
contraction signaling pathways; this NO-stimulated glucose uptake may be 
associated with an activation of the α1 catalytic subunit of AMPK. 
 Lautt et al. (158-161) have recently described a novel neurohumoral 
mechanism by which hepatic sympathetic nerves, through permissive release of a 
putative hepatic insulin sensitizing substance (HISS), regulate the glucose 
disposal resulting from a bolus of insulin. According to this theory, immediately 
following a meal, the hepatic parasympathetic nerves increase NO concentrations 
which increase the release of HISS from the liver. HISS then stimulates peripheral 
glucose uptake and accounts for 50-60% of the glucose disposal that is seen 
following a bolus of insulin. HISS does not act as a true sensitizer but rather 
potentiates the glucose disposal induced by insulin administration. 
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  The parasympathetic signal involves the release of acetylcholine which in 
turn acts on hepatic muscarinic receptors, resulting in the production of  NO and 
the release of HISS (120, 240, 291). Sadri et al.(240) have shown that intraportal, 
but not systemic administration, of L-NAME, a nonselective NO synthase 
inhibitor, will cause significant insulin resistance at the peripheral tissues. 
Alternatively, intraportal, but not intravenous, administration of SIN-1 (3-
morphonylosydnonimide), a non-enzymatic NO donor, will restore insulin 
sensitivity in insulin resistant animal models (240). Following hepatic 
denervation, which results in a decrease in muscle insulin sensitivity, insulin 
responsiveness can be restored by intraportal administration of NO donors (224), 
indicating that there is a role for hepatically derived NO in insulin-mediated 
glucose disposal at the periphery. It has also been shown that hepatic glutathione 
levels, which are decreased by fasting and rapidly replenished during feeding, 
play an integral part of the HISS regulatory pathway (118) as does hepatic 
guanylyl cyclase (64).  
 Our earlier studies have exhibited a reciprocity between peripheral glucose 
uptake and hepatic glucose uptake in the presence of portal glucose delivery (3, 
134, 214). Since hepatically derived NO appears to have dramatic effects on 
peripheral glucose uptake, it is possible that NO may also demonstrate glucose 
regulatory ability at the liver. Both iNOS and eNOS have been found in 
hepatocytes while iNOS has also been localized to the hepatic Kupffer cells and 
Ito cells (11, 168). Under normal conditions, only eNOS can be found in the liver 
but iNOS can be rapidly upregulated in the liver under such conditions as 
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 endotoxemia, sepsis, infection, and liver regeneration (168). NO can elicit 
changes in hepatic metabolism either by exerting a direct effect on hepatic 
mechanisms such as uptake, storage, and clearance of glucose (123) or by 
exerting an indirect effect via the modulation of hepatic vascular tone(11). It is 
clear that NO may modulate both portal vein and hepatic artery resistance to 
hepatic blood flow via vasodilation (11) but little is known about NO’s ability to 
act directly on the liver.  
 Since NO is clearly an important mediator in insulin sensitivity at the 
muscle and in turn glucose uptake at the muscle, we hypothesized that NO would 
also have dramatic effects at the liver. Due to the reciprocity between hepatic and 
muscle glucose uptake, we hypothesized that NO may act as an inhibitor of 
hepatic glucose uptake. Thus in specific aim IV, a portal infusion of a nitric oxide 
donor, SIN-1, in the presence of the portal glucose signal, was used to increase 
NO levels at the liver and hepatic substrate balance was calculated in the presence 
and absence of this donor.  
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 CHAPTER II 
 
MATERIALS AND METHODS 
 
Animals and Surgical Procedures 
 
Animal Care 
 Experiments were conducted on 18h fasted conscious mongrel dogs (20-
28 kg) of either sex that had been fed once daily a meat (Kal Kan; Vernon, CA) 
and chow diet (Purina Lab Canine Diet No. 5006; Purina Mills, St Louis, MO) 
comprised of 52% carbohydrate, 31% protein, 11% fat, and 6% fiber, based on 
dry weight. Water was available ad libitum. Each dog was only used for one 
experiment. The surgical facility met the standards published by the American 
Association for the Accreditation of Laboratory Animal Care, and the Vanderbilt 
University Medical Center Animal Care Committee approved the protocols.  
 
Surgical Procedures 
 Approximately 16 days prior to the study, a laparotomy was performed 
under general anesthesia (0.01 mg/kg buprenophine HCl and prop, presurgery and 
1% isoflurane inhalation anesthetic during surgery) by making a midline incision 
1.5 cm caudal to the xyphoid process through the skin, subcutaneous layers and 
linea alba and extending caudally about 10 cm. A portion of the jejunum was 
exposed and a branch of a jejunal vein was selected for cannulation. The vein was 
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 separated from surrounding connective tissue and ligated with 4-0 silk (Ethicon, 
Inc., Sommerville, NJ). A silastic infusion catheter (0.03 in ID; Dow Corning 
Corp., Midland, MI) was inserted into the vessel through a small incision and 
passed anterograde until the catheter tip was at the next major jejunal vein 
junction. The catheter was secured in place with three ties of 4-0 silk. The 
jejunum was replaced in the abdomen and the spleen was exteriorized. One of the 
branches of the common splenic vein was cannulated in a similar manner to the 
jejunal vein and the spleen was then replaced in the abdomen. The jejunal and 
splenic catheters were used for intraportal infusion of pancreatic hormones 
(insulin and glucagon). 
 The liver was retracted, the left lateral lobe of the liver caudally and the 
central lobe cephalically. The left common hepatic vein and the left branch of the 
portal vein were exposed. A 14 gauge Angiocath (Benton Dickinson Vascular 
Access; Sandy, UT) was inserted in the left branch of the portal vein 2 cm from 
the central liver lobe. A silastic catheter (0.04 in ID) for blood sampling was 
inserted, advanced retrograde about 4 cm into the portal vein and secured with 
three ties of 4-0 silk through the adventitia of the vessel and around the catheter. 
An angiocath was inserted into the left common hepatic vein 2 cm from its exit 
from the left lateral lobe. A silastic sampling catheter (0.04 in ID) was inserted 
into the hole and passed retrograde 2 cm and secured into place with three ties of 
4-0 silk. These catheters were used for obtaining blood samples from the portal 
vein and hepatic vein, respectively. 
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  An arterial sampling catheter was inserted into the left femoral artery 
following a cut-down in the left inguinal region.  A 2 cm incision was made 
parallel to the vessel.  The femoral artery was isolated and ligated distally. The 
sampling catheter (0.04 in ID) was inserted and advanced 16 cm in order to place 
the tip of the catheter in the abdominal aorta.  Again, like all afore mentioned 
catheters, the catheter was secured, filled with heparinized saline (1U/ml; Abbott 
Laboratories, North Chicago, IL), knotted and placed in a subcutaneous pocket 
prior to closure of the skin. This catheter was used to obtain arterial blood.   
 For specific aim I, the duodenum was exposed, and a small incision was 
made through the duodenal mucose, 3-4 cm below the pylorus. A 0.08 in ID 
silastic catheter was then inserted through the incision and secured to the 
duodenum with a purse string stitch. This catheter was used for the infusion of 
glucose. 
 For specific aim II, selective sympathetic denervation or sham denervation 
occurred at the celiac nerve bundle near the common hepatic artery. The nerve 
fibers that heavily encased the common hepatic artery were resected from 1-2 cm 
distal to the origin of the hepatic artery at the celiac trunk to several cm past the 
hepatic branches of the common hepatic artery. The hepatic arterial branches 
themselves were also skeletonized and the gastroduodenal artery was stripped of 
nerves. All nerves surrounding the portal vein and its branches, as well as the 
vagus nerve, were left intact. 
 For specific aim III, hollow coils were placed around the vagus nerves in 
order to cool each vagus nerve thus eliminating signal transmission or for sham 
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 cooling. A ventral midline incision was made 3 cm superior to the manubrium of 
the sternum that extended 8 cm rostrally through the sternocephalicus muscle. 
Blunt dissection bilaterally through the anterior fascia and between the 
sternocleidomastoid and sternohyoid muscles provided exposure of the carotid 
sheaths. Each vagus nerve was carefully isolated from the carotid artery over a 
length of 4 cm. It was then elevated with umbilical tape to facilitate placement of 
the coil. Hollow stainless steel coils of ~1.5 cm in length and five complete 
revolutions (ID 0.04 in., OD 0.625 in) were placed around each vagus nerve 
(194). This length of coil was great enough to prevent saltation of nerve 
transmission over the block. Silastic tubing (ID 0.04 in., OD 0.085 in.) was 
secured to each end of each coil. The coils were then insulated with tygon tubing 
(ID 0.375 in., OD 0.129 in.) to prevent cooling of the surrounding tissue and 
carotid blood. The sternocephalicus muscle was sutured to the sternothyroideus 
muscle to create a wall between the nerve and carotid artery at the level of the coil 
on both sides of the neck. The end of the Silastic tubes were placed in a 
subcutaneous pocket and the incision was closed. The morning of the experiment, 
the Silastic tubes connected to the cooling coils were exteriorized from their 
subcutaneous pockets under local anesthesia (2% lidocaine: Abbott Laboratories, 
North Chicago, IL). The ends of the Silastic tubes connected to the vagal cooling 
coils were either connected to inflowing lines (ID 0.125 in., OD 0.25 in.) from the 
cooling bath or to outflowing lines to the collection reservoir. The vagus nerves 
were cooled by perfusing the previously implanted coils with a cold solution 
(50% methanol: 50% saline). A reservoir temperature in an isotemp refrigerated 
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 circulator bath (Digital Temperature Controller, PolyScience) of -10°C was 
associated with an exiting neck temperature of ~0°C and a bath return temperature 
of ~3°C and resulted in a vagal blockade. Effective cooling was confirmed by 
observation of a doubling in heart rate and bilateral Horner’s syndrome (44, 58, 
165, 243).  
 Sections of the portal vein and hepatic artery were exposed by retracting 
the duodenum laterally.  A small section of the portal vein was exposed by blunt 
dissection taking care not to disturb the nerve bundle located on the vessel.  A 6 
or 8 mm ID ultrasonic flow probe (Transonic Systems Inc, Ithaca, NY) was 
placed around the vessel.  A small portion of the common hepatic artery was also 
carefully exposed and a 3 mm ID ultrasonic flow probe was secured around the 
vessel.  The flow probes were used to determine portal vein and hepatic artery 
blood flow during experiments. The gastroduodenal vein was isolated and ligated 
to prevent blood from entering the portal vein beyond the site of the flow probe.  
Blood that would normally flow through the gastroduodenal vein was shunted 
through the caudal pancreatoduodenal vein draining the tail of the pancreas. The 
ultrasonic flow probe leads were positioned in the abdominal cavity and secured 
with the ends of the catheters to the abdominal wall.   
 The subcutaneous layer was closed with a continuous suture of 2-0 
chromic gut (Ethicon, Inc.).  The skin was closed with horizontal mattress sutures 
of 3-0 Dermalon (Ethicon, Inc.).  The dogs received penicillin G (Procaine; 
Anthony Products, Irwindale, CA) intramuscularly (106 U) immediately after 
surgery to minimize the possibility of infection.  Flunixin (Meglumine 50 mg/ml; 
 53
 Phoenix Scientific, Inc., St. Joseph, MO) was injected intramuscularly (1 mg/kg 
body weight) after wound closure for acute pain relief.  Animals awoke from 
surgery within 2 h, were active, and ate normally approximately 8 h after surgery.  
They also received 500 mg ampicillin (Principen; Bristol-Myers Squibb, 
Princeton, NJ) orally twice a day for 3 days post-operatively or as needed.  
 All dogs studied had: 1) leukocyte count <18,000/mm3, 2) a hematocrit 
>35%, 3) a good appetite, and 4) normal stools at the time of study.  On the 
morning of the study, the free ends of the catheters and ultrasonic leads were 
removed from their subcutaneous pockets under local anesthesia (2% lidocaine; 
Abbott Laboratories, North Chicago, IL). The contents of each catheter were 
aspirated, and they were flushed with saline. Blunt needles (18 gauge; Monoject, 
St. Louis, MO) were inserted into the catheter ends and stopcocks (Medex, Inc, 
Hilliard, OH) were attached to prevent the backflow of blood between sampling 
times. Twenty gauge Angiocaths (Beckton Dickson) were inserted percutaneously 
into the left and right cephalic veins and into a saphenous vein for the infusion of 
tracers, dye and glucose, when appropriate. A continuous infusion of heparinized 
saline was started via the femoral artery at a rate to prevent any clotting in the 
line.  Animals were allowed to rest quietly in a Pavlov harness for 30 min before 
the experiments started. At the end of the experiment, dogs were euthanized with 
an intravenous injection of Euthansia-5 (Veterinary Laboratories, Inc., Lenexa, 
KS) and the position of the catheter tips was confirmed upon autopsy. 
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 Collection and Processing of Samples 
 
Blood Samples 
 Arterial and portal blood samples were taken simultaneously 
approximately 30 s before collection of the hepatic venous samples to compensate 
for the transit time of glucose the liver (115). Prior to sampling, a catheter was 
cleared of saline by withdrawing 5 ml of blood into a syringe. The blood sample 
was then drawn into a separate, pre-labeled syringes that had been flushed with 
heparinized saline (1U/ml; Abbott Laboratories, North Chicago, IL). After 
sampling, the blood taken during the clearing process was re-infused into the 
animal, and the catheter was then flushed with heparinized saline (1U/ml; Abbott 
Laboratories, North Chicago, IL). Before the experiment started, a blood sample 
was drawn and centrifuged. The plasma from this blood sample was used for the 
preparation of hormone infusions, various recovery standards, and the 
indocyanine green standard curve.  After onset of the experiment, samples were 
taken at various time points depending on the specific protocol. If a glucose clamp 
was performed, small arterial samples of 0.3 ml were taken every 5 minutes for 
the measurement of the plasma glucose concentration. For all studies, no more 
than 20% of the animal’s total blood volume was withdrawn during the study, and 
two volumes of saline (0.9% sodium chloride; Baxter Healthcare Co., Deerfield, 
IL) were given for each volume of blood withdrawn. 
 Immediately after each sample was obtained, the blood was processed. A 
small arterial aliquot (20 µl) was used immediately for determination of the 
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 hematocrit in duplicate using capillary tubes (0.4 mm ID; Drummond Scientific 
Co., Broomall, PA). One ml of the collected blood was placed in a tube 
containing 20 ul of 0.2M glutathione (Sigma Chemical Co.) and 1.8 mg EGTA 
(Sigma Chemical Co.) for catecholamine measurement. This tube was vortexed, 
centrifuged at 3000 rpm for 7 minutes, and the supernatant was stored in a 
separate tube for later analysis. The remaining blood was placed in a tube 
containing potassium EDTA (1.6 mg EDTA/ml; Sarstedt, Newton, NC). After 
gentle mixing, 1 ml of whole blood containing EDTA was pipetted into a tube 
containing 3 ml of 4% perchloric acid (PCA; Fisher Scientific, Fair Lawn, New 
Jersey). The tube was vortexed, centrifuged, and the supernatant was stored in a 
separate tube for later analysis of metabolite levels. A portion of this sample was 
used for the measurement of lactate in all of the specific aims and glycerol in 
specific aims I, II, and IV. The remainder of the whole blood containing EDTA 
was also centrifuged, to obtain plasma. 
 The plasma samples were used for all other measurements. Glucose 
concentrations were immediately determined on at least four 10 µl aliquots of 
plasma using the glucose oxidase method with a glucose analyzer (Beckman 
Instruments, Inc., Fullerton CA or Analox Instruments; Lunenburg, MA).  Insulin, 
non-esterified fatty acids (NEFA), and cortisol were measured from aliquots of 
plasma (1.0, 1.0, and 0.5 ml respectively). Glucagon was processed for future 
measurement; 1 ml aliquot of plasma was added to 50 µl of 10,000 KIU/ml 
aprotinin (Trasylol; FBA Pharmaceuticals, New York, NY) a protease inhibitor. 
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  Plasma for measurement of NEFA was frozen immediately in dry ice to 
inhibit lipase activity, while the remainder of the samples remained on ice 
throughout the experiment. The arterial and hepatic insulin samples were used for 
measurement of indocyanine green, as will be described later, and then frozen at -
70ºC until insulin was measured. All solutions were placed at -70ºC after the 
experiment until assays were completed.  
 
Tissue Samples 
 After completion of the experiment in all of the protocols, the animal was 
euthanized with pentobarbital (390 mg/ml Fatal-Plus; Vortech Pharmceutical Inc., 
Dearborn, MI) at 1ml/5kg. In specific aim II, the laparotomy incision was 
reopened and samples from each of the seven lobes of the liver were taken from 
all 9 dogs in each group for analysis of liver norepinephrine content by HPLC. 
This was done to ensure complete sympathetic denervation. In specific aim III, 
the liver was examined for signs of ischemia and damage due to the presence of 
the vagal cooling coils. 
 
Sample Analysis 
 
Plasma Glucose 
 Plasma glucose levels were determine during the experiment using the 
glucose oxidase method (145) with a Beckman glucose analyzer (Beckman 
Instruments, Fullerton, CA). The reaction sequence was as follows: 
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    glucose oxidase 
α-D-glucose + O2 -------------------------------------Æ gluconic acid and H2O2        (1) 
 
    catalase 
H2O2 + ethanol -------------------------------------Æ acetaldehyde + H20        (2) 
 
   molybdate 
H2O2 + 2H+ + 2I- -------------------------------------ÆI2 +2 H20         (3) 
 
The plasma glucose concentration is proportional to the rate of oxygen (O2) 
consumption, and the glucose level in the unknown plasma samples is determined 
by comparison with the rate of oxygen consumption in a standard solution. The 
second and third reactions quickly remove all hydrogen peroxide (H2O2), so that 
there is no end-product inhibition of the process. Glucose was measured a 
minimum of 4 times at each sampling time point for each vessel and a minimum 
of 2 times for samples drawn to clamp glucose.  
 
Plasma Non-esterified Fatty Acid (NEFA) 
 Plasma NEFA levels were determined spectrophotometrically using the 
Packard Multi Probe Robotic Liquid Handling System (Perkin Elmer; Shelton, 
CT) and a kit from Wako Chemicals (Richmond, VA). In essence, coenzyme A 
(CoA) is acylated by fatty acids in the presence of added acyl-CoA synthetase. 
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 The acyl-CoA that results is oxidized by acyl-CoA oxidase, leaving H2O2 as a 
byproduct. Subsequent addition of peroxidase, in the presence of H2O2, allows for 
oxidative condensation of 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline with 4- 
aminoantipyrine to form a purple colored adduct. The purple color adduct optical 
density is measured at 550 nm and is proportional to the NEFA concentration in 
the sample. The NEFA values are obtained from a calibration curve with known 
amounts of oleic acid. The reactions were run at 37ºC. The specific reactions were 
as follows: 
   Acyl-CoA synthetase 
NEFA + ATP + CoA -----------------------------Æ Acyl-CoA + AMP + Ppi         (4) 
 
   Acyl-CoA oxidase 
Acyl-CoA + O2  --------------------------------Æ 2,3-trans-enoyl-CoA + H2O2      (5) 
 
 
2 H2O2 + 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline + 4- aminoantipyrine 
     Peroxidase  
    --------------------------Æ Purple color adduct        (6) 
 
 
Whole Blood Metabolites: Lactate and Glycerol 
 Whole blood concentrations of lactate and glycerol were measured 
according to the method of Llyod et al (170) adapted to the Packard Multi Probe 
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 Robotic Liquid Handling System (Perkin Elmer; Shelton, CT). Enzymes and 
coenzymes for these metabolic assays were purchased from Sigma Chemical Co 
and Boehringer-Mannheim Biochemicals (Germany). The general reaction for the 
procedure involves the addition of an excess amount of NAD and an enzyme to 
the metabolite samples. NAD becomes reduced to NADH upon oxidation of the 
metabolite, and NADH has a native fluorescence that the oxidized form lacks. A 
fluorometer in the system detects changes in the florescence resulting from 
changes in NADH levels. The concentration of the metabolite present is 
proportional to the NADH produced. 
 Metabolites were measured from the PCA treated blood samples described 
under Sample Processing. A standard curve was constructed for each metabolite 
using known concentrations diluted in 3% PCA. Finally, each sample value was 
corrected for the dilution with PCA that had occurred during processing.  
The lactate assay involved the following reaction: 
   Lactate deyhdrogenase 
Lactate + NAD+ ---------------------------------------Æ Pyruvate + NADH + H+    (7) 
 
The enzyme buffer used was 0.24 M glycine, 0.25 M hydrazine dihydrochloride, 
and 7 mM EDTA, pH 9.6. The amount of NAD+ added was 4.6 mg and the 
amount of lactate dehydrogenase added was 0.1 U (to 10 ml of buffer). 
 The glycerol assays involved the following reaction: 
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   Glycerokinase 
Glycerol + ATP --------------------------------Æ L-glycerol-1phosphate + ADP    (8) 
 
     Glycerol-3phosphate dehydrogenase 
L-glycerol-1 phosphate + NAD+ -----------------------------------------------------Æ 
    Dihydroxyacetone phosphate + NADH + H+        (9) 
 
The enzyme buffer used was 0.09 M glycine, 1 mM hydrazine, and 0.01 mM 
MgCl2, pH 9.5. The amount of ATP added was 15.4 mg, the amount of 
Glycerokinase added was 0.3U, the amount of NAD+ added was 15.4 mg, and the 
amount of glycerol-3-phosphate dehydrogenase added was 0.6U (to 10 ml buffer). 
 
Hormones 
 The plasma levels of insulin, glucagon, and cortisol were measured using 
radioimmunoassay (RIA) techniques (284). In general, a sample containing an 
unknown amount of hormone was incubated with an antibody specific for that 
hormone. A known amount of radiolabeled hormone was added to the mixture to 
compete with the antibody binding sites. The sample was then treated so as to 
separate unbound hormone from the antibody-hormone complexes, generally by 
utilizing a double antibody procedure (single antibody procedure for cortisol) 
which caused precipitation of the bound complex. The radioactivity of the 
precipitate was measured via a Cobra II Gamma Counter (Packard Instrument Co, 
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 Meriden, CT). The binding of the radiolabeled hormone was inversely 
proportional to the amount of unlabeled hormone present, and a standard curve 
was constructed using known concentrations of the unlabelled hormone. 
Insulin 
 Immunoreactive plasma insulin was measured using a double antibody 
RIA as described previously (193). Insulin antibodies and 125I tracers were 
obtained from Linco Research Inc (St. Charles, MO). A 100 µl aliquot of the 
plasma sample was incubated for 18 h at 4ºC with 200 µl of  125I- labeled insulin 
and 100 µl of a guinea pig specific antibody to insulin. Next, the samples was 
incubated with 100 µl goat anti-guinea pig IgG (2nd antibody) and 100 µl IgG 
carrier for 30 min at 4ºC. One ml of wash buffer was added, and tubes were 
centrifuged at 3000 rpm. The liquid portion of the samples was decanted and the 
remaining pellet containing the total radioactivity bound to the antibody was 
counted in a Cobra II Gamma Counter. 
 The log of the amount of hormone in the samples was inversely 
proportional to the log of (bound label/fee label). The insulin concentration in 
each samples was determined by comparison to a standard curve obtained using 
known amounts of unlabeled hormone. The samples were corrected for non-
specific binding, and the sample detection range was 1-150 µU/ml. The antibody 
is specific to porcine, canine, and human insulin, but cross-reacts with bovine 
insulin (90%), human proinsulin (38%), and the split proinsulin products Des 
31,32 (47%) and Des 64,65 (72%). Overall, less than 15% of the basal insulin 
level is due to non-insulin material. There is no cross-reactivity with glucagon, 
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 pancreatic polypeptide, C-peptide, or somatostatin. The recovery for the assay 
was between 90-100% (based on spiking samples with known amounts of 
insulin), and the interassay coefficient of variation (CV) was approximately 7-8% 
for the entire range of the dose response curve.  
 HIM-2 in specific aim 1 was measured in the exact same manner as 
described above. A comparison of standard curves was performed using Humulin 
and HIM2. The two curves were similar but not identical, having slightly different 
ED50’s. When human insulin standards were used, the assay slightly 
underestimated (5%) HIM2 values at the high end of the standard curve (~150 
uU/mL) and slightly overestimated (20%) them at the lower end of the curve (~10 
uU/mL). At the mid points of the curves, the values were similar. Samples for 
insulin and HIM-2 were diluted when necessary to achieve a value near the mid 
point of the curve. 
Glucagon 
 Immunoreactive plasma glucagon was also measured using a double 
antibody RIA (Linco) (85). The protocol was modified by utilizing primary and 
secondary antibodies specific for glucagon (kit with glucagon antibodies and 125I 
tracers from Linco). A 100 µl aliquot of the samples was incubated for 24 h at 4ºC 
with 100 µl of guinea pig specific antibody to glucagon. Next, 100 µl 125I-labelled 
glucagon was added, and the solution was incubated for an additional 24 h at 4ºC. 
The samples was then incubated with 100 µl goat anti-guinea pig IgG (2nd 
antibody) and 100 µl IgG carrier for 2 h at 4ºC. One ml of wash buffer was added, 
and the tubes were centrifuged at 3000 rpm. The samples were decanted and the 
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 portion of total radioactivity bound to the antibody (pellet) was counted in a 
Cobra II Gamma Counter. 
 The log amount of hormone in the samples was inversely proportional to 
the log of (bound label/free label). The glucagon concentration in each sample 
was determined by comparison to a standard curve using known amounts of 
unlabeled hormone. The samples were corrected for non-specific binding, and the 
sample detection range was 20-400 pg/ml. The antibody is 100% specific for 
glucagon, with only slight cross reactivity with oxytomodulin (0.01%), and no 
cross reactivity with human insulin, human proinsulin, human C-peptide, 
somatostatin, pancreatic polypeptide, or glucagon like peptide-1. A protein effect 
in the assay causes zero glucagon to read as 15-20 pg/ml. This represents a stable, 
constant background in all samples. The recovery for the assay was between 80-
100%, and the interassay CV was approximately 6-10% for the entire range of the 
dose response curve.  
Cortisol 
 Immunoreactive plasma cortisol was measured with a single antibody 
technique (98) using a gamma coat RIA from Diagnostic Products Corporation 
(Los Angeles, CA). A 25 µl aliquot of plasma and 1 ml of 125I-labeled cortisol 
were pipetted into a cortisol specific antibody-coated tube with the antibody 
immobilized on the lower inner wall of the tube. They were incubated for 2 hours 
in a 31ºC water bath. Next, the tubes were decanted and rinsed with deionized 
water. The tubes were allowed to dry, then counted in a Cobra II Gamma Counter 
for 4 min. 
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  The log of the amount of hormone in the samples was inversely 
proportional to the log of (bound label/free label). The cortisol concentration in 
each sample was determined by comparison to a standard curve using known 
amounts of unlabeled hormone. The sample detection range was 0.5-50 ug/dl. The 
antibody is 100% specific for cortisol, with only slight cross-reactivity with 11-
deoxycortisol (6%) and 17-hydroxyprogesterone (1%), and no cross reactivity 
with corticosterone, aldosterone, progesterone, deoxycorticosterone, and 
tetrahydrocortisone. The recovery for the assays was > 90%, and the interassay 
CV was approximately 8-10% for the entire range of the dose response curve. 
Catecholamines 
 The catecholamines were the only hormones not measured by RIA. 
Instead, a high-performance liquid chromatography (HPLC) method was used to 
determine epinephrine and norepinephrine levels as previously described by 
Goldstein et al (113). Four hundred microliters of the plasma samples were 
partially purified by absorption to 10 mg of acid-washed alumina (Bioanalytical 
Systems, West Lafayette, IN) in 600 µl of Tris/EDTA, pH 8.6, and 50 µl of an 
internal standard (final concentration 500 pg/ml dihydroxybenzylamine (DHBA); 
Sigma Chemical Co.). Samples were shaken for 15 min, centrifuged for 4 min, 
and aspirated. The alumina pellet was rinsed with 2 ml water, then the solution 
was vortexed, centrifuged, and aspirated, and the process was repeated twice. 
Next, the catecholamines were eluted with 200 µl 0.1M perchloric acid (PCA) 
according to Anton and Sayre (15). 
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  Samples were then injected onto an HR-80, reverse phase, 3 µm 
octadecylsilane column. The mobile phase was composed of 14.2 g of disodium 
phosphate, 440 mg of sodium octyl sulfate, 37 mg of sodium EDTA, pH 3.4, and 
43 ml of methanol. The system utilized a Coulchem II Detector, Model 5021 
Conditioning Cell, and Model 5011 Analytical Cell (all obtained from ESA, 
Bedford, MA). Samples were measured against a linear calibration curve that was 
comprised of 5 standards(ranging from 50-1000 pg/ml) prepared from 
epinephrine bitartrate and (-)-arterenol bitartrate (norepinephrine) salts (Sigma 
Chemical Co.). In addition, a known amount of epinephrine and norepinephrine 
were added to the sample taken at the start of each experiment to ensure precise 
identification of the peaks, and to measure recovery. 
 Data reduction was performed with ESA 500 Chromatograph and data 
station software to identify peaks. The ratio of the peak height of the internal 
standard to the catecholamine was calculated, and the concentration of 
catecholamine was determined by comparison with the standard curve. The limit 
of detection of the assay was 20 pg/ml and 5 pg ml for epinephrine and 
norepinephrine, respectively. Recovery was between 80-100% for both hormones. 
The interassay CVs was 3-11% for epinephrine; the low and high ends of the 
curve resulted in large variances. The interassay CVs was 4-6% for 
norepinephrine for the entire range of the dose response curve. 
 To measure tissues catecholamines (liver), frozen tissue samples were 
ground into powder using mortars and pestles chilled in liquid nitrogen. Next, 5 
mM glutathione in 0.4 N perchloric acid was added to achieve 10% w:v extract. 
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 The solution was homogenized, the sample was centrifuged at 3000 rpm for 20 
min, and the supernatant was decanted and frozen at -70ºC. Epinephrine and 
norepinephrine were then measured by HPLC as described for the plasma 
catecholamine levels, and the concentrations were corrected for the dilution of 
samples. 
 
Blood Flow 
 Blood flow was determined directly in the hepatic artery and portal vein 
with the use of ultrasonic flow probes implanted during surgery. Total hepatic 
blood flow was also assessed using the indocyanine green (ICG) dye extraction 
method, according to Leevy et al (163). The results presented in this thesis were 
calculated using ultrasonic-determined flow, as this flow does not require an 
assumption about the distribution of arterial versus portal flow. ICG-determined 
flow was used as a backup measurement. However, the same conclusion were 
drawn when the ICG flows were used to calculate the data.  
 Ultrasonic flow probes allowed for instantaneous measurement of 
variation in velocity and provided blood flow in individual vessels. Each probe 
worked by determining the mean transit time of an ultrasonic signal passed back 
and forth between two transducers within the probe that were located upstream 
and downstream of the direction of blood flow in the vessel. The two transducers 
were piezoelectric, a material which is capable of both receiving and transmitting 
the ultrasonic signal. The downstream transducer first emitted an ultrasonic pulse 
into the blood vessel that was received upstream by a second transducer. After the 
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 upstream transducer received the ultrasonic signal, it re-emitted the ultrasonic 
pulse signal back to the downstream transducer. The transit time of each 
ultrasonic beam as measured by the upstream and downstream transducers (∆Tup 
and ∆Tdown, respectively) was defined by the following relationships: 
 
∆Tup = D / (vo – vx)        (10) 
 
∆Tdown  = D / (vo + vx)        (11) 
 
where D was the distance traveled by the ultrasonic beam within the acoustic 
window of the probe, vo was the phase velocity, or the speed of sound, in blood, 
and vx was the component of fluid velocity that was parallel or antiparallel to the 
phase velocity. The parallel component augmented the phase velocity when the 
signal was traveling in the same direction of blood flow, while the antiparallel 
component subtracted from phase velocity if the ultrasonic signal was moving 
against the flow of blood in the vessel. Combining the two expressions for transit 
time yielded the following equation: 
 
∆Tup - ∆Tdown  = (D / (vo – vx))-( D / (vo + vx))    (12) 
 
Since the transit times measured by both transducers, the distance traveled by the 
beam, and the speed of sound in blood were all known quantities, this equation 
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 was used to calculate vx. Once vx was attained, the transit velocity (V) of blood 
traveling through the vessel could be found according to the following equation: 
 
V cos θ = vx         (13) 
 
where θ was the angle between the centerline of the vessel and the ultrasonic 
beam axis. Finally, blood flow was determined as the product of the transit 
velocity and the cross-sectional area of the vessel. The cross-sectional area of the 
vessel was pre-determined by the size of the acoustic window according to the 
probe model. Since transit time was sampled at all points across the diameter of 
the vessel, volume flow was independent of the flow velocity profile. If a flow 
probe failed during the experiment, the missing values were estimated by one of 
two methods: either the mean blood flow for that vessel in a given protocol was 
used, or the values from the functional flow probes were subtracted from the 
corresponding ICG values (for example, values from the arterial flow probe were 
subtracted from the ICG vales to yield estimates of the portal vein flow). 
 The ICG method is based on the Fick principle, according to which the net 
balance of a substrate across an organ is equal to the concentration difference of 
the substrate across the organ multiplied by the blood flow through the organ. The 
equation can be rearranged to calculate hepatic blood flow from the ratio of 
hepatic ICG balance divided by the arteriovenous difference of ICG across the 
liver. Because the liver is assumed to be the only site of ICG clearance, hepatic 
ICG uptake is equal to the ICG infusion rate in steady state conditions. The 
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 extraction of ICG across the liver remains constant for brief infusions. However, 
if ICG is infused for a longer time (> 4 h), the dye level in the plasma gradually 
increases, resulting in a slight overestimation (5-10%) of hepatic blood flow 
(126). 
 Arterial and corresponding hepatic vein plasma samples were centrifuged 
at 3000 rpm for 30 min without the brake to pellet particulate matter. Optical 
density was then measured on a Spectronic spectrophotometer at 810 nm. The 
procedure was then repeated, and the values obtained for each sample were 
averaged. A standard curve was constructed by adding successive 5 µl aliquots of 
diluted dye (1:10 dilution) to 1 ml of plasma obtained from the animal before the 
dye infusion commenced. Hepatic plasma flow (HPF) was then calculated as 
follows: 
 
HPF= (IR x 10 x SCMD)/(dog weight (kg) x (0.005) x (A-H))  (14) 
 
where IR is the ICG infusion rate (ml/min), SCMD is the standard curve mean 
difference per 5 µl increments and A-H is the difference in absorbance between 
the arterial and the hepatic venous sample. The value of 10 was used to correct for 
the dilution of ICG used in the standard curve, and 0.005 was the volume in ml 
used as increments in the standard curve. Hepatic blood flow (HBF) was derived 
from HPF: 
 
HBF = HPF/(1-hematocrit)       (15) 
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Because this technique measured total hepatic blood flow only, the distribution of 
blood flow in the vessels supplying the liver was assumed. The normal 
distribution of flow was assumed to be 20% artery and 80% portal vein at 
baseline. However, flow distribution was altered during somatostatin infusion, 
since the latter decreases portal flow modestly. Flow distribution was therefore 
assumed to be 28% artery and 72% portal in the presence of somatostatin (116).  
 
Glucose Mixing in the Portal Vein 
 When glucose is infused in the slow, laminar flow of the portal vein, 
mixing of the glucose in the blood can be problematic. The paraaminohippuric 
acid (PAH) method was used in specific aims III and IV in this thesis to assess 
whether good mixing of glucose had occurred in the portal vein during intraportal 
glucose infusion. 
 The liver PAH method is based on the principle that this substance, not 
being extracted by the liver or erythrocytes, should maintain a constant 
concentration across the liver. PAH is mixed with the glucose that is infused in 
the portal vein, so that the PAH infusion rate is 0.4 mg/kg/min. The concentration 
of PAH is then measured on whole blood samples from arterial, portal venous, 
and hepatic venous blood (39). The assay involves a 1:5 dilution of the blood 
sample in a reagent solution (10 g p-dimethyamino-benzaldeyhyde, 600 ml 95% 
ethanol, 40 ml 2N HCl, deionized H2O up to 1000 ml). Light absorbance of the 
diluted samples is then measured on a spectrophotometer at 465 nm, and 
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 compared with a standard curve built with increasing PAH concentrations in 
blood drawn from the animal before the start of the PAH infusion. The ratio 
between the recovery of PAH in portal and hepatic veins, and the actual 
intraportal PAH infusion rate is then used as an index of mixing of the intraportal 
infusate with the blood entering and exiting the liver. A ratio of 1.0 would 
represent perfect mixing. 
 Because of the magnitude of the CV for assessing mixing, samples were 
considered unmixed if the hepatic vein PAH recovery was >140% or <60% of the 
actual amount of PAH infused. Animals were excluded from the study if poor 
mixing, as defined above, occurred in more than two out of the five time points of 
the intraportal glucose infusion period.  
 
Blood Pressure and Heart Rate 
 For specific aims III and IV, systolic and diastolic blood pressure and 
heart rate were determined throughout the experiments at each sampling time 
point using a Digi-Med Blood Pressure Analyzer (Micro-Med, Inc., Louisville, 
KY). 
 
Calculations 
 
Net Hepatic Substrate Balance 
 Both ICG and ultrasonic flow probes were used to estimate total hepatic 
blood flow in these studies via the arterio-venous difference technique. The net 
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 hepatic balances and net hepatic fractional extraction of blood glucose, lactate, 
glycerol, and plasma NEFA were calculated using both ultrasonic-determined and 
ICG-determined flow. As previously mentioned, the data shown are those 
calculated using ultrasonic-determined flow as this flow does not require an 
assumption about the distribution of arterial versus portal flow.  
 For both the indirect and direct method of calculation, the net balance of a 
substrate across an organ, otherwise known as the A-V difference technique, 
utilized the Fick Principle as described for ICG blood flow. In short, net hepatic 
substrate balance (NHSB) was calculated directly as the difference between the 
substrate load exiting the liver (Loadout) and the substrate load entering the liver 
(Loadin), as shown in the following equation: 
 
NHSB = Loadout - Loadin (D)       (16) 
 
The Loadout was calculated from the ultrasonic data according to the equation: 
 
Loadout = [S]H x HBF        (17) 
 
where [S]H is the substrate concentration in the hepatic vein and HBF is the total 
hepatic blood flow, as determined by adding the arterial flow to the portal vein 
flow. The hepatic artery supplies blood directly to the liver and the portal vein 
drains the digestive oranges and the spleen, and then supplies blood to the liver. 
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 Thus, Loadin (D) calculated from the ultrasonic data was the sum of the loads in 
the two vessels as calculated according to the following equation: 
 
Loadin (D) = ([S]A x ABF) + ([S]P x PBF)     (18) 
 
where [S]A and [S]P are substrate concentration sin the hepatic artery and the 
portal vein, respectively, and ABF and PBF are blood flow in the hepatic artery 
and the portal vein, respectively. For all glucose balance calculations, glucose 
concentrations were converted from plasma to blood values by using previously 
determined correction factors (CF: the mean of the ratio of the blood value to the 
plasma concentration for each period and for each blood vessel). Mean CFs 
during basal and experimental period were 0.74 and 0.74 for the artery, 0.74 and 
0.73 for the portal vein and 0.73 and 0.73 for the hepatic vein, respectively. (134, 
214). For NEFA calculations, plasma substrate concentrations and plasma flow 
were used rather than blood concentrations and blood flow. Plasma flow was 
determined by multiplying blood flow by (1-hematocrit). Positive numbers for net 
hepatic substrate balance indicate net production while negative numbers indicate 
net uptake. When the data were plotted as net hepatic uptake, positive values were 
used.  
 To circumvent any potential errors arising from incomplete mixing of 
glucose in the circulation during intraportal glucose infusion, a second, indirect 
method was also used for the calculation of the NHGU. This method differs from 
 74
 the direct calculation described above in that Loadin is determined using the 
equation: 
 
Loadin (I) = (GA X HBF) + GIRPO – GUG     (19) 
 
where GA is the arterial blood glucose concentration, GIRPO is the portal glucose 
infusion rate, and GUG is the uptake of glucose by the gastrointestinal tract. GUG 
is measured in each animal in the absence of intraportal glucose infusion, and this 
value is then corrected for differences in glucose load reaching the gut during 
intraportal infusion. The glucose balance data presented in the results sections of 
specific aims II, III, and IV of this thesis were determined by use of the indirect 
method; there was no statistical difference between using the indirect method 
versus the direct method. 
 Net hepatic fractional extraction (FE) was also calculated using ultrasonic-
determined blood flow according to the following equation: 
 
FE = NHSU / Loadin        (20) 
 
where NHSU is net hepatic substrate uptake and could represent NHGB. 
 Net hepatic substrate balances and net hepatic fractional extractions were 
also calculated using the ICG blood flow data. These calculations were performed 
to verify the ultrasonic results, and to ensure that conclusions drawn from either 
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 method were similar, as explained earlier. The only difference in the ICG method 
is that Loadin and Loadout were calculated difference as shown below: 
 
Loadout = [S]H x HBF        (21) 
 
Loadin = (0.28 x [S]A + 0.72 x [S]P) x HBF     (22) 
 
where HBF is total hepatic blood flow calculated using the ICG method, and 0.28 
and 0.72 are estimates of the normal distribution of flow in the artery and portal 
vein during somatostatin infusion (116) as explained earlier. 
 Limitations of the arterio-venous difference technique include: 1) 
variability of vascular anatomy and heterogeneity of tissue structure and function, 
2) imprecision in measurement of local blood flow, 3) measurement of net rather 
than absolute flux across the organ, and 4) access to the portal vein is required, 
making this procedure only useful in animals. In addition, transit time through the 
organ must be taken into account. Because arterio- venous difference represents 
net flux across an organ, it is most valid during steady state conditions.  
 
Nonhepatic Glucose Uptake and Clearance 
 Nonhepatic glucose uptake (nonHGU) was calculated over time intervals 
by the following overall equation: 
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 NonHGU = average total glucose infusion between T1 and T2 + (T1NHGB + 
 T2NHGB)/2 –glucose mass change in the pool    (23) 
   
where T1 and T2 represent the two time points for which the parameter is being 
measured over. Note that the ((T1NHGB + T2NHGB)/2) term will be a negative 
number in the presence of NHGU. The glucose mass change in the pool is 
calculated using the following equation: 
 
Glucose mass change in the pool = ((([GA]T2 - [GA]T1) / 100) *  
     ((0.22 * body wt in kg * 1000 *0.65) / body wt in kg)) / (T2-T1) (24) 
 
where [GA] is the blood glucose concentration, T1 and T2 are the two end time 
points of the interval, 0.22 represents the volume of extracellular fluid (the 
volume of distribution) or 22% of the dog’s weight (13), and 0.65 represents the 
pool fraction (65). 
 Nonhepatic glucose clearance was calculated using the following 
equation: 
 
Nonhepatic glucose clearance = NonHGU / (([GA]T1 + [GA]T2) /2 / 100) (25) 
 
where [GA] is the blood glucose concentration and T1 and T2 are the two end time 
points of the interval. 
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 Sinusoidal Hormone Concentrations 
 Because the liver is supplied by blood flow from both the hepatic artery 
and the portal vein, neither represents the true inflowing hepatic blood flow 
supply. For this reason, hepatic sinusoidal hormone levels (of insulin and 
glucagon) were calculated as follows: 
 
Hepatic Sinusoidal Hormone Level = [S]A x  (APF/TPF) +  [S]P x (PPF/TPF) (26) 
 
where A and P are arterial and portal vein plasma substrate concentration; APF 
and PPF are the arterial and portal vein plasma flow measured by the ultrasonic 
flow probes; TPF (total hepatic plasma flow) = APF + PPF.  Note this calculation 
represent the average inflowing hepatic sinusoidal hormone level, rather than the 
average sinusoidal level. 
 
Statistical Analysis  
 Data are expressed as means ± standard error of mean. The specific 
statistical tests used in the studies are described in the experimental design 
sections of Chapters III-VI.
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 CHAPTER III 
 
SIMULATED FIRST-PHASE INSULIN RELEASE USING HUMULIN OR 
HIM2 IS ASSOCIATED WITH PROLONGED IMPROVEMENT IN POST 
PRANDIAL GLYCEMIA 
 
Aim 
 The goals of specific aim 1 were two-fold. The first was to examine the 
ability of first phase insulin release to modify NHGU under conditions mimicking 
oral glucose loading in an insulinopenic state. The second was to explore whether 
a pulse of an insulin analog (hexyl-insulin monoconjugate 2, HIM2, Nobex 
Corp.), created to facilitate the absorption of orally delivered insulin, also has the 
ability to modify postprandial hepatic glucose metabolism.  
 
Experimental design 
 Each experiment consisted of a 100-min equilibration period (-140 to –40 
min), a 40-min basal period (-40 to 0 min), and a 270-min experimental period (0 
to 270 min). In all experiments, a constant infusion of indocyanine green dye 
(0.076mg/min) was initiated at –140 min. At 0 min, a constant infusion of 
somatostatin (SRIF) (0.5 µg⋅kg-1⋅min-1) was begun to suppress endogenous insulin 
and glucagon secretion, and glucagon (0.55 ng⋅kg-1⋅min-1) and human insulin 
(0.25mU⋅kg-1⋅min-1) were replaced intraportally to maintain basal levels in each 
protocol. The rate of SRIF infusion was lower than that used in past studies so 
that the inhibitory effect of the peptide on gastric emptying seen with higher SRIF 
doses could be eliminated. This rate of SRIF infusion did not affect gastric 
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 motility as indicated by the fact that 98% of the intraduodenal glucose that was 
infused was absorbed and yet both the insulin and glucagon levels were 
successfully clamped. Thus a somatostatin rate of 0.5 µg⋅kg-1⋅min-1 was adequate 
to clamp the pancreatic hormones while not impeding glucose absorption. 
  In the first group, insulin was infused into the portal vein at a basal rate of 
0.25 mU⋅kg-1⋅min-1 throughout the study (BI, n=6). In the second group, a pulse of 
human insulin was given into the portal vein from 0 to 5 minutes at an infusion 
rate of 10 mU⋅kg-1⋅min-1 to mimic first phase insulin release postprandially (HI, 
n=6) followed by basal insulin infusion as above. In the third group HIM2 (an 
orally active modified insulin created by the Nobex Corp. Ltd, North Carolina) 
was infused into the portal vein at 10 mU⋅kg-1⋅min-1 (HIM2, n=6) over five 
minutes followed by a basal infusion of human insulin as above. Glucose (50% 
dextrose) was infused peripherally at 5mg⋅kg-1⋅min-1 from 5 to 10 min and then at 
10mg⋅kg-1⋅min-1 from 10 to 15 minutes to prevent hypoglycemia from occurring. 
At 15 minutes, the duodenal glucose (20 % dextrose) infusion was started and 
continued at 5mg⋅kg –1⋅min –1 for the duration of the experiment. The purpose of 
the 15 minute delay in starting the duodenal glucose infusion was to simulate 
insulin dosing prior to a meal. Femoral artery, portal vein, and hepatic vein blood 
samples were taken every 20 min during the basal period (-40 to 0 min) and every 
30 min after t=30 minutes. 
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 Statistical Analysis 
  All data are presented as means ± SE. Time course data were analyzed 
with repeated-measures analysis of variance. Independent t-tests were used for 
any comparisons of mean data. Statistical significance was accepted at p<0.05 
 
Results 
 
Plasma glucagon and insulin concentrations: Arterial and liver sinusoidal 
plasma glucagon levels were basal throughout the study in all three groups (Table 
3.1). The arterial and liver sinusoidal plasma insulin levels in the basal insulin 
group remained basal (6 ± 1 and 18 ± 2 uU/ml respectively) throughout the 
experiment (Figure 3.1). The arterial plasma insulin level in the HI group rose 
rapidly and peaked at 52 ± 15 uU/ml while the liver sinusoidal insulin level 
peaked at 171 ± 66 uU/ml; these levels returned to baseline by 30 minutes. The 
arterial and liver sinusoidal plasma insulin levels in the HIM2 group peaked at 
164 ± 44 and 427 ±185 uU/ml respectively. These values did not return to 
baseline until ~ 1 hr. 
 
Net gut balance, glucose absorption, and arterial glucose level: Net gut 
glucose uptake was similar in all three groups during the control period and 
averaged 0.50 ± 0.05 mg/kg/min. The switch from net gut glucose uptake to net 
glucose output occurred about 10 minutes after the initiation of the intraduodenal 
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 glucose infusion in all three groups. Net gut glucose output averaged 3.7 ± 0.4 
mg/kg/min over the study period (Figure 3.2).  
Glucose absorption occurred at a steady state (4.9 ± 0.8 mg/kg/min) in the basal 
insulin group and caused the plasma glucose level to rise to a plateau of 265 ± 20 
mg/dl (Figure 3.2) during the last hour of the study. At steady state, glucose 
absorption accounted for 98% of the infused glucose; the remaining 2% was 
presumed to be metabolized by the gut.  
 In the group given a pulse of human insulin, glucose absorption was 
similar (4.8 ± 0.5 mg/kg/min) to that seen in the basal insulin group. In this case, 
however, the arterial plasma glucose rose less, reaching only 214± 15 mg/dl by 
the last hour of the study. Glucose absorption in the group given the pulse of the 
insulin analogue (HIM2) was identical to that in the other two groups (4.9 ± 0.5 
mg/kg/min) but the glycemic profile was markedly different. The rise in arterial 
plasma glucose occurred more slowly, eventually reaching a plateau of only 193 ± 
14 mg/dl during the last hour of the study. Despite very similar glucose absorption 
rates, the glycemic profiles in the three groups were markedly different indicating 
that the insulin spike augmented disposition of the absorbed glucose and resulted 
in glycemic improvement even 4.5 hours later.   
  
Hepatic glucose load, net hepatic glucose balance (NHGB), and hepatic 
fractional glucose extraction: Average hepatic blood flows were similar among 
the three groups.  In the BI group, the total blood flow was 33 ± 3 ml/kg/min 
while in the HI and HIM2 groups it was 36 ± 3 and 31 ± 4 ml/kg/min, 
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 respectively. At the end of the experiment, the hepatic glucose loads were 70 ±5, 
60 ± 1, and 50± 7 mg/kg/min in the BI, HI, and HIM2 groups, respectively ( p< 
0.05 in BI vs. HIM2, Figure 3.3).  
 During the basal period net hepatic glucose output was similar in all three 
groups (~1.7± 0.1 mg/kg/min). In the basal insulin group, it did not decrease 
significantly until 90 minutes after the initiation of glucose absorption. By the last 
hour of the study however, net hepatic glucose uptake (NHGU) occurred at the 
rate of 2.7 ± 0.7 mg/kg/min. Net hepatic glucose output (NGHO) declined more 
rapidly in the HI group, ceasing by 60 minutes and most rapidly in the HIM2 
group in which it ceased at 30 minutes. By the last hour of the study, NHGU was 
2.7 ± 0.6 and 2.0 ± 0.3 mg/kg/min in the HI and HIM2 groups respectively 
(Figure 3.3). At that time, the fractional extraction of glucose by the liver was 
approximately 3-5% in all three groups (Table 3.1). 
 
NEFA and glycerol: In the basal insulin group, glycerol levels and net hepatic 
glycerol uptake fell slightly and eventually plateaued (Figure 3.4). In the HI 
group, the glycerol levels and net hepatic glycerol uptake fell rapidly in the first 
15 minutes then rose slightly and then drifted down. In the HIM2 group, the 
glycerol levels and the net hepatic glycerol uptake fell rapidly over the first 30 
minutes, reached a minimum at 60 minutes and then drifted up slightly. By the 
end of the experiment, there were no significant differences in glycerol levels or 
net hepatic glycerol uptake among the three groups. In general, the plasma NEFA 
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 levels (Figure 3.5) and net hepatic NEFA uptakes paralleled the changes in 
glycerol.  
 
Lactate levels and hepatic balance: The liver exhibited net lactate uptake in the 
basal periods in all three groups and hyperglycemia resulted in a switch to net 
hepatic lactate output (Figure 3.6). At the end of the experiment, net hepatic 
lactate output was 11.2 ± 4.4, 8.8 ± 1.4, and 5.4 ± 3.2 umol/kg/min in the BI, HI, 
and HIM2 groups respectively. The arterial blood lactate levels steadily rose in all 
three groups due to the switch in net hepatic lactate balance and reached an 
average value of 1500 umol/L by the end of the experiment.  
 
Nonhepatic glucose uptake and nonhepatic glucose clearance: By the end of 
the experiment, the HIM2 pulse was associated with a significantly greater 
nonhepatic glucose clearance (1.61 ± 0.29 ml/kg/min) than basal insulin (BI= 0.62 
± 0.11 ml/kg/min) or the Humulin pulse (HI= 0.76 ± 0.26 ml/kg/min) (Fig 3.7).  
These differences in nonhepatic glucose clearances are also reflected in the 
nonhepatic glucose uptake values (Table 3.1). 
 
Discussion 
 These data indicate that simulation of first phase insulin release during an 
intraduodenal glucose infusion, given on the background of a pancreatic clamp, 
resulted in a significant improvement of the glycemic profile for as long as four 
hours. We also showed that a modified insulin (HIM2) molecule improved 
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 glycemia even more than Humulin, probably as a result of its modified 
pharmokinetics. It would appear that a pulse of insulin improves postprandial 
glycemia by two different mechanisms. The early blunting of the glycemic rise is 
mediated by a quick increase in NHGU while the later improvement is associated 
with an increase in nonhepatic glucose clearance. 
 Following the 5 minute pulse of human insulin, arterial plasma insulin 
levels rose rapidly and remained elevated for ~30 minutes.  Administration of 
HIM2 caused an elevation in plasma insulin levels that lasted almost 60 minutes. 
Despite infusion of the same amount of insulin in both groups, the HIM2 spike 
created a significantly higher arterial plasma insulin level than did the HI spike. 
The AUC for HIM2 was almost 3 times greater than that seen in the HI group. 
These data suggest that clearance of the insulin analog was significantly reduced 
relative to that of Humulin. HIM2 clearance was undoubtedly altered as a result of 
the structural modification of the molecule.  Its structure is composed of a single 
ampiphilic oligomer of low molecular weight covalently linked to a free amino 
group on the Lys-B29 residue of recombinant human insulin via an amide bond. It 
is readily absorbed due to its amphiphilic nature and has enhanced resistance to 
enzymatic degradation by enzymes, such as insulin protease(82), which is unable 
to reach its sites of action due to steric interference (264). It remains unclear 
whether the biological activity of HIM2 insulin was reduced relative to Humulin 
but since the HIM2 spike brought about an improvement in glycemia relative to 
the Humulin spike, any decrease in its biological action cannot have been in 
proportion to its altered clearance. It has also been suggested that HIM2 may have 
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 an increased binding affinity and/or capacity with the insulin receptor in such 
tissues as the liver and muscle; this increased binding affinity may differ from that 
which is seen with native insulin, thus leading to a more prolonged activation of 
the receptor itself (282).  
 Clearly any improvements in glycemia seen in response to the pulse of 
insulin cannot be due to the difference in glucose delivery since all three groups 
received glucose intraduodenally at the same rate. Furthermore, the calculated 
glucose absorption rate was identical in all three groups. Therefore, the difference 
in the arterial plasma glucose levels must be attributed to changes in glucose 
utilization. In the early part of the response (15-120 minutes), the liver ceased 
glucose production and began to take up glucose most rapidly in the HIM2 group.  
There are three major factors which control NHGU: the glucose load to the liver, 
the insulin level, and the portal signal (i.e. generated when the plasma glucose 
concentration in the portal vein is higher than the arterial plasma glucose 
concentration). In these experiments, the portal signal was the same in all three 
groups and thus the differences in NHGU must be related to the glucose load 
and/or the insulin concentration (214). The increased hepatic response in the 
Humulin group must have been attributable to the increase in insulin since the 
hepatic glucose loads over the first 2 hours in the BI and HI groups were equal. In 
the HIM2 group, the hepatic glucose load was less than that in the basal insulin 
group, but the insulin spike was much larger.  Clearly the latter therefore was 
responsible for the more rapid increase in NHGU seen in this group.  
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  At the end of the experiment, there were minimal differences between the 
three groups in either net hepatic glucose balance or hepatic fractional glucose 
extraction. The rate of NHGU was slightly less with HIM2 as a result of the 
decreased hepatic glucose load. Nevertheless, differences in NHGU cannot 
explain the prolonged improvement that the insulin spikes had on the arterial 
plasma glucose level. Instead it appears to be attributable to the effect of insulin 
on nonhepatic tissues.  This is somewhat surprising given that the plasma insulin 
levels returned to baseline no later than 60 min after dosing even in the HIM2 
group.  One possible explanation for the finding, however, is that the insulin 
levels in the interstitial fluid may still be elevated at these latter time points as 
suggested by Getty et al. (109). Additionally, altered insulin kinetics in the 
interstitial fluid may have prolonged the effect of HIM2 on nonhepatic tissues 
even further. In agreement with this, nonhepatic glucose clearance in the HIM2 
group was significantly greater than it was in the BI group. Nonhepatic glucose 
clearance in the HI group, on the other hand, was only slightly greater than that 
seen in the basal group. 
 Free fatty acids are known to alter muscle and liver glucose metabolism. 
There exists an inverse relationship between plasma free fatty acid concentrations 
and insulin sensitivity (256). In normal individuals, an increase in free fatty acids 
has been shown to cause hepatic insulin resistance by interfering with the normal 
suppression of glycogenolysis by insulin (34). Insulin resistance in skeletal 
muscle can also be attributed to an increase in fatty acids. Type 2 diabetics who 
are given nicotinic acid in order to induce a decrease in plasma FFA levels have a 
 87
 decrease in gluconeogenesis with no compensatory increase in glycogenolysis; 
this leads to an overall decrease in endogenous glucose production(33). It has 
been shown (259) that hepatic glucose production can be suppressed by an 
increase in peripheral insulin partly due to an inhibition of lipolysis. We have 
shown in the dog that FFA levels control the glycolytic flux in the liver(242). A 
fall in FFA levels and as a result in the net hepatic uptake of FFA, directs 
intrahepatic carbon into glycolysis eventually giving rise to lactate (259). Given 
that the FFAs fall most dramatically in the HIM2 group and substantially in the 
Humulin group, the early differences in net hepatic glucose output might in part 
be attributable to changes in plasma free fatty acid levels. Wajcberg et al. (282) 
have suggested that HIM2’s prolonged biological action may be attributed to a 
persistent suppressive effect on FFA. There may be a prolongation of antilipolysis 
due to an enhancement of HIM2 binding to the insulin receptors in the adipocytes. 
Unless these early changes in free fatty acids had a prolonged effect on glucose 
uptake by muscle, it seems unlikely that they were affecting the glucose profile 
towards the end of the experiments since the plasma FFA levels were similar in 
all three groups by then.  
 In summary, a brief 5 minute pulse of insulin infused intraportally at a rate 
of 10 mU/kg/min simulated the first phase insulin release seen postprandially, 
increased plasma insulin levels for 30 minutes, and eliminated net hepatic glucose 
production by 60 minutes. It still had a significant effect on plasma glucose levels 
4.5 hours later. HIM2 was cleared less efficiently than Humulin, resulting in 
higher plasma insulin levels at both the liver and the periphery. This pulse 
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 increased plasma insulin levels for almost 60 minutes, eliminated net hepatic 
glucose production by 30 minutes, and continued to have a significant effect on 
plasma glucose levels even at the end of the experiment (4.5 hours). These data 
demonstrate the ability of a brief burst of insulin secretion to result in prolonged 
glycemic improvement and speak to the importance of first phase insulin release 
in postprandial glucose homeostasis. They also point to the need to further 
evaluate the pharmacokinetic and pharmacodynamic properties of the HIM2 
insulin analogue. Subsequent comparison studies will be done using HIM2 and 
Humulin and matching the concentrations of insulin by adjusting the rates of 
infusion. Several other studies have also more recently examined oral doses of 
HIM2 in individuals with Type I diabetes, Type II diabetes, and nondiabetic 
subjects (60, 148, 282) and found them to be effective. Thus it should be possible 
to administer HIM2 via the oral route in future studies.
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Figure 3.1: Arterial plasma insulin (top) and liver sinusoidal plasma insulin 
(bottom) in 42-h-fasted conscious dogs maintained on a pancreatic clamp. During 
the experimental period, insulin was kept basal (BI), or Humulin spike (HI), and 
HIM2 spikes  (HIM2) were created on the background of basal insulin (n 
=6/group). SRIF, somatostatin; GGN, glucagon. Data are mean ± SE.     = P<0.05 
from BI † = P<0.05 from HI. 
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Figure 3.2: Net gut glucose balance (top) and arterial plasma glucose levels 
(bottom) in 42-h-fasted conscious dogs maintained on a pancreatic clamp during 
the basal and experimental periods in the BI, HI, and HIM2 groups (n = 6/group). 
Data are mean ± SE.    = P<0.05 from BI  † = P<0.05 from HI   
     BI (n=6)
     HI (n=6) 
     HIM2 (n=6) 
†
.  
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Figure 3.3: Net hepatic glucose balance (top) and hepatic glucose load (bottom) 
in 42-h-fasted conscious dogs maintained on a pancreatic clamp during the basal 
and experimental periods in the BI, HI, and HIM2 groups (n = 6/group). Data are 
mean ± SE.     = P<0.05 from BI  † = P<0.05 from HI 
. 
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Figure 3.4: Arterial blood glycerol levels (top) and net hepatic glycerol uptake 
(bottom) in 42-h-fasted conscious dogs maintained on a pancreatic clamp during 
the basal and experimental periods in the BI, HI, and HIM2 groups (n = 6/group). 
Data are mean ± SE.       = P<0.05 from BI  † = P<0.05 from HI. 
†
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Figure 3.5: Arterial plasma non-esterified fatty acid (NEFA) levels (top) and net 
hepatic NEFA uptake (bottom) in 42-h-fasted conscious dogs maintained on a 
pancreatic clamp during the basal and experimental periods in the BI, HI, and 
HIM2 groups (n = 6/group). Data are mean ± SE.     = P<0.05 from BI † = P<0.05 
from HI. 
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Figure 3.6: Arterial blood lactate levels (top) and net hepatic lactate balance 
(bottom) in 42-h-fasted conscious dogs maintained on a pancreatic clamp during 
the basal and experimental periods in the BI, HI, and HIM2 groups (n = 6/group). 
Data are mean ± SE.   = P<0.05 from BI  † = P<0.05 from HI. 
 
      
 95
  
 
 
 
 
0.0
0.5
1.0
1.5
2.0
BI HI
NON
HEPATIC
GLUCOSE
CLEARANCE
( ml/kg/min )
HIM2
BI  (n=6)
HI  (n=6)
HIM2  (n=6)
 
†
 
Figure 3.7: Non hepatic glucose clearance in 42-h-fasted conscious dogs 
maintained on a pancreatic clamp during the experimental period in the BI, HI, 
and HIM2 groups (n = 6/group). Data are mean ± SE..  * = P<0.05 from BI  † = 
P<0.05 from HI
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CHAPTER IV 
 
THE ROLE OF THE HEPATIC SYMPATHETIC NERVES IN THE 
REGULATION OF NET HEPATIC GLUCOSE UPTAKE AND THE 
MEDIATION OF THE PORTAL GLUCOSE SIGNAL 
 
Aim 
 Specific aim II was to examine the role of the sympathetic nerves in 
mediating the effects of the portal glucose delivery. We hypothesized that the 
sympathetic nervous system exerts a restraining effect on hepatic glucose uptake 
that can be reversed by the entry of glucose into the portal vein. We suggested 
that eliminating the sympathetic nerves using selective hepatic sympathectomy 
would result in an increase in NHGU in response to peripheral glucose infusion 
and a reduction in the augmentation of NHGU in response to the portal glucose 
signal. 
 
Experimental Design 
 Each experiment consisted of a 100-min equilibration period (-140 to –40 
min), a 40-min basal period (-40 to 0 min), and a 270-min experimental period (0 
to 270 min) which was divided into three 90 minute periods denoted as P1, P2, 
and P3. In all experiments, a constant infusion of indocyanine green dye 
(0.076mg/min) was initiated at –140 min. At 0 min, a constant infusion of 
somatostatin (0.8 µg⋅kg-1⋅min-1) was begun to suppress endogenous insulin and 
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 glucagon secretion. Glucagon (0.57 ng⋅kg-1⋅min-1) and insulin (0.3mU⋅kg-1⋅min-1) 
were then replaced intraportally at basal rates. In addition, a primed continuous 
peripheral infusion of 50% dextrose was begun at time 0 so that the blood glucose 
could quickly be clamped at the desired hyperglycemic level (~ 235 mg/dl).  
During P1 (t=0 to t=90), glucose was infused peripherally to double the hepatic 
glucose load (HGL) in both groups. During P2 (t=90 to t= 180), a portal glucose 
infusion of 20% dextrose at (3-4 mg/kg/min) was initiated to activate the portal 
signal, and the peripheral glucose infusion was decreased so that the same glucose 
load to the liver seen in P1 was maintained in P2. During P3 (t=180 to t=270), the 
portal glucose infusion was terminated and the peripheral glucose infusion was 
again adjusted to match the HGLs across the three periods. The peripheral glucose 
infusion rate was adjusted based on the plasma glucose levels and the hepatic 
blood flow in each individual dog. PAH was added to the portal glucose infusate 
to assess proper mixing with the blood in the portal and hepatic veins. In each 
group, 13 dogs were studied and 3 dogs were not included due to poor mixing as 
defined previously in the Methods section. In the control and denervated animals 
that were retained, the ratio of PAH recovery in the portal vein to the PAH 
infusion rate was 1.0±0.1 and 1.0±0.1 whereas the ratio of PAH recovery in the 
hepatic vein to the PAH infusion rate was 0.9±0.03 and 1.0±0.04, respectively.  
 Femoral artery, portal vein, and hepatic vein blood samples were taken 
every 20 min during the basal period (-40 to 0 min) and every 15 minutes for the 
last half hour of each experimental period (P1, P2, and P3). Arterial blood 
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 samples were also taken every 5 min from 0 to 270 minutes of the experimental 
period to allow changes to be made in the glucose infusion rate as necessary.  
 
Statistical Analysis 
 Time course data were analyzed with repeated-measures analysis of 
variance. Independent t-tests were used for any comparisons of mean data. 
Statistical significance was accepted at p<0.05. 
 
Results 
 
Hepatic sympathetic denervation: Liver norepinephrine levels (Table 4.1) were 
assessed using HPLC. The average norepinephrine level in the CON group was 
658 ± 68 ng/g liver while in the DEN group, it was only 10 ± 4 ng/g liver. These 
values indicate a >98% denervation.  
 
Arterial and portal plasma glucose levels: The arterial plasma glucose levels in 
the control group was 238±3, 236±7, and 242±3 mg/dl during P1, P2, and P3 
respectively while the portal vein plasma glucose levels were 235±3, 255±8, and 
239±3 mg/dl respectively (Figure 4.1a). The arterial plasma glucose levels 
(236±3, 223 ±3, 235±2 mg/dl) in the DEN group were similar to those seen in the 
control group as were the portal vein glucose levels (234±3, 243±4, and 233±2 
mg/dl) during P1, P2, and P3 respectively (Figure 4.1b). 
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 Arterial plasma and liver sinusoidal insulin and glucagon: Arterial and liver 
sinusoidal plasma insulin and glucagon levels were maintained at basal values 
throughout the experiment in both groups (Figure 4.2).  
  
Hepatic blood flow and glucose load: Hepatic blood flow (ml/kg/min) was 
similar in all three periods (P1, P2, and P3) in CON (32±2, 30±2, 32±2) and DEN 
(31±2, 32±2, 33±2) respectively (Table 4.2). Since the glucose levels and hepatic 
blood flows were similar in the two groups, there were no differences in the 
hepatic glucose load across time or between treatments (Table 4.2). The average 
HGLs (mg/kg/min) in the CON and DEN groups were 53±3 and 54±4 in P1, 55± 
3 and 55± 4 in P2, and 57± 3and 55± 5 in P3, respectively. There were no 
statistical differences in the total glucose infusion rates between the two groups 
across the three periods. The total glucose infusion rates (mg/kg/min) in P1, P2, 
and P3 were 3.5±0.4, 4.1±0.2, and 4.1±0.2 in the CON group, respectively. The 
total glucose infusion rates in the DEN group were 4.3±0.4, 4.8±0.5, and 4.6±0.3 
in P1, P2, and P3, respectively.   
  
Blood levels and net hepatic balance of lactate and glycerol: Both groups 
exhibited net lactate uptake in the basal period. Hyperglycemia resulted in a 
switch to net hepatic lactate output that was similar in both groups and constant 
over time. The arterial blood lactate levels rose steadily over the three periods in 
both groups due to net hepatic lactate output (Table 4.3). 
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  Arterial glycerol levels and net hepatic glycerol uptake fell rapidly in 
response to hyperglycemia in both groups and eventually plateaued at an average 
of  ~50 µmol/L and  ~1 µmol/kg/min (Table 4.3) respectively (no differences 
between groups). 
 
Net hepatic glucose balance and non-hepatic glucose uptake: Basal net hepatic 
glucose output was not statistically different between the two groups (1.8±0.3 and 
1.9±0.2 mg/kg/min in the CON and DEN groups, respectively). Due to the drift 
that is typically seen in NHGU over time (Table 4.4), P1 and P3 can be averaged 
to obtain the mean NHGU response to peripheral hyperglycemia. Thus, the 
average NHGU during peripheral glucose infusion in the CON group was 1.7±0.3 
mg/kg/min. NHGU in response to peripheral glucose infusion was significantly 
greater (P<0.05) in the DEN group (2.9±0.4 mg/kg/min; Figure 4.3a).  NHGU 
significantly increased during P2 (portal glucose infusion) in the CON group, 
increasing to 2.9±0.3 (∆1.2) mg/kg/min, but did not change significantly in the 
DEN group (3.2±0.2 (∆0.3) mg/kg/min). 
Net hepatic fractional glucose extraction was 3.1% and 5.4% in response to 
peripheral glucose infusion in the CON and DEN groups, respectively. It 
increased in response to portal glucose infusion in CON group (5.4%) (P<0.05) 
but failed to increase significantly (6.5%) in the DEN group (Table 4.4). 
 The average non hepatic glucose uptake rate seen in response to peripheral 
glucose infusion was 2.2±0.1 mg/kg/min in the CON group and 1.6±0.4 
mg/kg/min in the DEN group (Table 4.4). Non hepatic glucose uptake decreased 
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 significantly (P<0.05) during portal glucose infusion (P2) in the CON group to 
1.2±0.4 (∆1.0) mg/kg/min but it did not change during the same time period in the 
DEN group (1.6±0.4 (∆0.0) mg/kg/min; Figure 4.3b). 
 
Discussion 
 In this study we tested the hypothesis that a basal inhibitory sympathetic 
tone to the liver blocks NHGU and that this inhibition is relieved by entry of 
glucose into the portal vein. Our findings support this concept. There was almost 
a doubling of NHGU during peripheral glucose infusion in dogs that had 
undergone selective hepatic sympathectomy compared to those that had not. 
Furthermore, when the liver was sympathetically denervated, the response to 
portal glucose delivery was reduced by ≈75%. The data regarding nonhepatic 
glucose uptake are less clear. Although nonhepatic glucose uptake was lower 
during peripheral glucose infusion in DEN and it did not change in response to 
portal glucose infusion, the study lacked the statistical power to allow definitive 
conclusions to be drawn. 
 Sympathetic nerve fibers reach the liver through the celiac ganglia, celiac 
plexus, and the splanchnic nerves (134, 136, 247-249). The sympathetic fibers 
form an anterior plexus around the hepatic artery and Alexander showed that the 
hepatic artery receives only sympathetic fibers (12). The parasympathetic fibers 
form a posterior plexus around the portal vein. The postganglionic 
parasympathetic nerves are derived from ganglia located at the hepatic hilus and 
within the portal spaces (100). These parasympathetic fibers are separate from any 
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 aminergic nerves found in the area (14, 62, 181, 231, 261, 269). In order to 
selectively eliminate sympathetic input to the liver, we removed the nerves 
associated with the hepatic arterial circulation. The success of the denervation was 
confirmed by a reduction of norepinephrine in all seven lobes of the liver which 
averaged 98%. Neural regeneration and hepatic reinnervation of the dog liver 
requires 3 months (139) and thus the denervation was still virtually complete two 
weeks post surgery. It is possible that some vagal innervation may have been 
compromised during surgery, but given the association of parasympathetic nerves 
with the portal vein, we believe that most of the parasympathetic fibers remained 
intact. They were thus still able to exert any regulatory effects which they might 
have on NHGU and nonhepatic glucose uptake. It should be noted that there were 
no differences in body weight, food consumption, or basal NHGU between the 
two groups, suggesting that the chronic decrease in hepatic sympathetic tone did 
not have any demonstrable baseline effect on the animals. It is important to note 
that we did not directly measure hepatic sympathetic tone during these 
experiments but assumed that the level of norepinephrine in the liver reflected an 
elimination of sympathetic input to the liver.  
 Several variables that affect NHGU were minimized in order to accurately 
assess the effect of the selective sympathetic denervation on NHGU. Arterial 
insulin was maintained at a basal level in both groups in order to avoid the 
variability seen in the response of NHGU to a rise in insulin. Likewise, the arterial 
plasma glucagon concentrations were kept constant and basal. The arterial plasma 
glucose concentration was doubled and clamped across the three periods in both 
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 groups. Since there was no change in hepatic blood flow, the hepatic glucose load 
to the liver was the same throughout the three experimental periods and was equal 
in both groups. Thus, the differences in NHGU between the two groups cannot be 
explained by differences in plasma insulin or glucagon levels or the glucose load 
to the liver.  
 Prior work in our laboratory has examined the effect of portal glucose 
delivery on NHGU. In hyperglycemic experiments performed by both Pagliassotti 
et al. (214) and Hseih et al. (134) in which both insulin and glucagon were kept 
basal while plasma glucose was doubled, peripheral glucose delivery resulted in 
average NHGUs (mg/kg/min) of 0.4±0.3 and 1.5±0.3, respectively. Thus the 
NHGU of 1.7±0.3 mg/kg/min which we observed in response to peripheral 
glucose administration in the control animals of the present study is consistent 
with previous data. In our earlier studies (134, 214), when glucose was given 
intraportally at ~3.5 mg/kg/min and the hepatic glucose loads were matched to 
those seen during peripheral glucose administration, NHGU (mg/kg/min) 
increased to 2.3±0.7 and 3.4±0.5, respectively. Thus we have shown previously 
that the portal signal, on the background of hyperglycemia, basal insulin, and 
basal glucagon, increases NHGU an average of ~1.9 mg/kg/min. In the present 
control experiments, the increase in NHGU during portal vs. peripheral glucose 
delivery was 1.2±0.2 mg/kg/min, in line with the increase we have observed 
previously. 
 The dogs with sympathetically denervated livers responded to 
hyperglycemia quite differently from the normal animals. The average NHGU 
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 during the peripheral glucose infusion period was 2.9±0.4 mg/kg/min, a value 
almost double (P<0.05) that seen under the same conditions in the dogs with 
innervated livers. With portal glucose delivery, NHGU increased to 3.2±0.2 
mg/kg/min in the DEN group, which is a similar value to that seen in the control 
animals (2.9±0.3 mg/kg/min), yet only ~0.3 mg/kg/min greater than that seen 
during average peripheral glucose administration. This limited increase is not due 
to a saturation of the hepatic response since these rates of NHGU are significantly 
lower than rates we have previously shown to occur during portal glucose 
infusion (254) and lower than the peak rates observed during oral glucose delivery 
(1). Thus we conclude that the sympathetic efferents play an important role in the 
regulation of NHGU by exerting a basal inhibitory tone which limits glucose 
uptake in response to hyperglycemia of peripheral origin. This is consistent with 
previous work from our laboratory (45) which showed that cooling the vagus 
nerves (decreasing afferent vagal firing) in the presence of euglycemia  and 
euinsulinemia decreased net hepatic glucose output, presumably by reflexively 
decreasing the efferent sympathetic outflow to the liver. It is interesting to note 
that we saw no differences in basal net hepatic glucose output between the two 
groups in this current study despite hepatic denervation. There are several 
possible explanations for the discrepancy between our two studies. First it is 
possible that vagal cooling results in changes in addition to reduced sympathetic 
input to the liver. Alternatively, there may be a difference between acute and 
chronic sympathectomy.  
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  The question arises as to whether cutting the sympathetic efferents 
changed NHGU in response to glucose per se(i.e. regardless of the site of 
delivery) or if, in addition, it blocked the effect of the portal glucose signal. If the 
response was to glucose per se, then the portal glucose signal should have caused 
a change of ~1.2 mg/kg/min when glucose was delivered intraportally in the 
hepatic denervated dogs. Since the change was only 0.3 mg/kg/min, these data 
suggest that reduced sympathetic tone to the liver is responsible for a significant 
portion of the increase in NHGU attributed to portal glucose delivery. It must be 
remembered, however, that we chronically removed sympathetic efferents to the 
liver. Chronic removal of sympathetic input may result in changes which increase 
the ability of glucose to increase NHGU which might not occur in response to the 
acute removal of sympathetic input associated with portal glucose delivery.  It is 
also possible that sympathetic denervation resulted in a saturation of the response 
to the portal glucose signal, thus masking any further input (i.e., positive stimuli) 
generated by portal glucose delivery. Thus while our data suggest that the portal 
glucose signal increases NHGU by causing a decrease in sympathetic tone, further 
proof of this concept is still required. 
 Based on our data, we cannot draw a definitive conclusion about the 
additional involvement of a stimulatory signal in the response to portal glucose 
administration. In the control dogs, the response to portal glucose infusion was 
~1.2 mg/kg/min while in the denervated animals it was ~0.3 mg/kg/min. Taken at 
face value, this would suggests that 75% of the response to portal glucose delivery 
is caused by removal of an inhibitory tone and 25% is due to the activation of a 
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 stimulatory signal. In the presence of the portal signal, there is an increase in 
glycogen synthase activation which could act as the stimulatory factor (214). It 
has also been suggested that the portal signal may cause the translocation of 
glucokinase thus also contributing a stimulatory input (47). Unfortunately, the 
present study lacks the power needed to determine the quantitative contribution of 
any putative stimulatory signal to the overall response, so that equal contribution 
by inhibitory and stimulatory factors remains possible. 
 Previous work in our laboratory by Shiota et al. (255) showed that an 
intraportal infusion of α- and β-adrenergic receptor antagonists (phentolamine and 
propanolol, respectively) did not enhance NHGU during hyperinsulinemia and 
hyperglycemia (achieved via peripheral glucose infusion). This is in apparent 
conflict with our current findings but several issues should be noted. Intraportal 
infusion of the adrenergic blockers would have caused only a partial blockade of 
sympathetic tone to the liver if the dose of the blockers used was inadequate. 
Likewise, it is not clear if blockers delivered via the portal vein can reach the 
synapse and block endogenously released norepinephrine effectively. 
Additionally, phentolamine has been shown to stimulate postsynaptic (α1) 
receptors while inhibiting presynaptic (α2) receptors, resulting in an enhanced 
output of norepinephrine (283). It has also been shown that propanolol can have 
an intrinsic (partial agonist) effect on β-adrenergic receptors in the liver (55). The 
partial agonistic properties of these adrenergic antagonists may thus have 
counteracted any effects attributable to adrenergic blockade. Another way to 
reconcile our current observations and our previous findings would be to conclude 
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 that, in the present study, we removed afferent nerve fibers that travel with the 
efferent sympathetic nerves. For that to be the case, the afferent fibers would 
initiate an inhibitory signal to the liver through non-adrenergic mechanisms which 
would be blocked by sympathetic nerve section. This seems unlikely since it has 
been shown that glucose sensitive afferent fibers originating in the liver travel 
with the vagus nerves.  
 It has been shown that portal glucose delivery not only leads to an increase 
in hepatic glucose uptake but also to a decrease in nonhepatic glucose uptake (3, 
134, 214). Under conditions similar to those seen in this experiment, Hsieh 
showed an average nonHGU of 4.3±0.5 mg/kg/min during peripheral glucose 
administration, which decreased to 1.0±0.3 mg/kg/min during portal glucose 
administration and then returned to 4.6±0.7 mg/kg/min at the termination of the 
portal glucose signal. In the control animals of the current study, the average 
nonHGU during the first peripheral glucose infusion period was 2.1±0.2 
mg/kg/min, decreasing significantly to 1.2±0.4 mg/kg/min with portal glucose 
delivery. At the termination of the portal glucose administration, nonHGU 
returned to 2.3±0.2 mg/kg/min. Thus the response to portal glucose delivery in the 
control animals was consistent with previous data although the nonHGU was 
lower in P1 and P3 than in earlier studies for reasons which are not clear. In the 
animals with denervated livers, nonHGU was only slightly less in response to 
peripheral glucose infusion (1.6±0.4 mg/kg/min) than in the control dogs. There 
was no change in nonhepatic glucose balance in response to portal glucose 
infusion in the DEN group. Given the subtle difference noted above, however one 
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 cannot draw a definitive conclusion regarding the role of sympathetic nerves in 
the mediation of the change in nonHGU. 
 In summary, the sympathetic nerves exert an inhibitory tone on liver 
glucose uptake. Removal of this inhibition by selective hepatic sympathetic 
denervation leads to an increase in NHGU in response to hyperglycemia induced 
by peripheral glucose infusion. It also results in a blunting of the increase in 
NHGU seen in response to intraportal glucose delivery. The portal signal, 
therefore, leads to the removal of an inhibitory tone to the liver which in turn 
allows NHGU to increase. Whether hepatic sympathetic nerves act in concert with 
an additional stimulatory signal still needs to be determined. 
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Table 4.1: Hepatic norepinephrine content in each of the seven lobes of  
42 hr fasted dogs with innervated (CON) or denervated (DEN) livers
     Norepinephrine Content
Lobe                    ng/g liver      % NE Remaining
CON DEN
Caudate 476±83 2.5±2.7 0.5
Left Central 524±126 4.3±3.8 0.8
Left Lateral 545±90 3.8±3.2 0.6
Left Posterior 939±202 3.8±2.3 0.4
Quadrate 582±82 29.1±21.4 5.0
Right Lateral 546±94 27.6±12.6 5.0
Right Central 716±149 4.4±3.6 0.6
 Data are mean ± SE. n=10 group  
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 Table 4.3: Arterial blood lactate and glycerol and net hepatic balance of lactate
and glycerol during the basal and experimental periods in experiments on 42 hr fasted dogs
with innervated (CON) or denervated (DEN) livers
Arterial Blood Lactate (umol/L)
Basal P1 P2 P3
CON 384±52 845±104 1064±78 1036±107
DEN 532±114 1195±153∗ 1318±131∗ 1331±128∗
Net Hepatic Lactate Balance (umol/kg/min)
Basal P1 P2 P3
CON -5.9±0.8 5.8±2.4 6.9±1.5 5.4±1.6
DEN -7.0±1.5 8.3±2.7 7.3±1.9 7.7±1.8
Arterial Blood Glycerol (umol/L)
Basal P1 P2 P3
CON 84±10 53±10 47±8 48±6
DEN 84±10 56±7 50±7 49±7
Net Hepatic Glycerol Uptake (umol/kg/min)
Basal P1 P2 P3
CON 1.8±0.2 1.1±0.2 1.0±0.2 1.0±0.2
DEN 2.1±0.3 1.2±0.2 1.1±0.2 1.0±0.2
Data are mean ± SE. n=10 group *= Significant statistical difference (P<0.05) from CON
(-) indicates uptake
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 Table 4.4: Net hepatic glucose uptake, net hepatic glucose fractional extraction, and 
non hepatic glucose uptake during the experimental periods in experiments on 42 hr 
fasted dogs with innervated (CON) or denervated (DEN) livers.
Net Hepatic Glucose Uptake (mg/kg/min)
Basal P1 P2 P3
CON 1.8±0.3 1.4±0.4 2.9±0.3§ 2.0±0.3
DEN 1.9±0.2 2.5±0.4* 3.2±0.2 3.3±0.5*
Net Hepatic Glucose Fractional Extraction (%)
CON 2.6±0.6 5.4±0.4§ 3.6±0.3
DEN 4.9±0.5* 6.5±0.7 6.1±0.5*
Non Hepatic Glucose Uptake (mg/kg/min)
CON 2.1±0.2 1.2±0.4§ 2.3±0.2
DEN 1.9±0.2 1.6±0.4 1.4±0.5
Data are mean ± SE. n=10 group    *= Significant statistical difference (P<0.05) from CON
§= Significant statistical difference (P<0.05) from P1 and P3
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Figure 4.1: Arterial and portal plasma glucose levels in control (a) and hepatic 
denervated (b) 42-h-fasted conscious dogs maintained on a pancreatic clamp during the 
basal and experimental periods (n=10/group). Data are mean ± SE. 
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Figure 4.2: a) arterial plasma insulin, b) arterial plasma glucagon, c)liver 
sinusoidal insulin, and d) liver sinusoidal glucagon levels in 42-h-fasted conscious 
dogs maintained on a pancreatic clamp during the basal and experimental periods 
in both the CON and DEN groups (n=10/group). Data are mean ± SE 
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 CHAPTER V 
 
THE EFFECT OF SIMULATING THE PORTAL GLUCOSE SIGNAL BY 
VAGAL COOLING ON CANINE NET HEPATIC GLUCOSE 
METABOLISM IN THE PRESENCE OF PERIPHERAL 
HYPERGLYCEMIA 
 
Aim 
 Specific aim III used the vagal cooling method to simulate the decrease in 
afferent firing seen after glucose delivery to the portal vein to further elucidate the 
role of those nerves involved in the mediation of the effect of the portal glucose 
signal.  
 
Experimental Design 
 Each experiment consisted of a 100-min equilibration period (-140 to –40 
min), a 40-min basal period (-40 to 0 min), and a 180-min experimental period (0 
to 180 min) which was subsequently divided into two 90 minutes periods. In all 
experiments, a constant infusion of indocyanine green dye (0.076mg/min) was 
initiated at –140 min. At 0 min, a constant infusion of somatostatin (0.8 µg⋅kg-
1⋅min-1) was begun to suppress endogenous insulin and glucagon secretion, and 
glucagon (0.57 ng⋅kg-1⋅min-1) and insulin (1.2mU⋅kg-1⋅min-1) were replaced 
intraportally. In addition, a primed continuous peripheral infusion of 50% 
dextrose was begun at time 0 so that the blood glucose could quickly be clamped 
at the desired hyperglycemic level (~ 235 mg/dl).  Glucose was infused 
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 peripherally to double the hepatic glucose load (HGL) during the entire 
experimental period. At t=90, the vagal coils were infused with a 50/50 
methanol/saline solution at body temperature (37°C) in the SHAM dogs (n=6) or 
at ~ -10°C in the COOL dogs (n=6).  
 Femoral artery, portal vein, and hepatic vein blood samples were taken 
every 20 min during the basal period (-40 to 0 min) and every 15 minutes for the 
last half hour of each experimental period. Arterial blood samples were also taken 
every 5 min from 0 to 180 minutes of the experimental period to monitor the 
glucose level. 
 
Statistical Analysis 
 Time course data were analyzed with repeated-measures analysis of 
variance. Independent t-tests were used for any comparisons of mean data. 
Statistical significance was accepted at p<0.05. 
 
Results 
 
Cardiovascular parameters and hepatic blood flow (Fig. 5.1): Blockade of 
vagal transmission during the cooling period was confirmed by the presence of a 
significantly greater heart rate in the COOL (183±3 bpm) group when compared 
to the SHAM (102±5 bpm) group. In addition, all COOL dogs exhibited prolapse 
of the 3rd eyelid (Horner’s sign) and a deepening and slowing of respirations 
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 during the cooling period. There were no significant changes in blood pressure 
during the basal or experimental periods in either group. 
 As expected, with the onset of somatostatin infusion arterial blood flow 
increased slightly while portal blood flow decreased modestly. Hepatic blood 
flow (Table 5.1) was initially similar in both groups and, as a result of the above 
changes, fell slightly but not significantly during the first experimental period in 
both groups. It increased significantly during the cooling period as the result of a 
significant rise in arterial blood flow (9±1 to ~13±2 ml/kg/min). Sham cooling 
was without effect on arterial blood flow. 
 
Arterial and portal plasma glucose levels (Fig 5.2): The average arterial plasma 
glucose level (mg/dl) in the COOL dogs prior to vagal cooling was similar to that 
seen in the SHAM dogs (230±2 and 231±2, respectively). The average glucose 
infusion rates (mg/kg/min) were 7.9±1.6 and 6.8±0.4 in the SHAM and COOL 
dogs, respectively. During nerve cooling, the arterial plasma glucose 
concentration was allowed to fall to an average of 194±4 mg/dl in order to hold 
the hepatic glucose load constant in the presence of the increase in arterial blood 
flow. During coil perfusion, the average glucose infusion rates were 10.0±1.5 vs 
7.5±0.9 mg/kg/min in the SHAM and COOL dogs, respectively. It was slightly 
less in the latter group as a result of the need to lower the arterial glucose levels to 
compensate for the increase in hepatic blood flow while clamping the hepatic 
glucose load. As expected the portal vein glucose levels were slightly lower than 
the arterial plasma glucose levels in both groups throughout the study. 
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Arterial plasma and liver sinusoidal insulin and glucagon, cortisols, and 
catecholamines (Table 5.2): Arterial and liver sinusoidal plasma insulin levels 
were maintained at ~3-4X basal throughout the experimental periods in both the 
SHAM and COOL groups. The arterial plasma and liver sinusoidal glucagon 
levels, on the other hand, were maintained at basal values throughout the 
experimental periods in both groups.  
 Cortisol (Table 5.2) and catecholamine (data not shown) levels did not 
change from basal in either the SHAM group or the COOL group and were not 
statistically different from one another at any time point during the experiment.  
  
Hepatic glucose load, net hepatic glucose balance, and net hepatic fractional 
extraction (Fig 5.3): By adjusting the peripheral glucose infusion rate to 
compensate for the increase in total hepatic blood flow which occurred in 
response to cooling, the hepatic glucose load was kept constant overtime in the 
two experimental periods and was not significantly different in the two groups. 
The average hepatic glucose load throughout the entire experiment was 46±1 and 
50±2 mg/kg/min in the SHAM and COOL groups, respectively.  
 With the onset of peripheral hyperglycemia, net hepatic glucose balance 
switched from output to uptake. Net hepatic glucose uptake (NHGU), in the 90 
minutes prior to the cooling period, averaged 2.2±0.5 and 2.9±0.8 mg/kg/min in 
the SHAM and COOL dogs, respectively. During cooling, the average NHGU 
was 3.0±0.5 and 3.4±0.6 in the SHAM and COOL dogs, respectively. Thus 
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 NHGU was not affected by vagal cooling. Likewise, the fractional extraction of 
glucose by the liver was not altered by the decrease in parasympathetic signaling. 
 
Blood levels and net hepatic balance of lactate (Table 5.3): The liver exhibited 
net lactate uptake in the basal period in both groups. Hyperglycemia resulted in a 
switch to net hepatic lactate output that was similar in both groups and waned 
over time. The arterial blood lactate levels initially rose due to the change in net 
hepatic lactate balance and then fell slightly over time. Given our ability to 
measure net hepatic glucose and lactate balance, we were able to indirectly 
calculate the average glycogen synthetic rate. The hepatic glycogen synthetic 
rates prior to cooling (1.4±0.5 and 2.2±0.5 mg/kg/min) and during sham cooling 
or cooling (2.5±0.5 and 3.1±0.6 mg/kg/min) were not significantly different in the 
SHAM and COOL dogs, respectively. 
 
Nonhepatic glucose uptake and clearance (Figure 5.4): There was a slight drift 
up in nonhepatic glucose uptake over time in each group. Vagal cooling had no 
effect on this parameter in either group. Likewise, no changes were apparent in 
nonhepatic glucose clearance. 
 
Discussion 
 In the current studies NHGU was stimulated by hyperinsulinemia and 
hyperglycemia brought about in the absence of portal glucose delivery. Vagal 
nerve activity was then blocked using a nerve cooling technique to simulate the 
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 decrease in afferent firing seen after glucose delivery into the portal vein (202-
205, 208). The efficacy of cooling was evident from the increase in heart rate and 
the 3rd eyelid response. Blocking vagal nerve activity had no effect on either net 
hepatic or nonhepatic glucose uptake. 
 There have been several studies that have explored the role of the hepatic 
nerves in the mediation of the portal glucose signal. In a recent study by Cardin et 
al (44), NHGU was stimulated by hyperinsulinemia, hyperglycemia, and the 
portal glucose signal. When vagus nerve activity was blocked using the same 
method as employed in the present study (vagal cooling), NHGU did not change. 
In an earlier study by Shiota et al. (255), adrenergic blockade (portal vein 
phentolamine and propanolol infusion) and coincident cholinergic stimulation 
(portal vein acetylcholine infusion) brought about in the presence of 
hyperinsulinemia and hyperglycemia (produced by peripheral glucose infusion) 
increased NHGU by 1.8 mg/kg/min when compared to controls (255). These 
results were inconclusive, however, because portal vein administration of 
acetylcholine caused an increase in hepatic artery blood flow, leading to a rise in 
the glucose and insulin loads to the liver. Other studies have shown that delivery 
of glucose into the hepatic portal vein results in a fall in the firing rate of efferent 
fibers in the hepatic branch of the splanchnic nerve (206). More recently we have 
shown that selective sympathetic denervation results in a greater increase in 
NHGU in response to hyperglycemia  of peripheral origin than would otherwise 
be the case, suggesting that the sympathetic nerves exert a tonic inhibition of 
NHGU (78). This raises the possibility that the portal glucose signal may bring 
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 about its effect in part at least by causing a diminution in this inhibitory 
sympathetic tone. 
 There are three possible interpretations of the Cardin et al. (44) data. First, 
afferent signaling via the vagus nerve may have been maximally suppressed by 
portal glucose delivery, and thus vagal cooling would have caused no further 
reduction in afferent firing and would have had no effect on efferent sympathetic 
nerve activity to the liver. Since NHGU did not change, this would also indicate 
that inhibiting parasympathetic efferent activity was without effect. Thus one 
would conclude that parasympathetic nerve input is not involved in the response 
of the liver to the portal glucose signal. Second, it is possible that a further 
decrease in afferent firing did occur and that it led to a further reduction in 
sympathetic input to the liver which would have increased NHGU. Since NHGU 
did not change, however, this leads to the conclusion that elimination of efferent 
parasympathetic input must have resulted in an offsetting decrease in NHGU. The 
third possibility is that the vagus nerves do not play any role (afferent or efferent) 
in the transmission of the portal glucose signal, thus explaining why vagal cooling 
had no effect on NHGU. 
 The current study was undertaken in order to further elucidate the role of 
the vagus nerves in the mediation of the portal glucose signal. More specifically, 
we examined the role of the vagus nerves by creating hyperglycemia in the 
presence of increased insulin but in the absence of the portal glucose signal. Our 
hope was that by examining the data from the present study and that from the 
study of Cardin et al. (44) together, that we could clarify the role of the vagus 
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 nerves in control of hepatic glucose uptake. If the first interpretation of the Cardin 
et al (44) data were correct, NHGU should have increased in the current study in 
the presence of vagal cooling since there would have been a significant reduction 
in sympathetic tone (the latter being present in the absence of portal glucose 
delivery) and no consequences of efferent parasympathetic inhibition. This was 
not the case. In regard to the second possible interpretation, in the current study 
decreasing the afferent firing associated with the vagus nerves should have again 
inhibited sympathetic efferent firing leading to an increase in NHGU. Inhibition 
of parasympathetic efferent firing, on the other hand, would have had no effect if 
basal parasympathetic tone plays no role in augmenting NHGU in the presence of 
peripheral glucose. To the extent that it does exert an effect under these 
conditions, its removal would mitigate the rise in NHGU resulting from removal 
of the sympathetic tone. Total denervation of the liver results in an increase in 
NHGU compared to the totally intact liver (5) but not as large as seen with a 
selective sympathetic denervation (78) suggesting that the input from the 
sympathetic efferents plays a more important role in control of NHGU than that 
from the parasympathetic efferents. Thus, an increase in NHGU should again 
have been seen when vagal cooling occurred and this did not occur. 
 Based on the aforementioned data, it, thus, appears that the vagus nerves 
do not play a role in the mediation of the portal glucose signal. However, several 
caveats to this conclusion must be considered. First, it is possible the afferent 
signal is transmitted through the vagal parasympathetic nerves, but that the nerves 
were not adequately cooled. This seems unlikely, given that the heart rate 
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 increased significantly during cooling and Horner’s sign was present. In addition, 
it has been shown previously that this vagal cooling method is sufficient to halt 
vagal signaling in the dog (141) and cat (99) and that an injection of atropine is 
not able to increase the rate over the effect of  cooling at this temperature (141). 
The second caveat relates to the possibility that the increase in NHGU is due to a 
local reflex involving the parasympathetic nerves within the hepatoportal region 
as previously suggested (44, 267). This does not rule out a centrally mediated 
component of the portal signal (5, 44) but rather suggests that the two 
mechanisms (a centrally mediated (non-vagal) and a locally mediated (vagal) 
reflex) could work in concert with one another to elicit a full response. 
Additionally, the rise in arterial blood flow caused by vagal cooling, albeit small 
(50%), might be associated with a signal which could itself alter NHGU, thus 
complicating data interpretation. 
 It should be remembered that other neurotransmitters might be involved in 
the response of NHGU to portal glucose delivery. The effect of serotonin (5-HT) 
on NHGU has been previously examined in this laboratory. Intraportal infusion of 
5-HT enhanced NHGU  and blunted nonhepatic glucose uptake under 
hyperglycemic, hyperinsulinemic conditions (191) but also caused an increase in 
circulating levels of catecholamines and cortisol that caused gastrointestinal 
distress. To demonstrate that the response seen on NHGU was serotonin and not 
catecholamine dependent, a selective serotonin re-uptake inhibitor (fluvoxamine) 
was administered intraportally (189). Similar studies were also done by infusing 
5-hydroxytryptophan (5-HTP), a serotonin precursor, into the portal vein to 
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 eliminate the gastrointestinal side effects (192). Both 5-HTP and fluvoxamine 
enhanced NHGU without elevating circulating serotonin or catecholamine levels 
suggesting that hepatic targeted serotonin delivery may be effective in reducing 
postprandial hyperglycemia and that serotonin may be involved in the response to 
the portal glucose signal. 
 It is interesting to note that we observed a statistically significant effect of 
vagal blockade on hepatic arterial blood flow and, as a result, total hepatic blood 
flow. The former increased by 50% in response to vagal cooling. Studies of the 
effect of the hepatic vagal nerves on hepatic blood flow (HBF) are limited and the 
results are controversial; Bobbioni et al (32) showed that there was an increase in 
HBF in rats when the vagus nerve was electrically stimulated. Most other studies, 
however, have reported no change in HBF after vagal nerve stimulation (105, 
150, 152, 162) or hepatic vagotomy (273). It is unclear why there was an increase 
in hepatic arterial blood flow in response to vagal cooling in the present study 
since we did not observe such an effect in our earlier “cooling” studies (43-45). 
 In summary, vagal cooling to halt electrical transmission in the vagus 
nerves had no effect on NHGU under hyperglycemic and hyperinsulinemic 
conditions. Such is the case whether glucose was given via a peripheral or the 
portal vein. This makes it less likely that the vagus nerves are involved in the 
mediation of the portal glucose signal.
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Figure 5.1: Heart rate (bpm) in both sham cooled (SHAM) and vagally cooled 
(COOL) 42-fasted conscious dogs maintained on a pancreatic clamp during the 
basal and experimental periods (n=6/group). Data are mean ± SEM. * = P<0.05 
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igure 5.2: Arterial (a) and portal (b) plasma glucose levels in sham cooled 
HAM) and vagally cooled (COOL) 42-fasted conscious dogs maintained on a 
ncreatic clamp during the basal and experimental periods (n=6/group). Data are 
ean ± SEM. * = P<0.05 
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Figure 5.3: a) hepatic glucose load, b) net hepatic glucose balance, and c) net 
hepatic fractional extraction in  sham cooled (SHAM) and vagally cooled 
(COOL) 42-fasted conscious dogs maintained on a pancreatic clamp during the 
basal and experimental periods (n=6/group). Data are mean ± SEM. 
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Figure 5.4: a) nonhepatic glucose uptake and b) no
sham cooled (SHAM) and vagally cooled (COOL) 
maintained on a pancreatic clamp during the basal 
(n=6/group). Data are mean ± SEM. 
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 CHAPTER VI 
 
THE EFFECT OF AN INTRAPORTAL NITRIC OXIDE (NO) DONOR 
(SIN-1) ON CANINE NET HEPATIC GLUCOSE METABOLISM IN THE 
PRESENCE OF THE PORTAL GLUCOSE SIGNAL 
 
Aim 
 Nitric oxide (NO) is clearly an important mediator in insulin sensitivity at 
the muscle. Due to the reciprocity between hepatic and muscle glucose uptake, we 
hypothesized that NO would also have dramatic effects at the liver by inhibiting 
hepatic glucose uptake. In specific aim IV, a portal infusion of the nitric oxide 
donor, SIN-1, in the presence of the portal glucose signal, was used to increase 
NO levels at the liver and hepatic substrate balance was calculated in the presence 
and the absence of this donor. 
 
Experimental Design 
 Each experiment consisted of a 100-min equilibration period  (-120 to –20 
min), a 20-min basal period (-20 to 0 min), and a 240-min experimental period (0 
to 240 min) which was divided into one 90 minute period (P1) followed by a 150 
minute period (P2). In all experiments, a constant infusion of indocyanine green 
dye (0.076mg/min) was initiated at –120 min. At 0 min, a constant infusion of 
somatostatin (0.8 µg⋅kg-1⋅min-1) was begun to suppress endogenous insulin and 
glucagon secretion and basal glucagon (0.57 ng⋅kg-1⋅min-1) and 4-fold basal 
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 insulin (1.2mU⋅kg-1⋅min-1) were replaced intraportally. Glucose (20% dextrose) 
was delivered intraportally at 4mg/kg/min. In addition, a primed continuous 
peripheral infusion of 50% dextrose was begun at time 0 so that the blood glucose 
could quickly be clamped at the desired hyperglycemic level (~ 235 mg/dl).  From 
t=90 to t=240, normal saline (CON, n=9) or SIN-1 (SIN-1 4ug/kg/min, n=9) were 
delivered intraportally. The peripheral glucose infusion rate was adjusted to 
maintain a similar hepatic glucose load to that which was seen during the first 90 
minutes of the experimental period (P1). PAH was added to the portal glucose 
infusate to assess mixing of the infusate with the blood in the portal and hepatic 
veins as previously described (214). n the CON group, 9 dogs were studied and all 
were included due to adequate mixing as defined previously (197); 11 dogs were 
studied in the SIN-1 group and 9 were included using the same standards. In the 
control and SIN-1 animals that were retained, the ratio of PAH recovery in the 
portal vein to the PAH infusion rate was 0.9±0.1 and 0.9±0.1 whereas the ratio of 
PAH recovery in the hepatic vein to the PAH infusion rate was 0.9±0.1 and 
0.9±0.1, respectively (a ratio of 1.0 would represent perfect mixing). 
 Femoral artery, portal vein, and hepatic vein blood samples were taken 
every 20 min during the basal period (-20 to 0 min) and at pre-determined time 
points throughout the experimental periods. Arterial blood samples were also 
taken every 5 min from 0 to 240 minutes of the experimental period to monitor 
the glucose level and facilitate the clamp. 
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 Statistical analysis 
 Time course data were analyzed with repeated-measures analysis of 
variance. Independent t-tests were used for any comparisons of mean data. 
Statistical significance was accepted at p<0.05. 
 
Results 
 
Heart rate and systolic and diastolic blood pressure (Table 6.1): The average 
heart rates during the basal period tended to be lower in the CON group (88±5 
bpm) than in the SIN-1 group (100±6) but there were no statistically significant 
changes over time in either group. 
 The average systolic blood pressure during the basal period in the CON 
group was 172±6 mmHg and did not change significantly during P1 (167±5 
mmHg) or P2 (166±4 mmHg). The average systolic blood pressure in the SIN-1 
group was similar to that seen in the CON group in the basal period (162±4 
mmHg) and P1 (162±4) but fell significantly during P2 (112±7 mmHg). The 
diastolic blood pressure followed a similar pattern to the systolic blood pressure. 
 
Hepatic sinusoidal plasma insulin and glucagon (Figure 6.1): Hepatic 
sinusoidal plasma insulin was maintained at elevated levels as expected in both 
the CON (75±7 uU/ml) and SIN-1 (78±8) groups throughout P1. Neither SIN-1 
nor saline infusion had any effect on the plasma insulin level. The hepatic 
sinusoidal plasma insulin levels during P2 were unchanged (79±4 and 72±2 
uU/ml) in the CON and SIN groups, respectively.  
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 Hepatic sinusoidal plasma glucagon levels (Figure 6.1b) were basal and did not 
differ significantly between the CON and SIN-1 groups at any point in the study. 
 
Arterial plasma glucose levels, hepatic glucose load, net hepatic glucose 
balance, fractional glucose extraction, nonhepatic glucose uptake and 
clearance:  The arterial plasma glucose levels were doubled from basal values of 
113±2 and 114±2 mg/dl, in the CON and SIN-1 groups respectively, to average 
levels of 235±4 and 249±3 mg/dl, respectively in P1. During the SIN-1 infusion 
(P2), the arterial plasma glucose level was decreased to an average of 220±6 
mg/dl in order to hold the hepatic glucose load constant in the face of a rise in 
hepatic blood flow (22%). The arterial plasma glucose level was not changed 
appreciably during saline infusion (237±3 mg/dl) since total hepatic blood flow 
did not change (8%) (Figure 6.2a). 
 The hepatic glucose load in the control group (Figure 6.2b) was not 
significantly different in P1 and P2 (49±3 and 53±4 ml/kg/min, respectively). In 
the SIN-1 group, the average hepatic glucose loads were also similar in P1 and P2 
(43±3 and 46±3 ml/kg/min) and although they tended to be slightly lower than 
those seen in the CON group, this difference was not significant. 
Net hepatic glucose output was similar during the basal periods in both the CON 
and SIN-1 groups (1.7±0.3 vs 1.5±0.1 mg/kg/min, respectively). With the onset of 
hyperglycemia and the portal glucose signal, net hepatic balance switched from 
output to uptake in both groups (Figure 6.3). Likewise, net hepatic glucose uptake 
(NHGU) was similar in P1 in both groups with an average uptake of 4.1±0.4 and 
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 4.0±0.7 in the CON and SIN-1 groups, respectively. NHGU averaged 4.8±0.4 
mg/kg/min during P2 in the CON group. In the presence of the SIN-1 infusion, 
NHGU decreased significantly within 15 minutes and averaged 3.1±0.4 
mg/kg/min in P2 (P<0.05 vs CON). These differences were also reflected in the 
fractional extraction of glucose by the liver in that during P2, the liver extracted 
9.3% of the glucose it received in the control group and 7.0% in the SIN-1 group 
(P<0.05).  
 There was no change in non-hepatic glucose uptake or clearance in the 
presence of SIN-1 or saline in either group over time. There were also no 
significant differences between the two groups in either non hepatic glucose 
uptake or non hepatic glucose clearance (Figure 6.4). 
 
Blood levels and net hepatic balance of lactate (Figure 6.5): Both groups 
exhibited net lactate uptake in the basal period. The combination of increased 
insulin, hyperglycemia, and the portal glucose signal resulted in a switch to net 
hepatic lactate output (NHLO) and a rise in the arterial blood lactate levels rose. 
In response to saline infusion, NHLO drifted down over time causing a slow fall 
in the blood lactate level. Such a fall was not seen during SIN-1 infusion although 
NHLO at 90 minutes was only half that in the saline group.  
 
Plasma NEFA levels, net hepatic NEFA balance, arterial blood glycerol 
levels, and net hepatic glycerol balance (Figure 6.6):Arterial plasma NEFA 
levels fell as expected at the start of the experimental period and remained 
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 constant in both groups throughout the experimental period even in the presence 
of SIN-1. Likewise, net hepatic NEFA uptake fell to a very low rate in both 
groups. 
 Arterial blood glycerol levels and net hepatic glycerol uptake also fell 
rapidly in response to the combination of an increase insulin and hyperglycemia. 
However, with the onset of the SIN-1 infusion, arterial blood glycerol levels 
doubled to an average of 47±2 µmol/L during the last hour of the experiment. 
This was associated with an increase in net hepatic glycerol uptake. 
 
Hepatic blood flow (Table 6.2): Hepatic arterial blood flow increased slightly 
from basal, as expected, with the start of the somatostatin infusion (t=0) in both 
groups while portal vein blood flow decreased modestly, as expected. In P1, the 
average hepatic portal blood flow was 17.8±1.2 and 15.9±1.4 ml/kg/min in the 
CON and SIN-1 groups, respectively. In the CON group, it did not change 
significantly (18.7±1.4 ml/kg/min). In the SIN-1 group there was a rise in average 
hepatic portal vein blood flow to 19.6±1.4 ml/kg/min (P<0.05) during P2. The 
average hepatic portal blood flows were not significantly different between the 
two groups at any point.  
 The average total blood flow during P1 was 27±2 ml/kg/min and 22±2 
ml/kg/min in the CON and SIN-1 groups, respectively. In P2, the average total 
blood flow in the control group increased non-significantly to 29±2 ml/kg/min 
while in the SIN-1 group, it increased significantly to 27±2 ml/kg/min. The 
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 average total blood flow was significantly different between the two groups 
during P1 but not during P2. 
 
Discussion 
 In this study we tested the hypothesis that nitric oxide exerts an inhibitory 
effect on NHGU.  In the presence of hyperinsulinemia, hyperglycemia, and the 
portal glucose signal, a portal infusion of the NO donor SIN-1 caused a 35% 
decrease in NHGU. There were no significant effects on non-hepatic glucose 
uptake or clearance. 
 The effect of intraportal SIN-1 infusion on NHGU was rapid and 
significant. In the control group, NHGU increased slightly over time to an average 
of 4.8±0.4 mg/kg/min. Over the same time period, NHGU averaged 3.2±0.5 
mg/kg/min in the SIN-1 group. This decrease remained evident throughout. Thus, 
intraportal SIN-1 administration decreased NHGU by ~35% (P<0.05) compared 
to that seen in the control group. Intraportal SIN-1 infusion had no effect on non 
hepatic glucose uptake or clearance. Several variables that affect NHGU were 
controlled in order to accurately assess the effect of intraportal nitric oxide 
delivery on NHGU. The arterial plasma glucose concentration was doubled and 
the glucose load to the liver was kept constant over time in both groups. The 
hepatic sinusoidal plasma glucagon concentrations were kept basal while the 
hepatic sinusoidal plasma insulin concentrations were increased four fold in both 
groups. Thus the response of the liver cannot be ascribed to changes in insulin, 
glucagon, or the hepatic glucose load.  
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   Our lab has previously shown that portal glucose delivery and 
hyperinsulinemia have additive effects in enhancing glucose uptake by the liver. 
In hyperglycemic experiments by both Adkins et al. (3, 4) and Pagliassotti et al. 
(214) in which glucagon was kept basal and insulin was either basal or elevated 
four fold, portal glucose delivery enhanced NHGU compared to that which was 
seen with peripheral glucose delivery. In the present study, the average NHGU 
during the first experimental period in the control and SIN-1 groups was 4.1±0.4 
and 4.1±0.7 mg/kg/min, respectively. These rates are consistent with previous 
data (4, 5, 214) obtained under similar experimental conditions. 
 The question then arises as to how this effect of intraportal SIN-1 infusion 
was brought about. Did it occur because of a direct action of NO on the liver or 
through an indirect action mediated by some other means? One such indirect 
mechanism could involve an increase in sympathetic drive to the liver which 
resulted from the decreases in blood pressure caused by the intraportal infusion of 
SIN-1. There are two observations that support this hypothesis. These include an 
increase in the heart rate and an increase in lipolytic activity. The intraportal 
administration of SIN-1 had significant cardiovascular effects. Both systolic and 
diastolic pressure decreased significantly, although this was not surprising as 
orally absorbed SIN-1 has previously been shown to rapidly lower blood pressure 
(17). This in turn was associated with a slight increase in heart rate. Besides the 
cardiovascular effects seen with the intraportal administration of SIN-1, there was 
also an increase in the arterial blood glycerol level. An increase in norepinephrine 
and epinephrine have been shown to activate lipolysis via the B1, B2, and B3-, 
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 adrenoceptors and these sympathetic neurotransmitters are important lipolytic 
regulators in vivo (155, 156). An increase in lipolysis will in turn cause an 
increase in glycerol concentration due to the break down of the triglycerides to 
free fatty acids and glycerol. Thus the increase in arterial blood glycerol 
concentrations in the SIN-1 treated group suggests that SIN-1 may have increased 
sympathetic drive to fat and in turn activated lipolysis.  
 In further support of the concept that NO may be having an indirect effect 
via sympathetic nerve activation is our recent finding that removal of sympathetic 
input to the liver results in an increase in NHGU suggesting that the sympathetic 
nerves exert a tonic inhibition on NHGU (79). If the intraportal SIN-1 infusion 
increased sympathetic drive to the liver, it may well have resulted in a decrease in 
NHGU. 
 It is also possible that SIN-1 may be acting directly on both the hepatocyte 
and the adipocyte in eliciting its effects. The effect of endogenously gnerated NO 
has been shown to stimulates lipolysis in white adipose tissue and increase fatty 
acid oxidation in hepatocytes (101, 107, 147, 153). More recently, Fu et al. (102), 
showed that dietary L-arginine supplementation (a precursor of NO synthesis) in 
Zucker diabetic fatty rats increased NO synthesis and lipolysis. Thus the increase 
in arterial blood glycerol concentrations seen in the current study may have been 
due to the direct action of SIN-1 on NO release in adipose tissue. 
 The exact source of the endogenous hepatic NO is not clear. In addition, 
the direct mechanism by which NO decreases NHGU is not completely clear. It is 
known that cGMP can stimulate the hydrolysis of cAMP through the stimulation 
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 of cAMP phosphodiesterase (244). Others have shown that hepatocytes (29, 
66)and neighboring Kupffer cells (30) are also able to produce NO from L-
arginine in an inducible manner (involving iNOS, a Ca2+- independent NO 
synthase) which can in turn stimulate soluble guanylate cyclase and increase 
cGMP levels. Both iNOS and eNOS have been found in hepatocytes and in 
addition, iNOS has been localized to both the hepatic Kupffer cells as well as the 
Ito cells (11, 168). Only eNOS can be found in the liver under normal conditions 
but iNOS can be rapidly upregulated in the liver due to endotoxemia, sepsis, 
infection, and liver regeneration (168). Thus both isoforms of NOS may be 
involved with the direct action of NO on the liver.  In the perfused rat liver, 
infusion of NO (34 µmol/L) greatly increased the rate of glucose output and 
therefore increased glucose concentrations on average two fold (37). Lactate 
production also increased. The fact that both glucose and lactate output were 
increased suggested that glycogen was the source of the additional glucose output. 
The mechanism by which NO increases glycogenolysis in the perfused rat liver 
was suggested to be activation of glycogen phosphorylase. This requirement for 
the activation of phosphorylase was confirmed by the ineffectiveness of NO in 
phosphorylase-kinase deficient livers of gsd/gsd rats (37). 
 There are several NO donors (GEA 3162, V-PYRRO, SNAP, DEA/NO) 
but we specifically chose to use SIN-1. SIN-1 decomposes non-enzymatically in a 
two step reaction with the second step yielding NO and O2.- (35, 91)which will 
readily form peroxynitrite (137). The NO and O2.- can also lead to the formation 
of GSNO. This formation of GSNO outcompetes the formation of peroxynitrite as 
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 well as O2.- scavenging by superoxide dismutase (245). This makes SIN-1 the 
most favorable NO donor to use in these experiments due to its propensity to form 
the GSNO complex over the peroxynitrite radical. Although we did not measure 
NO or SIN-1 concentrations across the liver, it would appear that some SIN-1 did 
pass the liver since it had potent cardiovascular effects. 
 More recently, a liver-selective nitric oxide donor, V-PYRRO/NO has 
been developed which dissociates to NO rapidly (169, 238). It has a high first pass 
effect through the liver with a blood half-life of approximately 12 minutes. Once 
the V-PYRRO/NO is activated, the local NO half-life is very short. It might be of 
interest in the future to repeat these current studies using this liver-selective NO 
donor to eliminate or reduce the cardiovascular effects that were present although 
it is unclear whether V-PYRRO/NO has the ability to react with GSH. 
 The effect of NO on non-hepatic glucose metabolism, primarily muscle 
glucose uptake, has been explored more extensively than the effects of NO on 
hepatic glucose metabolism. Xie et al (288, 291)has suggested that insulin 
sensitivity may be mediated by a neurohumoral mechanism through which the 
liver releases a putative hormone referred to as hepatic insulin-sensitizing 
substances (HISS). This HISS then enters the blood and can sensitize the skeletal 
muscle to insulin action, possibly accounting for as much as~55% of total insulin 
action (159, 161). It has been shown that HISS release is dependent on the 
activation of hepatic muscarinic receptors by acetylcholine (presumably released 
from the parasympathetic nerves) and is clearly mediated by NO that is produced 
in the liver (120, 240, 291). In a study performed by Sadri et al. (240), intraportal, 
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 but not intravenous, administration of L-NAME (a nitric oxide synthase 
antagonist) significantly reduced insulin sensitivity as measured using the rapid 
insulin sensitivity test (RIST) in rats. This suggests that NOS inhibition at the 
liver causes insulin resistance. The authors then concluded that this insulin 
resistance caused by NOS antagonism was not due to a reduction in skeletal 
muscle perfusion but rather due to the blockade of the parasympathetic reflex 
release of HISS that occurred in response to insulin. 
  In these same experiments, the authors administered SIN-1 both 
intraportally and intravenously and only saw a reversal of the insulin resistance 
caused by the L-NAME in those rats that received the SIN-1 intraportally. Thus, 
the insulin resistance that was produced after the inhibition of NOS in the liver 
was reversed by providing NO to the liver. They also went on to show that 
intraportal SIN-1 delivery could completely restore insulin sensitivity in rats that 
had undergone hepatic denervation. These data suggest that there is an insulin-
induced hepatic parasympathetic reflex, which acts through the binding of 
acetylcholine to muscarinic receptors, resulting in production of NO in the liver, 
leading to the release of the putative hormone (HISS), which in turn sensitizes the 
skeletal muscle to the action of insulin. 
 It is interesting to note that in another complementary set of experiments, 
Guarino et al. (119) showed that whereas SIN-1 can restore HISS action after 
inhibition of NOS by L-NAME, acetylcholine (ACh) cannot. This suggests that 
NOS is one of the targets for the hepatic muscarinic receptors in the HISS 
 145
 pathway. Thus the release of endogenous NO in the liver is required for the HISS 
secretion in response to insulin.  
 Based on the above data, we expected to see an increase in non-hepatic 
glucose uptake when we infused SIN-1 to the liver. According to the theories 
proposed by several investigators (118, 159, 224), this increase of NO at the liver 
should have stimulated the release of HISS and increased insulin sensitivity at the 
muscle. We did not see an effect of SIN-1 on either non hepatic glucose balance 
or non hepatic glucose clearance. There are several possible explanations as to 
why this was the case. First, it could be solely a species phenomenon and thus not 
apparent in the dog. Second, it has been previously shown that HISS synthesis 
may be controlled by the prandial status with its synthesis being maximal in the 
post-prandial state and minimal in the fasted state (146). Most of the experiments 
that have been conducted on animals looking at HISS have been carried out under 
euglycemic conditions in animals that have been fasted and refed. In this study, 
42-h fasted dogs were used and a hyperglycemic clamp was maintained, and 
either or both of these conditions may have prevented us from seeing any effects 
of HISS on non hepatic glucose metabolism.  
  Another important consideration regarding our failure to see a peripheral 
action of portal SIN-1 involves the role of glutathione (GSH) on the action of the 
hepatic insulin-sensitizing substance. Glutathione levels in the liver are 
significantly lower following an overnight fast than seen after feeding. In 
experiments performed by Guarino et al.(119) in which they depleted hepatic 
GSH using the GSH synthesis inhibitor 1-buthionine-[S,R]-sulfoximine (BSO), 
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 SIN-1 did not reverse the insulin resistance brought about by the depletion of 
GSH in combination with the administration of L-NAME, suggesting that both 
NO and GSH are both essential for HISS-dependent insulin action. Nitrosylated 
derivatives of GSH, including S-nitrosoglutathione (GSNO), can act as 
endogenous NO reservoirs (120), since this compound is a very stable molecule 
and has a biologically active NO adduct (130). It has yet to be determined 
whether the GSNO compound is only a stable NO pool that in turn allows for 
HISS secretion or if it also has the ability to activate key enzymes and pathways. 
GSNO may activate other key enzymes by S-nitrosylation or S-thiolation. Thus 
we may not have seen the effect of NO on non hepatic glucose uptake due to the 
depletion of GSH following the 42-h fast.  
 In summary, an intraportal NO donor (SIN-1) decreased NHGU and net 
hepatic glucose fractional extraction while having no effect on non- hepatic 
glucose uptake. The presence of the NO donor also increased arterial blood 
glycerol concentrations and impeded the fall of arterial blood lactate levels over 
time suggesting that NO may play a role in the regulation of glycogen synthesis. 
It is also possible that intraportal administration of SIN-1 triggers a sympathetic 
response secondary to hypotension which can then account for the changes seen 
in hepatic glucose metabolism as well as lipolysis. Future studies need to 
elucidate the exact mechanism by which NO is exerting its effects and clarify the 
relationship between hepatic and non hepatic glucose metabolism in the light of 
HISS and NO. 
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 Table 6.2: Average hepatic arterial, portal, and total blood flow 
 in 42-h fasted conscious dogs during the basal and
experimental periods in the control and SIN-1 groups
Basal Experimental Experimental +/- SIN-1
Average Hepatic Arterial Blood Flow (ml/kg/min)
Control 6.0±0.4       9.0±0.8§           10.3±1.1§
SIN-1 4.9±0.4*       6.0±0.5*§            7.2±0.6*§
Average Hepatic Portal Blood Flow (ml/kg/min)
Control 22.4±1.7      17.8±1.2§           18.7±1.4§
SIN-1 22.1±1.8      15.9±1.4§           19.6±1.4¥
Average Total Hepatic Blood Flow (ml/kg/min)
Control 28.4±1.9      26.8±1.9           29.0±2.1
SIN-1 26.9±1.8      21.9±1.7*§           26.8±1.7
Data are mean+SE n=9/group
§ = Significant statistical difference (P<0.05) from basal period within the group
¥ = Significant statistical difference (P<0.05) from period within the group
* = Significant statistical difference (P<0.05) from control group
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Figure 6.1: Hepatic sinusoidal plasma insulin (a) and glucagon (b) levels in 42-h-
fasted conscious dogs maintained on a pancreatic clamp during the basal and 
experimental periods in both the control and SIN-1 treated groups (n=9/group). 
Data are mean ± SE.   
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Figure 6.2: Arterial plasma glucose levels (a) and hepatic glucose load (b) in 
control and SIN-1treated 42-h-fasted conscious dogs maintained on a pancreatic 
clamp during the basal and experimental periods (n=9/group). Data are mean ± 
SE. 
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Figure 6.3: Net hepatic glucose balance (a) and net hepatic glucose fractional 
extraction (b)  in 42-h-fasted conscious dogs maintained on a pancreatic clamp 
during the basal and experimental periods in both the control and SIN-1 treated 
groups (n=9/group). Data are mean ± SE   ∗= P<0.05 compared to control group 
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Figure 6.4: Non hepatic glucose uptake (a) and non hepatic glucose clearance (b) 
in 42-h-fasted conscious dogs maintained on a pancreatic clamp during the basal 
and experimental periods in both the control and SIN-1 treated groups 
(n=9/group). 
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Figure 6.5: Arterial blood lactate (a) and net hepatic lactate balance (b) in 42-h-
fasted conscious dogs maintained on a pancreatic clamp during the basal and 
experimental periods in both the control and SIN-1 treated groups (n=9/group). 
Data are mean ± SE.  ∗= P<0.05 compared to control group 
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Figure 6.6: Arterial plasma NEFA levels (a), arterial blood glycerol levels (b), hepatic 
plasma NEFA balance (c) and hepatic blood glycerol uptake (d) in 42-h-fasted conscious 
dogs maintained on a pancreatic clamp during the basal and experimental periods in both 
the control and SIN-1 treated groups (n=9/group). Data are mean ± SE. *= P< 0.05 
compared to control group 
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 CHAPTER VII 
 
SUMMARY AND CONCLUSIONS 
 
 Type II diabetes is characterized by both fasting and postprandial 
hyperglycemia (72, 80, 92, 96). In both of these situations, the extent of the 
hyperglycemia is determined by the net balance of glucose, i.e the amount of 
glucose entering and leaving the circulation. Following an overnight fast, the liver 
and kidney are primary sites of glucose production (46, 182). Glucose released 
from the liver is derived from both glycogenolysis as well as gluconeogenesis 
while the glucose released from the kidney is solely due to gluconeogenesis (83, 
182). This situation becomes more complex following carbohydrate ingestion (71, 
73, 80, 92). Since hepatic glycogenolysis is not fully suppressed following food 
ingestion (67, 173), the amount of glucose that is released into the systemic 
circulation from the splanchnic tissues represents the interplay between the rate of 
glucose absorption, the rate of splanchnic (gut and hepatic) glucose extraction, 
and the rate of hepatic glucose production (20). 
 It is well known that the arterial plasma insulin/glucagon level, the hepatic 
glucose load, and the route of glucose delivery are the three major determinants of 
NHGU (47). Recent studies have reported that the ability of insulin and glucose to 
stimulate splanchnic glucose uptake is impaired in individuals with type 2 
diabetes (21). Thus, in specific aim I of this thesis we explored the ability of first 
phase insulin release to control the glycemic excursion on the background of basal 
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 insulin and a duodenal glucose infusion. The pulse of insulin acutely affected net 
hepatic glucose production and increased NHGU while it still had significant 
effects on plasma glucose levels 4.5 hours later due to its ability to affect non 
hepatic glucose clearance. An analogue of insulin developed for oral 
administration (HIM2) was cleared from the body less efficiently than Humulin, 
resulting in higher plasma insulin levels at both the liver and the periphery. This 
pulse increased plasma insulin levels for almost 60 minutes, eliminated net 
hepatic glucose production by 30 minutes, and continued to have a significant 
effect on plasma glucose levels even at the end of the experiment (4.5 hours). 
With the focus in the pharmaceutical market turning towards new insulin 
therapies, this study demonstrated the ability of a brief burst of insulin secretion to 
result in prolonged glycemic improvement and speaks to the importance of first 
phase insulin release in postprandial glucose homeostasis. Unfortunately, the 
biologic activity of HIM-2 was only half that of regular insulin rendering it 
unsuitable for further clinical development. Future efforts will be directed towards 
the development of new insulin molecules which might allow oral insulin to be a 
treatment modality of the future.  
The role of the portal signal in the regulation of NHGU has been an area of 
research for many years. It is clear that when the portal vein glucose concentration 
is greater than that seen in the artery, i.e, what is seen following an oral glucose 
load, that there is an increase in NHGU. This increase in NHGU in response to 
the portal glucose signal is also affected by both the insulin concentration as well 
as the hepatic glucose load presented to the liver. It has been suggested that the 
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 portal signal may be impaired in diabetic individuals, resulting in a defect in 
splanchnic glucose uptake when glucose is given orally. Thus, it is critical to 
understand how NHGU is regulated. 
 Although it has been demonstrated that the portal glucose signal is an important 
regulator of NHGU, the mechanism of action by which it exerts its effects is not 
completely understood. Prior to the work completed in this thesis it was 
demonstrated that total hepatic denervation could eliminate the ability of the liver 
to increase NHGU in response to the portal glucose signal suggesting that neural 
input was important in regulating NHGU. The relative importance of the 
sympathetic and parasympathetic nerves, however, was not known.  Other 
investigators had suggested that the portal signal may exert its effects through an 
intrahepatic reflex involving other mediators and neurotransmitters. Thus the 
second aim of this thesis was to further elucidate the potential regulators of the 
portal glucose signal and NHGU. 
Our attention first turned towards the role of the sympathetic nerves in the 
regulation of NHGU. The data from specific aim II suggest that the sympathetic 
nerves exert a tonic inhibition on NHGU in the presence of hyperglycemia, and 
that removal of these nerves, results in an increase in NHGU. While our data 
suggest that the portal glucose signal increases NHGU, in part at least, by causing 
a decrease in sympathetic tone, further understanding of this event is still 
required. For example, it still remains to be determined whether there is additional 
involvement of a stimulatory signal in the response to portal glucose 
administration. 
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 Our conclusions from specific aim II led us to further investigate the vagus nerve 
and the role of the vagal afferents in mediating the portal glucose signal. The data 
from specific aim III suggested that the vagus nerve does not play a role in the 
regulation of NHGU suggesting that the afferent nerves found in the vagus are not 
the transmitters of the portal glucose signal.  
The data from specific aims II and III suggested that the sympathetic nerves 
exerted a dominant effect on NHGU while the input from the vagus nerve is not 
essential for the regulation of the portal glucose signal. Thus, the possibility exists 
that a local effect of the portal signal might be occurring via an intrahepatic 
reflex. With the idea that other signals and mediators may regulate NHGU, our 
work turned towards the role of nitric oxide in the regulation of NHGU. It is clear 
that the intraportal administration of the nitric oxide donor SIN-1 significantly 
decreased NHGU in the presence of the portal signal. As discussed in chapter VI, 
this may be due to either a direct or indirect effect on hepatic glucose metabolism. 
It is possible that the vasodilation caused by NO resulted in a decrease in blood 
pressure which in turn resulted in an increase in the response of the sympathetic 
nervous system. This may have caused a decrease in NHGU, an increase in 
lipolysis, and an increase in the heart rate. Alternatively, it is possible that the NO 
generated from the SIN-1 had a direct effect on the liver itself by affecting the 
glycogenoyltic pathway and in addition may have had a direct effect on the 
adipocyte to increase lipolysis.  
Thus the work presented in this dissertation demonstrates that NHGU is regulated 
by both neural mechanisms, primarily the sympathetic nerves, as well as other 
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 mediators which may be acting through neural pathways or having direct actions 
of their own. It now becomes important to determine whether the NO is 
decreasing NHGU indirectly by stimulating the sympathetic nervous system or 
directly by affecting the hepatocytes. In future experiments SIN-1 could be 
delivered peripherally to determine its effects. If SIN-1 still decreases NHGU, this 
suggests that the site of the SIN-1 administration is not important and that the 
effects seen may be due to the indirect mechanism. If, on the other hand, 
peripheral SIN-1 administration does not decrease NHGU then this suggests that 
the intraportal SIN-1 administration may be due to a direct effect of SIN-1 on the 
hepatocytes. Another way to examine the question of whether NO is exerting its 
effect via an indirect or direct mechanism would be to administer SIN-1 
intraportally in a denervated animal.  
Studies are currently underway to examine the role of L-NAME, a potent NOS 
antagonist, on NHGU. We hypothesize that the intraportal infusion of L-NAME 
will increase NHGU, opposite to that seen with the intraportal infusion of SIN-1. 
In summary, all studies described in this dissertation have clinical applications. 
Because post-prandial hyperglycemia is thought to predispose an individual to the 
development of complications, it is critical to understand the regulators that 
control this state. Insulin is a clear regulator of NHGU in the post-prandial state 
and we have demonstrate that “restoring” first phase insulin release can have a 
significant effect on the hepatic glycemic profile even 4.5 hours following a 5 
minute pulse of insulin. We have also suggested the importance of the 
sympathetic nerves in the regulation of NHGU and the possible regulatory role of 
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 NO in mediating NHGU. If it is found that the portal signal is not as effective in 
increasing NHGU in individuals with type 2 diabetes, then those factors which 
affect NHGU, including both neural input as well as other mediators such as NO, 
may become important in the treatment of the disease. 
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